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An electron micrograph
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(Cook and Cook, 2006)
Chapter 1: Introduction  
 
 
 
 
 
Bacteria, the oldest forms of life on earth, are remarkably diverse and exist in 
surprising numbers. Diseases caused by bacteria include some of the most common 
infections in the world, as well as some of the most important human 
present, and probably future
to phenotype, including size, shape, staining properties
since the beginning of microbiology. 
common, but there are other 
also found (Fig.1.1). In recent years, classification has been dominated by genotype, 
especially relying on conserved molecules such as 16S ribosomal RNA
1994). The aerobic and facultatively anaerobic Gram
into two families, Micrococcac
activity, cell morphology and aggregation. However, this classification may change, 
since genetic studies have indicated that 
Bacillus-Lactobacillus
(Kloos and Bannerman, 199
Fig. 1.1 Bacteria come in a variety of shapes, such as 
spirals. In addition to these shape differences, 
individually, some in pairs and
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 (Relman, 2002). Bacteria have been classified according 
 and biochemical properties, 
Both spherical and rod shaped bacteria are very 
varieties such as helical, comma-shaped and square are
-positive cocci were first divided 
eae and Streptococcaceae, on the basis of catalase 
Staphylococcus is more closely related to the 
-Streptococcus cluster than to Micrococcus 
5). 
spherical 
some species of bacteria thrive 
 some others in chains or clusters.
When a Lot of Remedies Are Suggested For a 
Disease That Means It Is Difficult To Cure
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1.1 Gram positive Staphylococcus 
 
The Staphylococcus genus contains 41 validly described species. These are 
traditionally grouped into coagulase positive (CPS) and coagulase-negative 
staphylococci (CNS) (Resch et al., 2008). Medically important Staphylococcus 
species contain coagulase positive S. aureus causing pyogenic infections in humans. 
CNS may behave as opportunistic pathogens, often introduced by medical devices or 
colonizing exposed wounds (Faria et al., 2009). Main habitats of these bacteria are 
skin, skin glands and mucous membranes of humans and animals (Kasprowicz et al., 
2011).  
 
 1.1.1 Staphylococcus aureus 
 
Members of the genus Staphylococcus are major human pathogens and cause a wide 
variety of hospital and community acquired infections worldwide. This bacterium is a 
highly `talented' organism capable of causing skin infections, food poisoning through 
to clinical problems such as medical device colonization. It is commonly responsible 
for wound-related infections and most worryingly for life-threatening illnesses, such 
as deep postsurgical infections, septicemia and toxic shock syndrome (Yee-Guardino 
et al., 2008), purpura fulminans (Hussain et al., 2007), necrotizing pneumonia (Kohli 
et al., 2011), endocarditis (Perazzi et al., 2011) and also causes protracted infections 
of bones (osteomyelitis) and joints (arthritis) because of its tendency to form biofilms 
on artificial materials, difficult-to-treat infections of catheters and other devices 
(Moreillon et al., 2005). Coagulase-negative staphylococci (CoNS) had been regarded 
as harmless skin commensals prior to the 1970s; however, they are now recognized as 
important causes of human infections (Sharma et al., 2011). Over the past 50 years, S. 
aureus has undergone genetic modification that has resulted in antibiotic-resistant 
strains (McCallum et al., 2010). S. aureus became resistant to penicillin due to the 
production of β-lactamases that hydrolyze the penicillins. For that reason, penicillins 
(PCN) that were resistant to the action of β-lactamases, such as the new semisynthetic 
penicillinase-resistant antimicrobial drugs methicillin and oxacillin were developed to 
treat staphylococcal infections caused by β-lactamase-producing strains (Barber, 
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1961). β-lactamase is an enzyme encoded by the bla gene that binds β-lactams, and 
rapidly hydrolyzes them into biologically inactive metabolites. Such inactive 
metabolites can no longer bind to the PBPs. This phenomenon necessitated the 
development of β-lactamase-resistant antibiotics, including methicillin, nafcillin, 
dicloxacillin and the cephalosporins in the late 1950s (Wright, 1999). Nosocomial 
infections with S. aureus in hospitals and nursing homes have become increasingly 
resistant to various antibiotics; these antibiotic-resistant strains are called methicillin-
resistant Staphylococcus aureus (MRSA) (Casey and Chasens, 2009). Nosocomial 
infections have a tremendous impact on the morbidity, mortality and costs of 
hospitalization (Feizabadi et al., 2011). Community-associated methicillin-resistant 
Staphylococcus aureus (CA-MRSA) is defined as a MRSA strain collected from a 
person with no history of the following risk factors such as hospitalization or surgery, 
permanent indwelling catheters or percutaneous medical devices, residence in a long-
term care facility, dialysis, MRSA culture >48 hours after hospital admission (Jombo 
et al., 2010), within the year prior to the MRSA culture date. After first being reported 
in 1961, MRSA has become endemic in hospitals worldwide, rendering the entire β-
lactam class of antibiotics ineffective (Chambers, 2001). There are several other 
antibiotics that are usually ineffective against MRSA, especially healthcare-associated 
MRSA (HA-MRSA), such as aminoglycosides, tetracycline and fluoroquinolones 
(Shore et al., 2005). The glycopeptide antibiotic vancomycin was first released in 
1958. Afterward, vancomycin has been the treatment of choice for serious infections 
caused by MRSA. For many years there was no indication that vancomycin resistance 
in S. aureus was likely to be a problem (Srinivasan et al., 2002). But, recently 
vancomycin has become redundant as the first-line treatment of severe staphylococcal 
infections (Pope and Roecker, 2007). The progress of MRSA therefore is an important 
step in the evolution of this pathogen. The growing incidence of MRSA infections has 
generated interest in the development of new anti-MRSA antibiotics (Le et al., 2011). 
 
1.1.2 Structure of Staphylococcus aureus 
 
The cell walls of gram-positive bacteria exhibit a wide diversity from simple to very 
complex structures (Fig.1.2). Staphylococcal cell walls have a rather extraordinary 
type of structural design and belong to the most highly cross-linked type but the walls 
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with deep-seated staphylococcal infections. Teichoic acid has no established role in 
virulence, and antibodies of this carbohydrate are not protective. The protein 
component of the cell wall includes protein A which reacts with IgG of normal human 
serum (Lowy, 1998) and it can be released from the bacterial surface by treatment of 
staphylococci with lysostaphin, a glycyl-glycine endopeptidase that cleaves the 
pentaglycyl cross-bridge of the cell wall (Sjoquist et al., 1972). Lysozyme, an N-
acetyl-muramidase that cuts the glycan strands (Hash and Rothlauf, 1967), releases 
protein a molecules as a spectrum of fragments with varying masses due to the 
presence of linked peptidoglycan fragments of different sizes (Navarre et al., 1998). 
Although bacterial peptidoglycan structure varies from one species to another, several 
structural or functional elements are conserved (Schleifer and Kandler, 1972). The 
glycan strands of all bacterial peptidoglycan consist of repeat disaccharide units, N-
acetylglucosamine–(β1–4)-N-acetylmuramic acid (GlcNAc–MurNAc). Glycan chains 
are cross-linked by short cell wall peptides and generate a three-dimensional 
molecular network that maintains the integrity of the bacterium (Tipper and 
Strominger, 1965). Finally, penicillin binding proteins catalyze the polymerization of 
lipid II subunits via trans-glycosylation and trans-peptidation reactions, thus 
generating the cross-linked peptidoglycan that constitutes the main component of the 
bacterial cell wall (Perry et al., 2002).  
 
 1.1.3 Classification 
 
Staphylococcus aureus was first discovered as a cause of post-operative wound sepsis 
in the late 1870s by Professor Sir Alexander Ogston of Aberdeen. In 1883 he named 
the clusters of grape-like organisms ‘Staphylococcus’ after the Greek word for a 
bunch of grapes and coccus means granule (Fig.1.3). It derives its specific epithet of 
aureus due to the golden colour of colonies grown on solid media.  Each year some 
500,000 patients in American hospitals contract a Staphylococcus infection. 
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Fig.1.3 An electron micrograph 
of Staphylococcus aureus  
(Cook and Cook, 2006) 
Scientific Classification  
 Domain:    Prokaryotes 
 Kingdom:  Eubacteria 
 Phylum:     Firmicutes 
 Class:        Bacilli 
 Order:       Bacillales 
 Family:      Staphylococcaceae 
 Genus:      Staphylococcus 
 Species:    aureus 
Binomial name 
Staphylococcus aureus  (Rosenbach, 1884)  
 
1.1.4 History 
 
Gram-positive Staphylococcus is enclosed in a thick cell wall (but no outer 
membrane, unlike Gram-negative bacteria); it was first discovered at the end of the 
19th century in pus from human abscesses (Moreillon et al., 2005). Before the 
availability of antibiotics, invasive infections caused by S. aureus were often fatal. In 
the early 1940s, the major treatment available to combat this organism was penicillin 
and all isolates were sensitive to penicillin. During the next 2 decades, this pathogen 
developed resistance to penicillin (Finland, 1979) and nowadays virtually all strains of 
S. aureus are resistant to natural penicillins, aminopenicillins, and antipseudomonal 
penicillins (Chambers, 2009). Resistance to these drugs occurs because of the 
acquisition of genes that encode drug-inactivating enzymes, initially known as 
penicillinases and now called β-lactamases (Rice, 2006). The prevalence of penicillin-
resistant strains increased in the 1960s. It was during this period that a new class of 
antibiotics was developed to target this pathogen specifically. One year after this class 
of antibiotics was developed, a resistant strain known as methicillin-resistant S. 
aureus (MRSA) was repotted (Zaoutis et al., 2006). Methicillin was considered to 
resist β-lactamases degradation, but MRSA strains that were resistant to all β-lactam 
antibiotics were identified soon after methicillin was introduced into clinical practice 
(Fischbach and Walsh, 2009). The first case of MRSA was identified as early as 
1961-1962, soon after the introduction of Methicillin in 1960 (Nixon and Bingham, 
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2006). By 1980 they had spread throughout the world. From the late 1970s to the 
early 1990s, MRSA was usually a hospital-acquired pathogen, rendering the entire β-
lactam class of antibiotics ineffective. In contrast, CA-MRSA was first discovered in 
the late 1990s to cause severe and fatal infections in children without precursor health 
care exposure (Herold et al., 1998). In the last 20 years, methicillin-resistant S. aureus 
has spread throughout the world in healthcare settings, leading to an increased 
reliance on vancomycin for empiric treatment (Jernigan et al., 1995). Vancomycin 
had been considered to be the “gold standard antibiotic” of the last resort and this 
drug has been the option for the treatment of MRSA infections over the last 3 decades 
(Peppard et al., 2009). Until recently vancomycin was believed to have retained 
activity against all strains of Staphylococcus aureus; therefore the spread of MRSA 
has led to increased vancomycin usage and hence increased selective pressure for the 
development of resistance. The first clinical strain of S. aureus resistant to 
vancomycin (Mu50) was reported in 1997 from Japan (Hood et al., 2000). 
Vancomycin resistance in S. aureus is a major problem from a clinical and public 
health standpoint (Srinivasan et al., 2002). Limited treatment options for infections 
caused by such multi-drug resistant microorganisms prompted the search for novel 
compounds with a wide spectrum of activity and new therapeutic strategies (Entenza 
and Moreillon, 2009).  
 
1.1.5 Survival strategy of S. aureus: super genomic agility 
 
Staphylococcus aureus is a well-armed super pathogen since it possesses extreme 
genetic plasticity and an array of virulence factors that confers resistance against 
different classes of antimicrobial agents.  Antimicrobial drugs generally act at three 
interfaces in the microbe viz. cell wall synthesis, protein synthesis and nucleic acids.  
 
1.1.5.1 Cell wall inhibitors 
 
β-lactams antibiotics with drugs like penicillin and methicillin basically inhibit cell 
wall synthesis by presenting them as pseudo-substrates for the transpeptidases that 
acylated them, thereby causing weak peptide bond formation susceptible to osmotic 
changes and leading to lyses of the bacterium. Five different types of PBP’s viz. 1, 2, 
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3, 3’, 4 have been described for susceptible strains of S. aureus. A variant, which is 
responsible for resistance to β-lactams, is PBP2a (Fuda et al., 2004). PBP2a has low 
affinity for β-lactam antibiotics and, therefore, is capable of substituting the 
biosynthetic functions of the normal PBPs even in the presence of the β-lactams, 
thereby preventing cell lysis (Georgopapadakou et al., 1986). Specific Methicillin 
resistance results in the presence of the mecA gene and this gene is carried on 
Staphylococcal Cassette Chromosome (SCC)mec, a unique mobile genetic element, 
integrated into the staphylococcal chromosome. mecA is also responsible for synthesis 
of PBP2a (Grundmann et al., 2006). In glycopeptides, vancomycin-induced 
susceptibility through the process of inhibition of trans-glycosylation and trans-
peptidation steps is achieved by blocking the precursor, D-Ala-D-Ala by the antibiotic 
through hydrogen bonding thus inhibiting the formation of UDP-MurNAc-
pentapeptide required for cell wall synthesis. The vancomycin-resistant microbes 
modify the precursor from D-Ala-D-Ala to D-Ala-D-Lac using the enzymes VanH 
dehydrogenase and VanA ligase which have low affinity for glycopeptides and 
thereby make the normal binding site unavailable (Chopra, 2003). 
 
1.1.5.2 Protein synthesis inhibitors 
 
Macrolides, aminoglycosides, tetracyclines and oxazolidinones are the major drug 
classes that function via inhibition of protein synthesis. Aminoglycosides are 
bactericidal whereas others, such as the tetracyclines and macrolides, have a static 
action against bacteria (Bryan et al., 1985). Macrolide (Mac) antibiotics consisting of 
a 12- to 16-membered lactone ring combined with a sugar moiety inhibit protein 
synthesis via binding to 23S ribosomal RNA in bacteria. The 14- and 16-membered 
macrolides are used for treating infectious diseases caused by Gram-positive and 
other bacteria. Bacteria resort to three methods to resist macrolides: (a) target site 
modification by methylation or mutation thereby preventing binding of the antibiotic 
to the ribosomal target; (b) efflux of the antibiotic; and (c) inactivation of the 
antibiotic (Matsuoka, 2000). The erm gene is responsible for the resistance of S. 
aureus to erythromycin by the expression of erm methylase, which dimethylates the 
single adenine residue in the nascent 23S rRNA, a part of the 50S ribosomal subunit. 
Aminoglycosides, despite being an important anti-staphylococcal drug class, have lost 
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sensitivity to MRSA by inactivation of their structure at particular amino groups thus 
loosing affinity to bind the 30S  ribosomal subunits and the ability to block protein 
synthesis (Magnet and Blanchard, 2005). The most commonly encountered 
mechanism of resistance to aminoglycosides is enzymatic inactivation, which is 
mediated by 3 distinct classes of enzymes: acetyltransferases (AACs) 
nucleotidyltransferases (ANTs), and phosphotransferases (APHs) (Shaw et al., 1993). 
However, it is the presence and action of aminoglycoside modifying enzymes that are 
the most relevant in the prevalence of resistant clinical isolates (Foster, 1983). The 
APHs and ANTs are ATP-dependent enzymes, whereas the AACs require acetyl 
coenzyme A (acetyl CoA). Resistance to neomycin, kanamycin, tobramycin and 
amikacin in Staphylococci are mediated by an ANT(4’) enzyme (Jacoby et al., 1990). 
Tetracyclines are broad-spectrum antibiotics which find use as the second line of 
treatment for bacterial infections after penicillin. Resistance to tetracycline and 
minocycline due to ribosomal protection mechanisms mediated by the genes tet(M) 
(Martin et al., 1986), tet(O) (Sougakoff et al., 1987), tet(Q) (Nikolich et al., 1992) and 
tet(S) (Charpentier et al., 1993) has been reported. tet(M) has been subsequently 
detected in a large variety of aerobic and anaerobic gram-positive and gram-negative 
bacterial genera, including Enterococcus, Streptococcus (Soge et al., 2008), 
Peptostreptococcus and  Haemophilus (Roberts and Hillier, 1990), Staphylococcus 
(Bismuth et al., 1990), Listeria (Facinelli et al., 1993), Clostridium (Mullany et al., 
1990), Neisseria and Kingella (Knapp et al., 1988), and Bacteroides (de Barbeyrac et 
al., 1991), and in cell wall-less organisms such as Mycoplasma and Ureaplasma spp. 
(Roberts, 1990). It is the most widely disseminated antibiotic resistance determinant 
which is associated with the conjugative transposon Tn916 (Flannagan et al., 1994). 
The transposon can be found on the bacterial chromosome or on plasmids (Bentorcha 
et al., 1992). Linezolid belongs to a new antibiotic class of synthetic agents, the 
oxazolidinones, and is effective against multidrug-resistant gram-positive bacteria, 
including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and 
vancomycin-resistant enterococci (Orsi et al., 2011). Its mechanism of action involves 
binding selectively to the bacterial 50S ribosomal subunit, where it inhibits the 
formation of a functional initiation complex. Linezolid has been effective in the 
treatment of complicated skin and soft tissue infections (Weigelt et al., 2005) and 
nosocomial pneumonia caused by methicillin-susceptible and methicillin-resistant 
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strains of S. aureus (Jones et al., 2006). The reduced Linezolid susceptibility in S. 
aureus occurs through specific point mutations in the central loop of the domain V of 
23S ribosomal RNA of the 50S subunit (Nannini et al., 2010). Domain V represents 
the peptidyl transferase, which catalyzes the peptide bond formation. An additional 
mechanism to resist antibiotics is via drug efflux proteins or transporters also known 
as efflux pumps. The prokaryotic kingdom possesses five different kinds of efflux 
pumps, namely MATE (multidrug and toxic efflux), MF (Major facilitator), SMR 
(small multidrug resistance), RND (resistance-nodulation-division) and ABC (ATP-
binding cassette). Efflux pumps export an extensive range of structurally unrelated 
antibiotics from the cell, resulting in reduced intracellular concentration of the biocide 
and thus reduced susceptibility (Borges-Walmsley et al., 2003). 
 
1.1.5.3 Nucleic acid breakdown (Mutation) 
  
Resistance due to mutational alterations is still significant for specific antibiotic 
classes under certain conditions. This is particularly true for the fluoroquinolone 
antibiotics and for rifampicin (Alekshun and Levy, 1999). The fluoroquinolones with 
C8 substitutions, such as gatifloxacin and moxifloxacin, appear to be more potent 
against S. aureus than the older drugs of this class, and may also be less likely to 
select resistant mutants, an effect that may be strengthened by the addition of rifampin 
(Shopsin et al., 2004). The general mechanism of fluoroquinolone resistance in S. 
aureus functions either by bringing a change in the chromosome responsible for the 
expression of topoisomerase IV or DNA gyrase or by inducing a multidrug resistance 
efflux pump (Wolfson and Hooper, 1989). The first resistance mechanism is alteration 
of the gyrA gene that encodes subunit A of DNA gyrase, i.e. topoisomerase 
(Sreedharan et al., 1990). Another mechanism to attain fluoroquinolone resistance 
relates to mutation in the SmaI A locus of the chromosomal DNA (Trucksis et al., 
1991). Amino acid substitutions in vital regions of the enzyme-DNA complex 
commonly referred as the quinolone resistance-determining region (QRDR) reduces 
affinity of quinolones for both of its targets (Ng et al., 1996). A special situation 
appears when the acquired resistance genes become integrated in the chromosome, 
hampering their identification. This is well illustrated by the mecA determinant of 
methicillin resistance in S. aureus (Spratt, 1992). 
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1.2 Emergence of methicillin-resistant Staphylococcus aureus (MRSA) 
 
From the beginning of the antibiotic era, selective pressure exerted by antibiotic usage 
was very soon reflected by resistance development in staphylococci. Since the 
introduction of antibiotics into clinical use in the mid-1940s, microorganisms have 
shown a remarkable ability to protect themselves by developing and acquiring 
antibiotic resistance. By 1942, penicillin resistance was reported in S. aureus after 
only a few months of limited clinical trials. By 1953, 64–80% of S. aureus isolates 
were resistant to penicillin, with development of resistance to tetracycline, 
streptomycin, chloramphenicol and erythromycin, other classes of antibiotics began to 
emerge (Bradley, 1992). By 1960, using aggressive infection control measures, strains 
of MRSA were first detected in the United Kingdom (UK) (Wise, 1989). The 
prevalence rate of MRSA varies among countries but continues to increase, 
approaching 70% in Japan (Noskin, 2001), 45% in the United Kingdom, 40% in Italy 
and Greece (EARSS, 2002), and 30% to 50% in the United States (Jones et al., 2003). 
Since then, the endemic and epidemic outbreaks of the organisms have been reported 
worldwide (McDougal et al., 2003) but overwhelmingly from developed economies 
of the world. Presently, hospitals of every size, education of healthcare workers, and 
increasing number of different population groups at different communities globally 
are facing the problem of MRSA infections (Tacconelli, 2009).  
 
Methicillin-resistant Staphylococcus aureus strains emerged soon after the 
introduction of methicillin into clinical practice but were generally rare until the 
1980s. In the late 1970s, however, MRSA emerged as a major pathogen of hospital 
infection worldwide and in addition it had also become a community pathogen 
(Swenson et al., 2007), first detected in Europe in the 1960s shortly after the 
introduction of methicillin (Shanson, 1981). Clinical infections are most common in 
patients in hospital intensive care units, nursing homes, and other chronic care 
facilities (Mertz et al., 2010) The increased frequency of community-associated 
MRSA infection has been associated with reports of increased morbidity and 
mortality—specifically, a longer duration of fever, prolonged hospitalization, a higher 
incidence of pulmonary complications along with bone and joint infections, and the 
re-emergence of a severe staphylococcal sepsis syndrome (Gonzalez et al., 2005). The 
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key determinant of methicillin resistance is the mecA gene, which encodes in a novel 
penicillin-binding protein (PBP2/PBP2a) which reduces the binding of all β-lactam 
drugs to the cell wall and therefore, mediates cross-resistance to all these compounds 
(Shore et al., 2005). The mecA gene is carried on a mobile genetic element designated 
the “staphylococcal cassette chromosome mec” (SCCmec) (Deurenberg and 
Stobberingh, 2008), which is inserted into the chromosome at a unique site (attBscc) 
located near the S. aureus origin of replication (Hanssen et al., 2004). SCCmec is 
composed of the mec gene complex, which confers resistance to methicillin, and the 
ccr gene complex, which encodes recombinases responsible for its mobility. There are 
two distinct types of MRSA. Each has a slightly different genetic makeup. To 
categorize the type of the bacteria and how the condition is spread, MRSA infections 
are classified as either hospital-acquired or community-acquired MRSA infections 
(HA-MRSA or CA-MRSA).  
 
 1.2.1 Hospital associated-MRSA (HA-MRSA) 
 
Hospital associated-MRSA is usually resistant not only to β-lactams but also to other 
types of antibiotics. Because many hospitalized patients are weak and their immune 
systems are compromised, HA-MRSA infections are often quite serious (Klevens et 
al., 2007). HA-MRSA infections represent a burden for both patients and health care 
systems and these problems arose initially in large tertiary care hospitals with patients 
in burn, post-operative, prolonged hospitalization and intensive care wards. Increased 
risk of MRSA infection was associated with the use of multiple broad spectrum 
antibiotics, indwelling devices, ventilatory support, severity of underlying disease and 
length of hospital stay (Elliott  et al., 2010). HA-MRSA first appeared in the United 
States in 1968. There are three types of Staphylococcal Chromosomal Cassette (SCC) 
mec in HA-MRSA: Types I, II and III (Mongkolrattanothai et al., 2003). Type I 
contains no additional resistance determinants, but Types II and III contain resistance 
determinants in addition to mecA, which are larger elements and may not be suited to 
Community-acquired MRSA (CA-MRSA) strains; these additional genetic elements 
account for the antimicrobial resistance to numerous antibiotics in addition to the β-
lactam agents (Kluytmans-Vandenbergh and Kluytmans, 2006). The three SCCmec 
types contained in HA-MRSA have an identical chromosomal integration site and 
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cassette chromosome recombinase genes, which are responsible for horizontal transfer 
of SCCmec (Daum et al., 2002). Thus, HA-MRSA is resistant to many different 
antibiotics and has a selective advantage as they are spread among patients by hands 
of personnel and contaminated environmental surfaces. The presence of underlying 
diseases and multiple types of instrumentation and procedures predisposes patients to 
colonization and infection by the multiple drug resistant strains of HA-MRSA.  
 
1.2.2 Community-acquired MRSA (CA-MRSA) 
 
MRSA infections are usually hospital acquired or caused by strains acquired during 
previous hospital or healthcare contact (HA-MRSA). CA-MRSA began to emerge in 
the 1990s in patients who do not have the risk factors usually associated with hospital-
associated MRSA (Zetola et al., 2005). Such as recent hospitalization, chronic 
diseases, kidney dialysis, human immunodeficiency virus infection, and intra-venous 
drug use (Palavecino, 2004). CA-MRSA strains are usually resistant to β-lactams but 
susceptible to other antimicrobials like trimethoprim-sulfamethoxazole, clindamycin 
and tetracyclines and carry mostly staphylococcal cassette chromosome mec 
(SCCmec) Type IV (Naimi et al., 2003). CA-MRSA strains are also more likely to 
possess unique combinations of virulence factors and seem to be genetically different 
from HA-MRSA (Fey et al., 2003). CA-MRSA strains carry genes of Panton-
Valentine leukocidin (PVL), belongs to a family of similar bi-component leukocidal 
toxins produced by staphylococci, with one component belonging to the F class and to 
the S class (Szmigielski et al., 1999). PVL is a cytotoxin produced by <5% of S. 
aureus in general and exhibits highly specific lytic activity against 
polymorphonuclear cells, monocytes, and macrophages in humans and these 
exoproteins of S. aureus have been linked to furuncles, cutaneous abscesses, severe 
necrotic skin infections and severe necrotising pneumonia (Schwartzman et al., 2007).  
 
1.2.3 Virulence factors 
 
Staphylococcus aureus is a pathogen expressing multiple virulence factors that 
mediate host colonization, invasion of damaged skin and mucosa, dissemination 
through the body and evasion of host defense mechanisms (Ferry et al., 2005). The 
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pathogenicity and virulence of S. aureus infections is related to various bacterial 
surface components (e.g., capsular polysaccharide and protein A) including those 
recognizing adhesive matrix molecules (e.g., clumping factor (clf) and fibronectin 
binding protein (fnBP) and to extracellular proteins (e.g., coagulase, hemolysins, 
enterotoxins, toxic-shock syndrome (TSS) toxin, exfoliatins toxin and Panton-
Valentine leukocidin (Fraser and Proft, 2008). Virulence factors can generally be 
separated into three based on their function: the adhesins, the toxins and the 
immunomodulators. The adhesins are surface-attached proteins that allow the bacteria 
to attach to a wide variety of human tissues. The toxins are secreted proteins that 
cause tissue damage and generate pus in abscesses, which is believed to facilitate 
transmission between hosts. The immunomodulators are proteins that interfere with 
host immunity preventing defense against infections (Collins et al., 2010). Several 
microbial surface proteins mediate the adherence of S. aureus to host proteins, such as 
fibrinogen and fibronectin. These plasma proteins coat indwelling medical devices, 
and the ability of the bacteria to adhere to the deposited proteins is believed to be an 
important factor in the pathogenesis of wound and foreign body infections (Foster and 
Hook, 1998). In S. aureus, the adhesin genes which include clf (Ni Eidhin et al., 1998) 
and fnb (Jonsson et al., 1991), that encode the fibrinogen- and the fibronectin-binding 
proteins, respectively. Fibronectin-binding protein (FnBP) A and Fibronectin-binding 
protein (FnBP) B, encoded by the fnbA and fnbB genes, respectively, play prominent 
roles in S. aureus attachment and colonization of host tissues or implanted 
biomaterials (Fischer et al., 1996). FnBPs also promote endocytic uptake of S. aureus 
by epithelial and endothelial cell lines and fibroblasts (Fowler et al., 2000). 
 
1.3 Molecular diagnosis 
 
Molecular diagnosis plays an increasing role in fast detection of microbial pathogens 
and identification of drug-resistance determinants. Results can be obtained within a 
few hours (Tenover et al., 2007). Over the past several years, a variety of DNA-based 
tests have been developed to detect MRSA carriage more quickly (Fang and Hedin, 
2003). Most of these assays are based on the detection of an S. aureus specific gene 
and the mecA gene, which encodes methicillin (oxacillin) resistance. Identification 
techniques based on molecular probing were recently established. One of these 
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techniques relies on fluorescent detection of 16S rDNA with a peptide nucleic acid 
probe (peptide nucleic acid fluorescence in situ hybridization [PNA-FISH]). It 
identified S. aureus in positive blood cultures in less than 3 hrs with a more than 95% 
sensitivity and specificity (Oliveira et al., 2003). The method allowed rapid 
discrimination between S. aureus and potential contaminant CoNS (Forrest et al., 
2006). In addition to PNA-FISH, multiplex real-time PCR is being developed to 
quantify organisms directly in clinical samples. Genes representative of both species 
and resistance mechanisms are amplified simultaneously. For MRSA, the resistance 
gene sought is mecA gene, which encodes low-affinity PBP2a. However, mecA is also 
present in methicillin-resistant CNS and thus detects simultaneously both MRSA and 
methicillin-resistant CNS (Harbarth et al., 2006). Molecular epidemiology data and 
the observation that MRSA spread has been successfully managed by the use of 
rigorous infection-control practices clearly demonstrate that transmission is the main 
factor contributing to the increasing prevalence of MRSA infection or colonization in 
patients (Verhoef  et al., 1999).  
 
1.3.1 Molecular nature of methicillin resistance 
 
The early introduction of β-lactam class antibiotics quickly selected for the outgrowth 
of S. aureus strains possessing, or having acquired, the ability to express β-
lactamases, achieved a resistance rate of 75% as early as 1952 (Finland, 1955). The 
outgrowth of β-lactamase producing S. aureus prompted the commercial development 
of β-lactamase–resistant derivatives of penicillin such as methicillin, which possess an 
acyl side chain that prevents hydrolysis of the β-lactam ring by β-lactamases. The 
narrow-spectrum staphylococcal β-lactamases exhibit minute activity against 
semisynthetic penicillins such as methicillin (Chambers, 1999).  
 
1.3.2 mec DNA 
 
mec DNA is a large (approximately 30–50 kb) DNA fragment that does not occur in 
MSSA, and is always situated at a fixed site in the S. aureus chromosome, specifically 
near the pur-nov-his gene cluster (Kuhl et al., 1978). mec DNA contains mecA, the 
Chapter 1: Introduction  
 
 
structural gene for PBP2a; 
transcription; and 20–45 kb of 
Fig.1.4 Organization of the 
 
The mec-associated DNA has been found to contain transposons and insertion 
elements providing a mechanism for the considerable variability found within the 
region. IS431 is a common insertion sequence in the staphylococcal chromosom
plasmids and is present within the 
resistance determinants with similar IS elements, accounting for the multiple drug 
resistance phenotype common in MRSA
the gene encoding for inducible erythromycin resistance, is located upstream from 
mecA in over 90% of MRSA (Kreiswirth 
 
1.3.3 mecA gene 
 
mecA, a structural gene located on the chromosome of 
characterizes methicillin
seven major types of SCC
Staphylococcal species (Deurenberg and Stobberingh, 2008). Most MRSA (>90%) 
harbor mecA, the gene encoding the PBP, PBP2a. 
76-kD PBP2a polypeptide. The 
resistant CNS and is highly conserved (Kobayashi 
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mecI and mecR1, regulatory elements controlling 
mec-associated DNA (Fig.1.4).  
mec region of DNA and chromosomal
(Chambers, 1999) 
mec DNA region. IS431 serves as a trap for 
. The transposon Tn554 that contains 
et al., 1993). 
Staphylococcus aureus
-resistant S. aureus. The mecA gene can be located in one of 
 elements that can be transferred horizontally between 
mecA is inducible and encodes the 
mecA gene occurs in both MRSA and methicillin
et al., 1994).   
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1.3.4 PBP2a 
 
PBP2a is a unique, inducible, acquired protein that has a molecular weight approx 76 
kDa, and it is produced only by methicillin resistant staphylococci but not present in 
methicillin susceptible strains (Chambers, 1997). PBP2a has low affinity for β-lactam 
antibiotics and, therefore, is capable of substituting the biosynthetic functions of the 
normal PBPs even in the presence of the β-lactams, thereby preventing cell lysis. The 
altered protein, PBP2a retains effective transpeptidase activity while having reduced 
affinity for penicillin and other available β-lactam antibiotics like penicillins, 
cephalosporins, β-lactam/β-lactamase inhibitor combinations, monobactams and 
carbapenems (Fuda et al., 2004). PBP2a is encoded by the mecA gene, a component 
of a larger DNA fragment designated the mec region (Katayama et al., 2000). Tests 
for the mecA or for the protein encoded by mecA, PBP2a, are the most accurate 
methods for the prediction of resistance to oxacillin and could be used to confirm 
results of staphylococci isolates from serious infections (CLSI, 2006). 
 
1.3.5 Regulation of mecA 
 
Both chromosomal regulator genes on the mec DNA, mecI and mecR1, are located 
immediately upstream of mecA, separated from mecA by its promotor and operator 
(Kobayashi et al., 1996), and are divergently transcribed. Downstream from mecA is a 
variable segment of DNA that ends with an insertion-like element, IS431, as well as 
recombinases necessary for site-specific integration and excision (Archer and 
Niemeyer, 1994). Therefore, mecA and its associated DNA act as a trap for integration 
of other determinants, including genes for resistance to fluoroquinolones, 
aminoglycosides, tetracyclines, macrolides and trimethoprim-sulfamethoxazole 
(Chambers, 2001). The MecI protein is a powerful repressor of mecA transcription 
(Hiramatsu et al., 1992) and is highly related in primary structure to BlaI, the 
repressor of staphylococcal β-lactamase. Because of the extensive resemblance to 
MecR1 and MecI, BlaR1 and BlaI can also regulate mecA transcription (Hackbarth 
and Chambers, 1993). mecA is present in all MRSA; there is considerable variation in 
the presence of the other genes (Archer et al., 1994). mecR1-mecI is present in 60–
95% of mecA-positive Staphylococcus aureus (Weller, 1999) because mecI is such a 
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powerful repressor, it has been concluded that phenotypically resistant mecA positive 
S. aureus strains either do not possess mecI, or have mutations within mecI which 
prevent it from functioning (Kobayashi et al., 1998). Inactivation of mecI, by either 
deletion or mutation, is a necessary step in the production of PBP2a and expression of 
methicillin resistance (Schentag et al., 1998).  
 
1.4 Clinical aspects and epidemiology 
 
The multiple antibiotics resistance of methicillin-resistant strains of Staphylococcus 
aureus has become a major clinical problem worldwide. The epidemiology of 
staphylococcal infections is beginning to modify again; strains generally associated 
with CA-MRSA are now showing up in nosocomial infections and some health care–
related strains are being acquired in the community. S. aureus has been a leading 
cause of human infections throughout history. From 1997 to 1999, S. aureus was 
reported as the most abundant cause of bloodstream, skin and soft tissue and lower 
respiratory tract infections in the United States, Canada, Europe, Latin America and 
the Western Pacific Coast (Diekema et al., 2001). The incidence of S. aureus related 
infections has increased dramatically since the emergence of methicillin resistant 
strains and high rates of mortality and morbidity are occurring world-wide (Oliveira et 
al., 2002). Combined with the increasing problem of multiple antibiotic resistances, 
these numbers underline the high social and economic burden of this fastidious 
pathogen.  
 
1.4.1 S. aureus infections: from harmless to life-threatening 
 
Staphylococcus aureus causes a wide variety of infections (Fig.1.5), most of which 
are localized to the skin and are nonfatal. The bacterium produces many superficial 
skin and soft infections such as hair, impetigo, follicles (Hisata et al., 2011). It also 
causes boils, which are deeper pus-filled abscesses of the skin and underlying tissue. 
Colonization of the anterior nares with S. aureus has been shown to be a risk factor 
for invasive infection. It is the second leading cause of hospital-acquired pneumonia. 
It can cause meningitis usually as a result of infection after brain surgery or as a 
consequence of a S. aureus infection in the blood. S. aureus also causes a painful 
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infection of joint fluid 
deep-seated infections such as osteomyelitis and an infection of the heart valves called 
endocarditis (Miller and Kaplan, 2009)
condition resulting in significant morbidity and health care costs and it is notoriously 
difficult to treat (Tuzuner
these surgical wound infections. Deeper wound infections are much more serious and 
almost always require additional surgery to remove infected tissue.
infections often occur in patients who have a surgical wound or are receiving 
intravenous (IV) medications or supplements, in people undergoing dialysis for 
kidney failure, in diabetics 
Fig.1.5 Common sites of infection and diseases 
 
1.5 Antibiotic misuse and the emergence of resistance
 
The appropriate use of antibiotics is one of 
disease. Hence, interventions need to target inappropriate patterns of use, specifically 
those that have contributed most significantly to the development of resistance 
(Lubelchek and Weinstein 2008). 
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1.5.1 Antibiotics 
 
The tendency for antibiotic use to support the emergence of resistant pathogens is 
called antibiotic pressure and there are several reports of resistance rising during 
increased antibiotic use and falling after a reduction in use (McGowan, 1983). Over 
the past 6 decades, bacterial populations have responded to the selective pressure of 
antimicrobial drugs by evolving resistance to all commercially available antimicrobial 
agents (Levin, 2001). Decreased discovery rates of novel classes of antimicrobial 
agents have substantiated a notion that, for some bacterial species, we might face 
clinical infections for which there are no treatment options (Projan and Bradford, 
2007). Treatment options for both outpatient management of mild soft tissue infection 
and inpatient management of severe infection are limited because of increasing rate of 
antimicrobial resistance (Patel et al., 2012) and this antimicrobial resistance has a 
significant negative impact on the outcome of therapy and increases the risk factor of 
cross-infection in hospitals. Resistance leads to inappropriate empirical therapy, delay 
in starting effective treatment and the use of less effective, more toxic and more 
expensive drugs (French, 2005). MRSA is at present one of the most commonly 
identified antibiotic-resistant pathogens in many parts of the world, including Europe, 
the Americas, North Africa, the Middle East and East Asia (Diekema et al., 2001). 
The emergence of MRSA organisms with reduced susceptibility to several antibiotics 
is a serious and ongoing concern. MRSA will continue to evolve, hence the absolute 
necessity to control it before it really does get out of hand. Therefore, action must be 
taken to reduce this problem. The ultimate goal is to offer appropriate and efficient 
antimicrobial drugs to the patient.  
 
1.5.2 Mechanisms of antibiotic resistance 
 
Resistance can be caused by a variety of mechanisms: (i) the presence of an enzyme 
that inactivates the antimicrobial agent; (ii) the presence of an alternative enzyme for 
the enzyme that is inhibited by the antimicrobial agent; (iii) a mutation in the 
antimicrobial agent’s target that reduces the binding of the antimicrobial agent; (iv) 
post-transcriptional or post-translational modification of the antimicrobial agent’s 
target that reduces binding of the antimicrobial agent; (v) reduced uptake of the 
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antimicrobial agent; (vi) active efflux of the antimicrobial agent; and (vii) over 
production of the target of the antimicrobial agent (Fluit et al., 2001; Chanda et al., 
2010). 
 
1.5.3 Mechanisms of methicillin resistance  
 
Since their first appearance in clinical specimens in the early 1960s, MRSA strains 
spread globally and by the mid-1980s they emerged as the most important nosocomial 
pathogens worldwide (Beck et al., 1986). Methicillin is a β-lactam antimicrobial 
which binds penicillin-binding proteins in the cell envelope and prevents cross-linking 
of the peptidoglycan (PG) chains in the cell wall. S. aureus renders methicillin 
ineffective by the production of an alternative PBP (PBP2a) that has reduced affinity 
for β-lactams (Utsui and Yokota, 1985). Resistant to β-lactam antibiotics is due to 
acquisition of the exogenous gene mecA, that is incorporated into a large segment of 
DNA called SCCmec that was first described by Katayama and co-workers in 2000 
and which encodes for the PBP2a (Katayama et al., 2000). 
 
1.6 Natural plants as antibacterial agent 
 
The increase in prevalence of multiple drug resistance has slowed down the 
development of new synthetic antimicrobial drugs and has necessitated the search for 
new antimicrobials from alternative sources. In general, bacteria have the genetic 
ability to transmit and acquire resistance to drugs used as therapeutic agents. One way 
to prevent antibiotic resistance is by using new compounds which are not based on the 
existing synthetic antimicrobial agents (Shah, 2005). Nature has served as a rich 
repository of medicinal plants for thousands of years and an impressive number of 
modern drugs have been isolated from natural sources, notably of plant origin 
(Cowan, 1999). Herbal medicine, based on their traditional uses in the form of 
powders, liquids or mixtures, has been the basis of treatment of various ailments in 
India since ancient times.  The use of herbs as complementary and alternative 
medicine has increased dramatically in the last 20-25 years (Rios and Recio, 2005). 
Screening active compounds from plants has lead to the discovery of new medicinal 
drugs which have efficient protection and treatment roles against various diseases, 
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including cancer (Sheeja and Kuttan, 2007) and Alzheimer’s disease (Mukherjee et 
al., 2007). Development of newer anti-infective and therapeutic regimes that revert or 
overcome drug resistance is the need of the hour (Usman and Osuji, 2007). Sixty 
percent of the world population and 80% of the population in developing countries 
rely on traditional medicine for curing many diseases (Kaur and Arora, 2009). 
Furthermore, most studies on the antimicrobial activity of plant extracts have been 
restricted to analysis of their bacteriostatic and bactericidal properties. Investigations 
into the antipathogenic potential of natural products may open new avenues for drug 
development in the control of antibiotic resistant pathogens (Quave et al., 2008). 
Natural products play a major role from ancient civilizations to the current 21th 
century and more than half of the drugs in the market are natural products or their 
derivatives. Pharmaceutical industries are giving importance to the compounds 
derived from traditional sources. Only a small percent of plants have been 
investigated for their bioactivity. Phytochemicals from medicinal plants showing 
antimicrobial activities have the potential of filling this need, because their structures 
are different from those of the more studied microbial sources, and therefore their 
mode of action may too very likely differ. The screening of plant extracts and plant 
products for antimicrobial activity has shown that plants represent a potential source 
of new anti-infective agents (Chanda and Baravalia, 2010; Pereira et al., 2011). 
Sometimes the use of single antibiotic or plant extract does not produce the desired or 
the effective inhibitory effects and to overcome this, combination of plant extract and 
drugs often exercise their synergistic effect which surpasses their individual 
performance.  
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1.6.1 Plants selected for anti
 
1.6.1.1 Polyalthia longifolia
 
Many bioactive natural products of 
2000). Polyalthia longifolia
a tall, ornamental, evergreen tree. Different parts of this plant have been reported by 
many authors for their medicinal uses 
activities have been studied
antibacterial, cytotoxicity, anti
ulcer, anti-leishmanial, anti
al., 2005; Ichino et al., 2006
efficacy of secondary metabolites of this plant 
2006; Faizi et al., 2008).
1.6.1.2 Mesua ferrea Linn
 
One of the well known plants in Ayurveda is 
the subcanopy of moist tropical and subtropical forests in India (Latif Khan 
1999).  Different parts of this plant are used in the preparation of cosmetics and 
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 (Sonn.) Thw. var. pendula 
Name:  Polyalthia longifolia 
pendula 
Family: Annonaceae 
Vernacular Name: ‘Ulta Ashoka’
Traditional uses: Fever, skin diseases, diabetes, 
hypertension and helminthiasis.
Polyalthia genus have been found (Chen 
 is commonly cultivated all over India and Sri Lanka. It is 
(Nair et al., 2007). Different biological 
 of extracts/isolated compounds of 
-fungal, anti-inflammatory, hepatoprotective, anti
-malarial etc. (Marthanda Murthy et al., 2005; Stévigny 
; Nair and Chanda, 2006; Misra et al.,
has also been studied (Chang 
  
.  
 
Name:  Mesua ferrea Linn
Family:  Guttiferrea  
Vernacular Name: Nagkeshar
Traditional uses: Asthma, cough, fever, 
itching, nausea, leprosy, skin disorders, 
erysipelas, mental disorders, bleeding 
piles, metrorrhagea, menorrhagea, 
excessive thirst, and sweating.
Mesua ferrea, which grows naturally in 
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-
et 
 2010). Anticancer 
et al., 
.  
 
 
et al., 
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unguents. Phytochemical analysis of various parts of the plant showed the occurrence 
of xanthones, coumarins, biflavones, cyclohexanedione derivatives, and an essential 
oil (Dennis and Akshaya Kumar, 1998). Studie
this plant showed it to be a potential agent as anticancer (Mahavorasirikul 
2010), antimicrobial (Parekh and Chanda, 2008; Konwarh 
(Yadav and Bhatnagar, 2010)
externally for poulticing wounds and all forms of skin eruptions (Perry and Metzger, 
1980).  
 
1.6.1.3 Rosa chinensis 
For centuries, roses have occupied a prominent place in the world of horticulture due 
to their distinctive shape and charming floral scents. Crosses involving just seven or 
eight of the more than 120 species of the genus 
than 35,000 rose cultivars and today roses are among the most important ornamental 
plants worldwide. (Channelière 
reported for its medicinal properties like 
(Tripathi and Dixit, 1977), antibacterial (
1.6.1.4 Callistemone lanceolatus
Callistemone lanceolatus 
and tropical regions (simpson, 2006). 
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s of different biological activities of 
et al., 2010), antioxidant 
, etc. The pounded kernels of the seeds are applied 
Jacq. 
 
Name: Rosa chinensis Jacq. 
Family:  Rosaceae  
Vernacular name: Kaantaa-
Traditional uses: wounds, injuries, sprains and 
foul ulcers. 
 
Rosa have led to the creation of mo
et al., 2002). Flower of this plant has also been 
antioxidant (Cai et al., 2005), antifungal 
Abu-Shanab et al., 2006) etc. 
 D.C.  
 
Name: Callistemone lanceolatus
Family: Myrataceae  
Vernacular Name: Bottle brush
Traditional uses: Anti
inflammatory, fungitoxic, antinociceptive 
activity. 
is native to Australia and is widely distributed in subtropical 
It is a stiff, upright shrub characterized by red 
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flower. Previous investigation has shown that essential oil of the leaves of this plant 
possesses antimicrobial and fungitoxic activity (Sudhakar and Raju, 2005). 
Furthermore several triterpenoids, flavonoids, fatty acids, tannin and phenolic 
compounds have been i
2008). It is also reported as 
(Dutta et al., 2007) and anti
1.6.1.5 Terminalia chebula
Terminalia well known for its medicinal properties is a genus of mostly deciduous 
trees. Different species of 
al., 2011). Terminalia
various ailments. ‘Triphala’ a combination of 
officinalis is extensively used in Indian System of Medicine for treating different 
kinds of diseases and to promote health, immunity and longevity 
Dried ripe fruit of T. chebula
Asia. T. chebula has been reported to exhibit a variety of biological activities
antimicrobial (Aqil et al
(Badmaev and Nowakowski, 2000), antioxidant (Lee 
(Arora et al., 2003), 
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solated from its leaves (Mahmoud et al
anti-thrombin (Chistokhodova et al., 2002), 
-inflammatory (Kumar et al., 2011) agent. 
 Retz. and Terminalia bellerica Roxb. 
 
Name: Terminalia chebula Retz
Family: Combretaceae 
Vernacular name: Harade 
Traditional uses: Antibacterial, antifungal, urinary tract 
infection, flatulence, constipation, diarrhea, dysentery, 
cyst, digestive disorders, vomiting, enlarged liver and 
spleen, cough and bronchial asthma, diuretic.
 
 
Name: Terminalia bellerica 
Family: Combretaceae 
Vernacular name: Baheda 
Traditional uses: Coughs, dropsy, piles, diarrhea, 
leprosy, fever 
 
Terminalia are found in most of the Indian forest (
 species have been frequently used as medicinal food to treat 
T. chebula, T. bellerica
(Kumar 
 has been traditionally used to treat various ailments in 
., 2005), antifungal (Vonshak et al
et al., 2007), 
antianaphylactic (Shin et al., 2001), anticaries (Jagtap and 
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anti-candidial 
 
. 
 
Roxb. 
Sarwat et 
 and Emblica 
et al., 2008). 
, like 
., 2003), antiviral 
antimutagenic 
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Karkera, 1999) antidiabetic (Gao et al., 2008) and anti-HIV (Ahn et al., 2002). T. 
bellerica is also reported for its several pharmacological activities including anti-
bacterial (Aqil and Ahmad, 2007), anti-oxidant (Bajpai et al., 2005), anti-mutagenic 
(Padam et al., 1996), anticancer (Kaur et al., 2005), anti-malarial, anti-fungal and 
anti-HIV (Valsaraj et al., 1997).  
 
1.6.1.6 Nelumbo nucifera Gaertn. 
 
Name: Nelumbo nucifera Gaertn. 
Family: Nymphaeaceae 
Vernacular name: Lotus 
Traditional uses: Anti-inflammatory, 
anticancer, antiemetic, antiviral, antiobesity 
remedies, hematemesis, eczema, stomach 
troubles, pharyngopathy, pectoralgia, 
leucoderma, strangury, dysentery, cough, 
haematemesis, skin diseases, diabetes, 
dyspepsia, piles and anticoagulant 
 
Nelumbo nucifera Gaertner (Nymphaeaceae), commonly known as lotus, is a 
perennial aquatic plant grown and consumed all over the world, especially in India 
and South East Asia (Mabberley, 1995). This species can be propagated both by 
sexual (seeds) and asexual (rhizomes) reproduction. The lotus flower is bowl shaped 
and nectarless with an obvious cantharophily syndrome (i.e. beetle pollinated), having 
a large chamber enclosed by petals and a large number of stamens, and releases 
odours (Li and Huang, 2009). Almost all parts of the plant may be eaten as a 
vegetable and it is also used for various medicinal purposes in oriental medicine (Jung 
et al., 2008). N. nucifera Gaertn is reported to be a potential agents as antidiarrhoeal 
(Mukherjee et al., 1995), diuretic (Mukherjee et al., 1996), antipyretic (Sinha et al., 
2000), antimicrobial (Mukherjee, 2002), anti-inflammation and hypoglycaemic effect 
(Mukherjee et al., 1997; Liu et al., 2006), Antiobesity and hypolipidemic effects (Ono 
et al., 2006; Huang et al., 2011) and antioxidant activity (Yen et al., 2006; Vinodhini, 
2010).  
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Considering the above, the objectives set forth are: 
 
 Review of literature  
 Review of literature of anti-staphylococcal antibiotics  
 Review of literature of plants: an alternative source for anti-
staphylococcal activity  
 Isolation of Staphylococcus strains from different clinical samples 
 Characterization of Staphylococcus strains using conventional methods 
 Biochemical identification test 
 Antibiotic susceptibility pattern 
 Minimum Inhibitory Concentrations (MICs) 
 Characterization of Staphylococcus strains using molecular methods  
 Identification of mecA gene using PCR 
 Sequences analysis of mecA gene 
 Sequences analysis of the 16S rRNA 
 Antibacterial activity of some plant extracts against MRSA  
 Screening of some plant extracts for antibacterial activity  
 MIC and MBC studies of selected plant extracts 
 Synergistic activity of plant extracts and antibiotic  
 Pearson’s correlation analysis  
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
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2.1 Staphylococcus aureus resistance to antibiotics: Growing global public health 
threat 
 
Antibiotic resistance has become a major public health problem on a global scale. The 
tendency to use antibiotics that promote the emergence of resistant pathogens is called 
antibiotic pressure, and there are many reports of resistance rising during increased 
antibiotic use and falling after a reduction in use (McGowan, 1983). For example 
serious infections due to staphylococci were curable with the discovery of penicillin, 
but after decades of misuse and over prescription of antibiotics created resistant to 
penicillin. S. aureus was a consequence of the acquisition of a plasmid, coding for 
penicillinase, a penicillin-hydrolyzing enzyme, which is able to cleave the β-lactam 
ring and thus inactivate antibiotic molecule (Turlej et al., 2011). After that methicillin 
was used to treat infections caused by S. aureus, which was also became resistant to 
methicillin after some time (Boyce et al., 1997). The worldwide increase of 
methicillin-resistant Staphylococcus aureus and the more recent emergence of 
vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus strains had a 
major impact on antibiotic policies and prompted an active reaction from the 
pharmaceutical industry concerning the discovery and development of new antibiotics 
to combat these strains (Cornaglia and Rossolini, 2009).  
 
2.2 Molecular and genetic factors predisposing to antimicrobial resistance in 
MRSA 
 
It is now recognized that coding for methicillin resistance in MRSA is facilitated by 
the mecA gene, which is located on the staphylococcal cassette chromosome (SCC), a 
large mobile genetic element which differs in size and genetic composition from other 
strains of MRSA. The mechanism of resistance involves changes or defects brought 
about by mutation on mecA gene which result in modification to 78-kDa penicillin 
binding protein 2a, which has a reduced affinity for β-lactam antibiotics that is able to 
mediate essential cell wall construction when β-lactam-susceptible PBPs have been 
inactivated (Hartman and Tomasz, 1986). The result of the event is that it renders the 
organism resistant to β-lactams and other antibiotics with a similar target site. In 
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addition, other antibiotic resistant genes may be present in the cassette thus conferring 
multiple-resistance to other antibiotics on the organism, (Ito et al., 2001). Apart from 
the inability of an antibiotic to bind to the target site due to structural defect of such 
site, other mechanisms that may usually play significant roles in the development of 
resistance in bacteria such as MRSA include efflux phenomenon resulting in 
continuous pumping of antimicrobial drugs out of the bacterial cell. Others are 
alteration in the outer-membrane proteins which limit the access of drugs to the cell; 
resistance can also occur from high level production of β lactamase (Hackbart et al., 
1995).  MRSA is produced when MSSA acquires a genetic element called SCCmec. 
SCC is a basic mobile genetic element that serves as the vehicle for gene exchange 
among staphylococcal species; it has been documented in some coagulase-negative 
staphylococci as well as in S. aureus (Luong et al., 2002).  
 
2.3 The impact of antimicrobial resistance 
 
Antimicrobial resistance has a significant negative impact on the outcome of therapy 
and increases the risk of cross-infection in hospitals. Resistance leads to improper 
empirical therapy, poor hygiene practice and the use of less effective, more toxic and 
more expensive drugs (Kollef, 2000) and this produced serious problems by the early 
1990s prompting several authorities to publish serious warnings of impending disaster 
in major international journals, with titles such as: ‘The crisis in antibiotic resistance’ 
(Neu, 1992), ‘Resistance to antimicrobial drugs – a worldwide calamity’ (Kunin, 
1993). 
2.4 Antibiotics for the treatment of MRSA 
 
2.4.1 β-lactams   
 
Under increased discriminating pressure, S. aureus developed multiple mechanisms of 
resistance to modified penicillins, including methicillin (Fig. 2.1). Although 
methicillin is resistant to hydrolysis by small quantities of staphylococcal β-
lactamase, strains of S. aureus have been isolated that are competent of producing 
Chapter 2: Review of literature
large amount of β-lactamase. These hyperproducers of β
methicillin through limited hydrolysis of the antibiotic, resulting in a phenotype that
with deference to methicillin is intermediate between susceptib
(McDougal and Thornsberry
methicillin by S. aureus
PBPs. S. aureus expresses at least four different PBPs, designated PBP1, 2,
that are the targets of  β
proteins that catalyze the transpeptidation reaction and attached to the cytoplasmic
membrane that cross-links the peptidoglycan of the bacterial cell wall; ther
binding of β-lactam antibiotics to PBPs leads to a lethal event. Low level resistance to
β-lactam antibiotics can be due to either a decrease in the binding affinities of PBPs
for penicillins, an increase in the production of PBPs or both. Isolat
PBP2a-mediated resistance mechanism are clinically resistant to all available β
lactams, including penicillins, β
cephalosporins, carbapenems and monobactams (Fasola
Penicillin
Methicillin
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2.4.1.1 β -lactam–β-lactamase
The β-Lactam–β-Lactamase inhibitor combinations (amoxicillin
available in oral formulation
ticarcillin-clavulanate [IV]; and piperacillin
effective against MSSA, but not MRSA, and are
Gram-negative bacilli
treatment of polymicrobial infections including MSSA, such as complicated SSTI
(Chambers, 2005).
Amoxicillin
Fig. 2.2 Structures of
2.4.2 Clindamycin
The lincosamide class of clindamycin
treatment of skin infections.
cocci, including MRSA.
associated with MRSA that are identified in the community.
23S ribosomal RNA in the 50S subunit of the ribosome
translocation of RNA during protein synthesis and blocks initiation of polypeptide
formation. Lincosamides are bacteriostatic but can be bactericidal against highly
susceptible bacteria (Le and Lieberman
clindamycin is more widely used to treat staphylococcal infections. It has specific use
in the treatment of patients with hypersensitivity to penicillins in the community and
is also used to treat serious infections because it blocks prote
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inhibitor combinations
in the United States; ampicillin
-tazobactam [IV]) (Fig. 2.2)
effective against anaerobes and
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coagulase-negative staphylococci, particularly nosocomial isolates, are resistant to 
clindamycin antibiotic (Biedenbach et al., 2007). The most common adverse reaction 
caused by clindamycin involves mainly the gastrointestinal system. Antibiotic-
associated diarrhea is not uncommon in patients receiving clindamycin, and in a 
subset of those patients is caused by the overgrowth of toxogenic Clostridium 
difficile, resulting in antibiotic- associated colitis with pseudomembrane formation. 
Clindamycin causes comparatively fewer significant drug interactions, but may 
potentiate neuromuscular blocking agents and may reduce the levels of cyclosporine 
(Thurnheer et al., 1999). Clindamycin may be administered orally, intramuscularly or 
parenterally. The dosing of clindamycin for CA-MRSA in children is dependent on 
the severity of the infection. For mild infections like cellulitis, the dosing is 30 
mg/kg/day by mouth, every 6 to 8 hours. For severe infections such as osteomyelitis, 
the dosing is 40 mg/kg/day, administered intravenously, and proportionately divided 
every 6 to 8 hours (Martinez-Aguilar et al., 2003). Common adverse effects of 
clindamycin include nausea and abdominal pain. The standard oral preparation is 
clindamycin hydrochloride, which may be given in doses ranging from 150 to 450 mg 
every 6 hours. Another oral preparation of clindamycin is a palmitate ester 
suspension. Oral preparations are absorbed fast and have approximately 90% 
bioavailability. For intravenous delivery, 600 to 900 mg of clindamycin phosphate is 
infused every 6 to 8 hours. This preparation may also be administered intramuscularly 
in doses as high as 600 mg. This drug penetrates most tissues and fluids except 
cerebrospinal fluid (Enoch et al., 2009). SSTI caused by S. aureus are often treatable 
with clindamycin. Because of its effectiveness against predominant clones of CA-
MRSA in some geographic locales, clindamycin has been used for empiric and 
directed treatment of SSTI, because of its cell-wall active agent, to stop toxin 
production in patients with infections caused by toxin-producing strain of S. aureus 
(Stryjewski and chamber, 2008). Detection of clindamycin resistance is very 
important in CA-MRSA because clindamycin is one of the antibiotics recommended 
to treat CA-MRSA infections, particularly in pediatric infections (Katopodis et al., 
2010).  
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(gyrA and gyrB) and topoisomeraseIV (
Resistance is usually related
may be associated with this cla
liver enzymes, cardiac conduction disturbances, hyperglycemia or hypoglycemia and
drug rashes (Hooper and Wolfson
include norfloxacin, ofloxacin, ciproflox
gemifloxacin but rapid development of ciprofloxacin resistance has been
demonstrated among clinical
1991).
2.4.4 Trimethoprim/Sulfamethoxazole
Trimethoprim/Sulfamethoxazole (TMP/SMX) is a combination of trimethoprim (Fig
2.5), a diaminopyrimidine, and sulfamethoxazole (Fig
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widely used as low-cost antibacterial agent for the treatment of community-acquired
non-serious MRSA infections as well as other infections such as urinary tract
infections. It is also used in combination with agents such as rifampicin and the
topical antibiotic mupirocin to eradicate MRSA colonization in patients. TMP/SMX is
bactericidal agent against S. aureus and inhibits bacterial replication (Kaka et al.,
2006). Clinicians have used TMP/SMX in the past as an alternative to penicillins or
vancomycin in the treatment of S. aureus infection and colonization. Although TMP-
SMX has demonstrated fair clinical efficacy against MRSA, it is not commonly used
to treat serious MRSA infections. TMP/SMX is well tolerated, but sulfonamides can
create a variety of untoward effects that are due partly to allergy and partly to direct
toxicity.
Fig. 2.5 Structure of Trimethoprim Fig. 2.6 Structure of Sulfamethoxazole
2.4.5 Rifampicin
Rifamycin (Fig. 2.7) inhibits only transcription and subsequent translation to proteins.
Its mechanism of antibacterial action involves the inhibition of a single target enzyme
the β-subunit of RNA polymerase (Wehrli, 1983). It binds RNA polymerase and 
prevents synthesis of RNA. Rifampicin is used primarily as adjunctive (i.e.
combination) therapy in difficult-to-treat staphylococcal infections, including MRSA
infections. Because it is highly bioavailable, rifampicin can be administered orally.
However, this antibiotic is rarely used as a single agent to treat CA-MRSA because
rapid resistance can emerge among S. aureus on exposure to this drug. It is used for
synergy with other antibiotics like fusidic acid (Jensen, 1968). Rifampicin has been
shown to be highly effective in eradicating staphylococcal infections related with
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foreign bodies (Widmer et al., 1990). Resistance to rifampicin occurs by mutations in 
the rpoB gene and single mutations in S. aureus selected in vitro and in vivo have 
been associated with both low and high levels of resistance depending on the nature of 
the amino acid change. Some clinical isolates of both Staphylococcus aureus and 
Streptococcus pneumoniae have been found to carry multiple mutations in the cluster 
regions (Padayachee and Klugman, 1999). Common adverse effects of this antibiotic 
include vomiting, anorexia, and abnormal pain. Rifampicin can cause discoloration of 
body fluids, such as urine, sweat, saliva, and tears. A rare but possible serious adverse 
effect associated with rifampicin is hepatotoxicity. 
 
 
Fig. 2.7 Structure of Rifampicin 
 
2.4.6 Tigecycline  
 
Tigecycline (Fig. 2.8) is the first clinically available drug in a new class of antibiotics 
called the glycylcyclines, which are structurally parallel to the tetracyclines in that 
they contain a central four-ring carbocyclic skeleton. Tigecycline antibiotic has a 
substitution at the D-9 position, which is believed to confer broad spectrum activity 
(Entenza and Moreillon, 2009). Tigecycline targets the bacterial ribosome and is a 
bacteriostatic agent. Tigecycline is effective against highly resistant gram-positive 
bacteria, including methicillin-resistant S. aureus and penicillin-resistant S. 
pneumoniae, as well as being effective against a variety of gram-negative bacteria, 
including those possessing extended-spectrum β-lactamase plasmids (Livermore, 
2005).  
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Fig. 2.8 Structure of Tigecycline 
2.4.7 Vancomycin  
 
More than 95% of patients with S. aureus infections worldwide do not respond to 
first-line antibiotics such as penicillin or ampicillin (Rubin et al., 1999). Many multi-
resistant MRSA strains are currently susceptible only to a single class of clinically 
available bactericidal antibiotic, the glycopeptides such as vancomycin (Fig. 2.9). 
However, if resistance to these agents emerges, some staphylococcal infections could 
be untreatable (Sieradzki et al., 1999). Vancomycin was first discovered in 1956 in 
some soil samples from Southeast Asia, where it was produced by an actinomycete, 
Streptococcus orientalis (Rolston et al., 1990). It is not absorbed in the 
gastrointestinal tract in clinically relevant concentrations and hence it must be used as 
a parenteral agent for systemic infections. It binds to the C-terminal end of late 
peptidoglycan precursors, preventing the effective formation of a bacterial cell wall. 
Its actions against bacteria are carried out on the outer surface of the bacterial cell 
membrane, as it cannot penetrate the cytoplasm. Thus, vancomycin depends upon the 
bacterial translocation of the cell wall precursors onto the outer surface of the 
microbial membrane. Because vancomycin is effective against cell wall synthesis, it is 
active only against gram-positive organisms. Gram-positive organisms stain as they 
do because of the presence of the peptidoglycan cell wall. Gram-negative organisms 
do not have such a cell wall and are thus unaffected by vancomycin (Reed, 2007). 
Vancomycin remains the standard treatment for serious MRSA infections and serious 
MSSA infections in patients with β-lactam allergies. Its label notes the effectiveness 
of vancomycin in the treatment of staphylococcal endocarditis and other indications 
including bone infections, septicemia, skin and skin structure infections and lower 
respiratory tract infections. The most commonly seen adverse effect of this antibiotic 
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is ‘‘Red Man Syndrome.’’ Patients with this syndrome can present flushing, red neck,
pruritus and rash involving the majority of the body (Savignon-Marinho et al., 2011).
‘‘Red Man Syndrome’’ is caused by an infusion-related release of histamine.
Additional possible adverse effects related with vancomycin include nephrotoxicity
and ototoxicity. Nephrotoxicity is not that common unless vancomycin is co-
administered with other nephrotoxic agents such as gentamicin. Ototoxicity may
occur only when the serum concentration of the antibiotic is extremely high. Even
though vancomycin is a potent antibiotic against CA-MRSA, more and more
resistance has surfaced. The first case of vancomycin-intermediate S. aureus (VISA)
was reported in 1996 (Ward et al., 2001). After more than 40 years of clinical use,
vancomycin-resistant S. aureus (VRSA) was first identified in Detroit, Michigan in
2002, mediated by the vanA gene complex acquired from vancomycin-resistant
enterococci (CDC, 2002); its mechanism relies on inhibiting cell wall synthesis. VISA
exhibits thickened peptidoglycan cell wall structures, differing from VRSA (Sakoulas
and Moellering, 2008).
Fig. 2.9 Structure of Vancomycin
2.4.8 Linezolid
Linezolid (Fig. 2.10) is a synthetic oxazolidinone class of antimicrobial agent that
binds to the ribosome and inhibits microbial protein synthesis (Champney and Miller,
2002). The antibiotic reversibly blocks the formation of protein synthesis initiation
complexes by binding to the 23S ribosomal RNA of the 50S ribosomal subunit, near
the interface formed with the 30S ribosomal subunit (Hutchinson, 2003). In vitro
studies have confirmed that linezolid is very effective against most medically
Chapter 2: Review of literature      Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
 
 
Page | 38  
 
important Gram-positive bacteria, including activity against MRSA and S. aureus 
with intermediate resistance to glycopeptides (Mutnick et al., 2002) and achieves 
better tissue penetration than vancomycin, but is bacteriostatic rather than 
bactericidal. Linezolid is approved in Europe and the USA for the treatment of 
complicated skin and skin-structure infections (cSSSIs) as well as hospital-acquired 
and community-acquired pneumonia. Linezolid is an extremely useful but expensive 
antistaphylococcal agent. It remains effective against most S. aureus isolates and 
because of its excellent bioavailability; the option of oral treatment is very appealing 
and can diminish length of hospital stay (Falagas et al., 2008). Headache, nausea and 
thrombocytopenia are the main side effects, the latter usually occurring about two 
weeks into therapy. Disadvantages include expense, hematologic side effects, and 
potential for resistance among S. aureus strains (Peeters and Sarria, 2005). 
 
                                                  
Fig. 2.10 Structure of Linezolid 
 
2.4.9 Daptomycin 
 
Daptomycin (Fig. 2.11) is a cyclic lipopeptide group in clinical use and approved for 
the treatment of complicated skin and skin structure infections and right-sided 
endocarditis. This agent was developed in the early 1980s, but was initially 
abandoned because of concerns about skeletal muscle toxicity. Daptomycin is 
effective in vitro against staphylococci and other gram-positive bacteria (Eisenstein, 
2004). It offers enhanced activity against resistant hospital pathogens such as MRSA. 
Its mechanism of action suggests that daptomycin causes a calcium-dependent rupture 
of the bacterial cell membrane, resulting in a net efflux of potassium that inhibits 
DNA, RNA, and protein synthesis. Daptomycin has rapid bactericidal activity without 
cell lysis, a feature that could reduce the release of bacterial molecules and lessen the 
inflammatory response (Fenton et al., 2004). It is effective at all growth phases, 
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MRSA but not against vancomycin-resistant enterococci (Jones et al., 2006). The
dosage of dalbavancin is 1000 mg, initially intravenously, and 500 mg 7 days later.
Dalbavancin is more potent than Oritavanacin. Infected patients who received weekly
dalbavancin had an overall success rate that was significantly higher than that of those
who received other antibiotics like vancomycin (Raad et al., 2005). Clinical trials
indicate that dalbavancin is a safe, well-tolerated and effective antimicrobial agent. In
the largest investigation evaluating dalbavancin for the treatment of complicated skin
and skin-structure infections, it appeared to be as effective as linezolid (Bennett et al.,
2008).
Fig. 2.12 Structure of Dalbavancin
2.4.11 Telavancin
Telavancin (Fig. 2.13) is another in the line of second generation semi-synthetic
lipoglycopeptide group antibiotics that has a double mechanism of action. First, it
inhibits peptidoglycan chain formation, blocking both trans-glycosylation and trans-
peptidation. Second, telavancin alters membrane potential and increases cellular
permeability (Leonard and Rybak, 2008). Telavancin has a high proportion of protein
binding (93%), a high volume of tissue distribution and a half-life of 7–9 h (Barrett,
2005). An interesting and potentially important finding was that telavancin was active
in an in vitro biofilm model where vancomycin and a number of other antibiotics were
much less effective (Gander et al., 2005). Telavancin is rapidly bactericidal against
staphylococci including VISA, and glycopeptide tolerant strains, and is bactericidal
for enterococci in contrast to vancomycin (Rubinstein et al., 2011). The drug will be
available only in parenteral form, probably for daily administration.
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Fig. 2.13 Structure of Telavancin 
 
2.4.12 Oritavancin  
 
Oritavancin (Fig. 2.14) is another second-generation glycopeptides group antibiotic 
(Mercier and Hrebickova, 2005). It inhibits peptidoglycan biosynthesis at the same 
site as vancomycin (trans-glycosylation), but also forms dimers with higher affinity 
and at lower concentrations than vancomycin. The drug may also act as an inhibitor of 
the transglycosylase enzyme. The activity of oritavancin against vancomycin-resistant 
organisms is owing to its ability to dimerize, allowing more favorable interactions 
with the bacterial peptidoglycan chain. In addition, it inhibits cell wall formation by 
blocking the trans-glycosylation step in peptidoglycan biosynthesis (Allen and Nicas, 
2003). Oritavancin has a spectrum of in vitro activity parallel to that of vancomycin, 
but is effective against VanA, VanB and VanC Enterococcus and is completely 
effective against MRSA, including some VRSA strains (Poulakou and Giamarellou, 
2008). Oritavancin is administered intravenously and is excreted slowly in urine and 
faeces. It accumulates in tissues and macrophages, and has an extremely long terminal 
half-life that permits once-daily dosing (Fetterly et al., 2005). 
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Fig. 2.14 Structure of Oritavancin
2.4.13 Ceftobiprole
Methicillin-resistant Staphylococcus aureus was cross-resistant to all other β-lactam 
drugs but a number of other new β-lactam agents are undergoing clinical trials, and 
will soon be added to the therapeutic armoury for MRSA infections. This drug looks
extremely promising, especially as empiric therapy against both hospital and
community acquired pathogens (Bogdanovich et al., 2005). Ceftobiprole (Fig. 2.15) is
a fourth-generation cephalosporin administered intravenously, with activities against
MRSA. It is characterized by a strong affinity for penicillin-binding protein PBP2a
and PBP2x, which are responsible for resistance in Staphylococcus spp. and
Streptococcus pneumoniae. It is active against gram-negative bacteria, including a
high proportion of Pseudomonas aeruginosa strains and gram-positive bacteria,
including MRSA (Zhanel et al., 2008). The terminal elimination half-life is 3 h and
the predominant mechanism responsible for elimination is glomerular filtration. It
does not significantly induce or inhibit relevant cytochrome P450 enzymes and is
neither a substrate for nor an inhibitor of P-glycoprotein (Murthy and Schmitt-
Hoffmann, 2008).
Fig. 2.15 Structure of Ceftobiprol
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Table 2.1 Anti-staphylococcal antibiotics, mechanism of action and mechanism of resistance
Antibiotic Class Antibiotics Site of action Mechanism of resistance Acquisition
Cell-wall biosynthesis inhibitors
Beta-lactam Oxacillin Binding to specific penicillin-bindingproteins (PBPs) (Bobba et al., 2011)
Altered PBP (mecA) (Severin et
al., 2004) CA-MRSA
Glycopeptide Vancomycin
C-terminal D-alanine-D-alanine residue of
the pentapeptide cell wall building block
(Barna and Williams, 1984)
Mutation and thickening of cell
wall due to accumulation of
excess amounts of peptidoglycan
(Hiramatsu, 2001)
HA-MRSA
Transcription inhibitors
Rifamycin Rifampicin Inhibiting DNA-dependent RNApolymerase (Wehrli, 1983)
Alterations in the target leading to
a reduced
affinity of the enzyme for the
antibiotic (Morrow and Harmon,
1979)
CA-MRSA
DNA inhibitors
Flouroquinolone Ciprofloxacin
Bacterial DNA gyrase (gyrA and gyrB)
and
Topoisomerase IV (parC and parE)
(Hooper et al., 1987)
Point mutations in the gyr or par
loci (Tankovic et al., 1996) CA-MRSA
Protein synthesis inhibitors
Lincosamide Clindamycin 50s ribosome subunit of the bacteria(Kehrenberg et al., 2005)
Ribosomal target modification
(Fiebelkorn et al., 2003) CA-MRSA
Oxazolidinone Linezolid 23S ribosomal RNA of the 50S ribosomalsubunit (Shinabarger, 1999)
mutations in more than one copy
of the 23S rRNA gene (Meka et
al., 2004)
CA-MRSA and
HA-MRSA
Cont…
Chapter 2: Review of literature Ph.D. Thesis | Harsha Patel | January, 2012
Saurashtra University | Sub: Microbiology
Page | 44
Antibiotic Class Antibiotics Site of action Mechanism of resistance Acquisition
Glycylcycline Tigecycline
30S ribosomal subunit of bacteria and
blocks entry of amino-acyl transfer RNA
into the A site of the ribosome. (Slover et
al., 2007)
Unknown HA-MRSA
Membrane alteration
Lipopeptide Daptomycin Calcium-dependent disruption of bacterialcell membrane (Micklefield, 2004)
may be blocking by the thickened
cell wall
before reaching the cytoplasmic
membrane (Cui et al., 2006)
HA-MRSA
Small molecule biosynthesis inhibitors
DHFR Inhibitor Trimethoprim
Inhibition of dihydrofolate reductase
(Pattishall et al., 1977) Reduced affinity for Dihydrofolatereductase (Maskell et al., 2001) CA-MRSA
Sulfonamide sulfamethoxazole Inhibition of dihydropterateSynthetase (Hong et al., 1995)
hyperproduction of p-
aminobenzoic acid (Then, 1982) CA-MRSA
New antibiotics
Glycopeptide Dalbavancin C-terminal D-alanyl-D-alanine ofpeptidoglycan chains (Ciabatti, 1997) Unknown HA-MRSA
Glycopeptide Telavancin
Binding to the D-alanyl-D-alanine
terminus of the peptidoglycan
intermediates and it also targets bacterial
cell membrane and causes disruption of
membrane potential (Higgins et al., 2005)
Unknown HA-MRSA
Glycopeptide Oritavancin trans-glycosylation step in peptidoglycanbiosynthesis (Allen and Nicas, 2003)
Unknown HA-MRSA
Cephalosporin Ceftobiprole Inhibiting PBPs (Bush et al., 2007) Multiple mecA mutations(Banerjee et al., 2008) HA-MRSA
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2.5 Plants: an alternative source for potent antibacterial agents  
 
Infectious diseases are caused by bacteria, viruses, parasites and fungi, and it is due to 
a complex interaction between the pathogen, host and the environment. The discovery 
of antibiotics is the most significant achievement of scientists because it decreases the 
spread and severity of microbial infections. But, recently, most of the antibiotics have 
become inactive against some pathogenic microbes like methicillin-resistant S. 
aureus, vancomycin-resistant enterococci, multidrug-resistant Gram negative bacteria, 
etc (Nseir et al., 2011; Wyllie et al., 2011). Resistance to antibiotics is one of the 
greatest threats to the success of modern medicine. It has recently become more 
serious because we can no longer be sure that any antibiotic selected empirically will 
work among bacterial infections. The lower effectiveness of antibiotics causes 
thousands of deaths worldwide (Allahverdiyev et al., 2011). The increase in isolates 
of S. aureus with resistance to methicillin and decreased susceptibility to vancomycin 
has created an urgent need for the development of new anti-staphylococcal agents 
(Saravolatz et al., 2010) that kill the resistant mutants. So, the identification of an 
alternative and safer drug for the control of MRSA is necessary to combat this 
worldwide problem. Nature is the only source to provide a verity of chemical 
compounds that can be used for new drug discovery especially from mineral, plant 
and animal products.  
 
Plants can be the major source for new drug development against pathogens. The 
control of major diseases by synthetic products is decreasing there is increased 
interest in the revival of herbal medicines leading to the current widespread belief that 
‘‘green medicine’’ is safe, more accessible and more affordable (Parekh and Chanda, 
2006) than costly synthetic drugs, many of which have adverse side effects. The use 
of the plants in medical practice is very old and common to all societies especially in 
the developing nations. India is a varietal emporium of medicinal plants and is one of 
the richest countries in the world with regard to genetic resources for medicinal 
plants, because it has a vast area with wide variation in climate, soil, altitude and 
latitude (Martins et al., 2001). About 60% of the total global population remains 
dependent on traditional medicines for their health care system; whereas about 80% of 
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the rural population of India depends on wild varieties of plants for the treatment of 
various diseases (Shrestha and Dhillion, 2003). Plants produce a higher number of 
naturally occurring secondary metabolites, many of them with unique pharmacologic 
activities. These metabolites include flavonoids, phenols and phenolic glycosides, 
saponins, cyanogenic glycosides, unsaturated lactones and glucosinolates (Kappel et 
al., 2008). Recently, pharmaceutical industries have started taking more interest in 
plant products to isolate active constituents from different plant parts and use them 
directly as drug or design them as pharmacologically active compounds with or 
without addition of synthetic ones (Tiwari, 2008).  
 
Fifty percent of currently available drugs in the market are natural products or 
derivatives of natural products. Recent studies of showed the plants either as pure 
compounds or as standardized extracts, supported to demonstrate unlimited 
opportunities for new drug discovery with different chemical nature. These types of 
studies should continue and a number of pivotal quality standards need to be set at the 
level of extract processing and primary evaluation in pharmacological screening 
models. Many researchers have conducted antimicrobial screening of plant extracts or 
isolated compounds (Anthony et al., 2011). The screening of plant extracts for 
antimicrobial activity is by itself a research area of major significance with resistance 
modifying action of interest. 
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Zone of
Inhibition
(mm)
Reference
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Terminalia avicennioides Guill & Perr. Ethanol extract 18.2 17.6 Akinyemi et al., 2005Phylantus discoideus muel. Muel-Arg. Ethanol extract 20.5 16
Rosa damascene Mill. 80% Ethanol extract - 34 Abu-Shanab et al., 2006
Olea europaea L. Leaf extract 12.5 - Sudjana et al., 2009
Atuna racemosa Raf. Ethanol extract 16-32 - Buenz et al., 2007
Punica granatum L. Water extract 12.5 - Gould et al., 2009
Planchonia careya (F. Muell.) R. Knuth Triterpene 800 - McRae et al., 2008
Baccharis grisebachii Hieron. Dichloromethane extract 125 - Feresin et al., 2001Oxalis erythrorhiza Gillies
Fabiana bryoides Phil. Ethanol extract 20 - Zampini et al., 2009
Calophyllun species Calozeyloxanthone 4-8 - Dharmaratne et al., 1999
Ulva lactuca L. ethyl-ether fraction 12.5 27 Kim et al., 2007
Amorphophallus campanulatus (Roxb.) Bl. Ethanol extract 16 22 Khan et al., 2007
Balanites aegyptiaca (L.) Delile Oil 2.5 µl 20 Al Ashaal et al., 2010
Perilla frutescens (L.) Britton Oil 0.4 µl Qiu et al., 2011
Caesalpinia spinosa (Molina) Kuntze ethyl gallate 125 Shibata et al., 2005
Carpobrotus muirii L.Bolus Ethyl acetate extract - 16.5 Springfield et al., 2003
Khaya anthotheca (Welw.) C. DC. Hexane/dichloromethane extract 80 - Suleiman et al., 2010
Centipeda minima L. Sesquiterpene lactones 300 - Taylor and Towers,1998
Thymus vulgaris L. Oil 18.50 12 Tohidpour et al., 2010Eucalyptus globules Labill. 51.36 17
Nigella sativa L.
Ethanol extracts
- 19
Dadgar et al., 2006Eucalyptus globules Labill. 180 17Hypericum perfoatum L. - 20
Artemisia dracunculus L. - 22
Table 2.2 Some examples of plant extracts/compounds/oil/combination of plant and antibiotic for potential anti-staphylococcal activity
Cont…
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Peganum hermala L. 20 18
Punica granatum L. 10 17
Ecballium elaterium (L.) A.
Ethanol extracts
512 -
Quave et al., 2008
Sambucus nigra L. 512 -
Achillea ageratum L. 256 -
Achillea millefolium L. 512 -
Cichorium intybus L. 512 -
Matricaria recutita L. 512 -
Cardaria draba (L.) Desv. 512 -
Melilotus alba Medik 512 -
Robinia pseudoacacia L. 512 -
Vicia craca L. 512 -
Vicia sativa Subsp. 512 -
Wisteria sinensis (Sims) Sweet 512 -
Castanea sativa Mill. 256 -
Erodium malacoides (L.) 128 -
Geranium columbinum L. 512 -
Hypericum perforatum L. 256 -
Rosmarinus officinalis L. 512 -
Salvia pratensis L. 512 -
Malva sylvestris L. 256 -
Rumex crispus L. 512 -
Prunus spinosa L. 512 -
Rosa canina var. Canina 512 -
Rubus ulmifolius Schott 512 -
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Centranthus ruber (L.) DC. 256 -
Cistus ladanifer L. Aqueous extract 154 - Barrajón-Catalán et al., 2010Cistus populifolius L. 344 -
Angelica dahurica (Fisch.) Benth, Falcarindiol 32 - Lechner et al., 2004
Zataria multiflora Boiss. Oil 0.25 µl - Mahboubi and Bidgoli, 2010
Piper regnellii (Miq.) C. DC. var. pallescens Eupomatenoid-5 8 - Marcal et al., 2010
Iostephane heterophylla (Cav.) Benth. Xanthorrizol 32 - Mata et al., 2001
Eucalyptus globules Labill. Aqueous extract 120-250 - Mulyaningsih et al., 2010
Cladonia rangiferina (L.) Web. Ddymic acid - 28 Yoshikawa et al., 2008
Inula hupehensis Ling. 8-hydroxy-9, 10- diisobutyloxythymol 62.8 - Zhao et al., 2010
Cassia tora L. seeds Anthraquinones 2 - Hatano et al., 1999
Ulmus davidiana Planch. var. japonica Mansonone F 1.56 - Shin et al., 2000
Calligonum leucocladum (Schrenk) Bunge (E)-Resveratrol
3-(6’’-galloyl)-O-β-D-glucopyranoside 
125 - Okasaka et al., 2004
Sphallerocarpus gracilis (Bess.) K.-Pol. Oil from seeds 160 22.4 Gao et al., 2011
Sambucus nigra L. Aqueous extract - 17 Hearst et al., 2010
Punica granatum L. Ellagitannins 62.5 - Machado et al., 2003
Rhodomyrtus tomentosa (Aiton) Hassk. Ethanol extract 30 - Limsuwan et al., 2009
Garcinia mangostana L. Xanthones isolated from
active fraction of benzene extract 6.25 - Iinuma et al., 1996
Plectranthus hadiensis (Roots) Methanol extract 16 Mothana et al., 2010
Garcinia nigrolineata Planch. Ex T. Anderson Nigrolineaxanthone N 4 Rukachaisirikul et al., 2003
Prosopis glandulosa Torr. var. glandulosa 2,3-dihydro-1H-indolizinium chloride 1.25 Samoylenko et al., 2009
Magnolia officinalis Rehder & Wilson Honokiol 12.5 19 Syu et al., 2004
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Calceolaria pinifolia Cav. 15-diene-19-ol 2 - Woldemichael et al., 2003
Cladonia rangiferina (L.) Weber Ddymic acid - 28 Yoshikawa et al., 2008
Mitrephora celebica Scheff. 13,14-dihydrooropheic
acid and oropheic acid 12.5; 25 - Zgoda et al., 2001
Guatteria multivenia Diels. Liriodenine 3.13 - Zhang et al., 2002
Laurus nobilis L. Ethanol extract (from bark) 500 18 Al-Hussaini and Mahasneh,2009
Camellia sinensis (L.) Kuntze Ethanol extract (Leaves) 1800-7500 11-23
Aqil et al., 2005
Delonix regia (Boj. ex Hook.) Raf. Ethanol extract (Flowers) 5000-7500 16-23
Holarrhena antidysenterica Roxb. ex Fleming Ethanol extract (Bark) 2800-5600 12-17
Lawsonia inermis L. Ethanol extract (Leaves) 1300-7500 11-22
Punica granatum L. Ethanol extract (Rind) 1800-7900 13-20
Terminalia bellerica (Gaertn.) Roxb. Ethanol extract (Fruit) 1800-7800 17-27
Terminalia chebula Retz. Ethanol extract (Fruit) 1500-8200 18-27
Ferula hermonis Boiss. 14-(4’-hydroxybenzoyloxy)dauc-
4,8-diene 6.25 - Galal et al., 2001
jaeschkeanadiol p-hydroxybenzoate 6.25 -
Acalypha communis Mull.Arg. 16R-hydroxymollic 32 - Gutierrez-Lugo et al., 200215R-hydroxymollic 64 -
Eucalyptus spp. Eucalyptus oil 2 - Hendry et al., 20091,8-cineole 64 -
Salvia officinalis L. Carnosol 64 - Horiuchi et al., 2007
Cleistopholis patens (Benth.) Engl.
et Diels
Cleistetroside-8 8 -
Hu et al., 2006Cleistrioside-5 8 -
Cleistetroside-2 0.5 -
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Vitex rotundifolia L.f.
Vitrofolals C 64 -
Kawazoe et al., 2001Vitrofolals D 16-64 -
Detetrahydroconidendrin 4-64 -
Caiophora coronate Hook. et Arn. 1β,3β-Dihydroxyurs-12-en-27-oic acid 4 - Khera et al., 2003
Croton tonkinensis Gagnep. Diterpenoids 32 23 Giang et al., 2006
Swietenia mahagoni (L.) Jacq. Limonoids - 23 Rahman et al., 2009
Callistemon rigidus R.Br. Fractions from methanol extract 1.25 29 Gomber and Saxena, 2007
Dictyota acutiloba J. Ag. Fractions from chloroform
and acetone extract 0.69 15
Solomon and Santhi, 2008
Erythrina variegate L. Isoflavonoids 6.25 - Tanaka et al., 2002
Andrographis paniculata (Burm.f.) Wall. Chloroform extract 1000 15 Roy et al., 2010
Sclerocarya birrea (A. Rich.) Hochst Hexane (oil) - 10 Mariod et al., 2010
Retama raetam (Forssk.) Webb & Berthel. butanol extract 0.512 - Hayet et al., 2008
Acacia catechu (L.) Willd. Oliv.
Punica granatum L.
Quercus infectoria Lam.
Uncaria gambir (W.Hunter) Roxb.
Aqueous, Ethanol extract 200-1200 16-21 Voravuthikunchai andKitpipit, 2005
Varthemia iphionoides Boiss, et Blanche. Ethanol extract + Cefotaxime Synergistic effect Abu Hijleh et al., 2009
Garcinia kola Heckel Acetone extract + Amoxycillin Synergistic effect Sibanda and Okoh, 2008
Ecballium elaterium (L.) A.Rich. Ethanol extract + penicillin Synergistic effect Adwan et al., 2011
Vangueria spinosa Roxb. Ethanol extract +
doxycycline/ofloxacin Synergistic effect Chatterjee et al., 2009
Camellia sinensis (L.) Kuntze Green tea extract + Imipenem Synergistic effect Aboulmagd et al., 2011
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2.6 Need of the Hour  
 
Resistance to antibiotics is one of the greatest threats to the success of modern 
medicine. It has recently become more serious because we can no longer be sure that 
any antibiotic chosen empirically will work and because of the emergence of totally 
resistant bacteria. It is increasingly clear that antimicrobial resistance is opposite to 
the good things in life: it is easy to get but hard to lose. MRSA infection is a persistent 
infection which may have serious effects on the healing process in the hospitals, other 
care centers and lately in the community has become a worldwide phenomenon. The 
wide spread dissemination of multiple-drug resistant strains and antibiotic clones of S. 
aureus facilitated by inherent or acquired molecular/genetic elements is worrying as it 
complicates diagnosis and chemotherapy. Resistance is a major concern with any new 
agent and will become even more important in the future as new classes of drugs are 
established. There are essentially two routes of drug discovery, firstly, synthesizing 
entirely new chemicals and evaluating them for a particular pharmaceutical use. 
Secondly, identifying the chemical of biological origin (natural product) and evaluate 
it for direct or indirect use as a template for the development of a new drug.  Many 
studies tried to find alternative ways to reduce and prevent the problem of antibiotic 
resistance in bacteria. Natural products, either as pure compounds or as standardized 
plant extracts provide unlimited opportunities for new drug leads because of the 
unmatched availability of chemical diversity. Hence, plants need a powerful and deep 
assessment of their antimicrobial qualities. Combination of plant extracts and 
antibiotics is also a new choice for treatment of infectious diseases.  
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
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3.1 Glass ware and plastic ware 
 
Glass ware used was purchased from Borosil, Mumbai, India. All plastic ware used 
was purchased from Tarsons, Kolkata, India either made up of polypropylene or 
polycarbonate. Glass ware and plastic ware (non-sterile) was cleaned with labolene, 
rinsed with distilled water and autoclaved before use. 
 
3.2 Chemicals, media, reagents and kits 
 
 Nutrient Agar (NA): Peptone (10 g), Beef extract (10 g), Sodium chloride 
(5 g), Agar (12 g), Distilled water (1 l), pH 7.3 
 Brain Heart Infusion Broth (BHB): Calf brain, infusion (200 g), Beef 
heart (250 g), Proteose peptone (10 g), Dextrose (2 g) Sodium chloride (5 
g), Disodium phosphate (2.50 g), Distilled water (1 l), pH 7.4 
 Mannitol Salt Agar (MSA): Peptic digest of animal tissue (5 g), 
Pancreatic digest of casein (5 g), Beef extract (1 g), D-Mannitol (10 g), 
Sodium chloride (75 g), Phenol red (0.025 g), Agar (15 g), Distilled water 
(1 l), pH 7.4 
 Oxacillin Resistance Screening Agar Base (ORSAB): Peptic digest of 
animal tissue (11.8 g), Yeast extract (9 g), Mannitol (10 g), Sodium 
chloride (55 g), Lithium chloride (5 g), Aniline blue (0.20 g), Agar (12.5 
g), Distilled water (1 l), pH 7.4 
 Phenolphthalein Phosphate Agar (PPA): Hiveg Peptone (5 g), Hiveg 
extract (3 g), Sodium chloride (5 g), Sodium phenolphthalein phosphate 
(0.012 g), Agar (15 g), Distilled water (1 l), pH 7.4 
 Muller-Hinton Agar No. 2 (MHA): Hydrolysate (17.5 g), Hiveg infusion 
(2 g), Starch,soluble (1.5 g), Agar (17 g), Distilled water (1 l), pH 7.3 
 Muller Hinton Broth (MHB): Beef, infusion from casein acid (3 g), 
Hydrolysate (17.5 g), Starch (1.5 g), Distilled water (1 l), pH 7.4 
 Antibiotics, HiComb strips, Gram’s stain reagent kit, Ethidium bromide, 
Sodium chloride (NaCl), Agarose Tris base, EDTA, Taq DNA 
polymerase, 10X buffer, 2’-deoxynucleoside 5’-triphosphates (dNTPs), 
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3.5 Primary identification  
 
A smear of the sample was prepared directly from the clinical material and stained by 
the method of Gram’s staining.  
 
3.5.1 Bacterial cultures:  
 
The Staphylococcus isolate were isolated using nutrient agar, blood agar and 
MecConkey’s agar under aerobic or anaerobic conditions within a temperature range 
of 10-42ºC, optimal temperature being 37ºC. 
3.6 Biochemical reactions (Prescott, 2002) 
 
3.6.1 Mannitol-Salt Agar (MSA) 
 
Mannitol is fermented by the production of acid by most strains of S. aureus. MSA is 
used for the selective isolation and differentiation of S. aureus that ferment mannitol 
and can grow on high salt concentration. 
 
3.6.2 Catalase test:  
 
Isolated bacterial colony was taken by straight wire loop and mixed with 30% H2O2 in 
a clean glass tube. Catalase positive showed clear effervescence (bubbles) that 
indicated the presence of cytochrome oxidase in bacteria.  
 
3.6.3 Slide and tube coagulase test 
 
The test suspension was treated with a drop of citrated plasma and mixed well. 
Agglutination or clumping of cocci within 5-10 seconds was taken as positive. Some 
strains of S. aureus may not produce bound coagulase, and such strains must be 
identified by tube coagulase test. 
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3.6.4 Oxacillin Resistance Screening Agar Base (ORSAB) 
  
Incorporation of aniline blue was used to detect mannitol fermentation, which resulted 
in intense blue colonies of staphylococci. This agar base was supplemented with 
polymyxin B (50,000 IU/l) and 2 mg/l oxacillin. A loop full cultured on brain heart 
infusion broth for enrichment was taken, streaked on ORSAB slant immediately in 
aseptic condition. Inoculated slants were incubated at 35ºC for 24 hrs. Colonies 
showing an intense blue coloration were considered to be positive for oxacillin 
resistant staphylococci (Al-Talib et al., 2009).  
 
3.6.5 Phenolphthalein Phosphate Agar (PPA) 
 
A suspension equivalent to McFarland 0.5 was prepared from each strain in brain 
heart infusion broth. A loop full culture was streaked on phenolphthalein phosphate 
agar plate and incubated at 35°C for 24 h (Merlino et al., 1996).   
 
3.7 Antibacterial susceptibility testing by agar disc diffusion method (Bauer et al., 
1966; CLSI, 2007; Vaghasiya and Chanda, 2010) 
 
The molten Mueller Hinton Agar No. 2 was poured into sterile petri plates and was 
allowed to solidify. A suspension equivalent to 0.5 McFarland was prepared from 
each strain. A swab was dipped and streaked on the surface of a Mueller-Hinton agar 
plates. Standard antibiotic discs (Fig. 3.4 - 3.6) were introduced on the upper layer of 
the seeded agar plate. The plates were incubated at 37oC for 18-24 h.  The experiment 
was carried out three times and the mean values are presented. The antimicrobial 
activity was evaluated by measuring the diameter of zone of inhibition in mm. 
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3.10 Preparation of bacterial genomic DNA 
 
3.10.1 Genomic DNA Isolation  
 
DNA was extracted from each of the seventy strains isolated. A loop full of each 
strain was inoculated in 25 ml of Brain heart infusion broth in a conical flask and then 
incubated in environmental shaker (37°C, 120 rpm) for 18 to 24 h in order to activate 
the test bacteria. 1.5 ml cell suspension was taken in microcentrifuge tube and 
centrifuged at 6000 rpm for 10 min. Supernatant was discarded and the pellet was 
collected. Genomic DNA of seventy isolated strains was extracted using the 
GeneiPureTM (GeNeiTM, Bangalore, India) Bacterial DNA Purification Kit following 
manufacturer’s protocol. Cells were re-suspended in 100 µL of Bacterial Lysis Buffer 
(BLB containing lysozyme (20 mg/ml) digestion and followed by addition of 180 µL 
Lysis Buffer I and 20 µl proteinase K (20 mg/ml) digestion (Mixed thoroughly by 
vortexing). It was then incubated at 55°C for 1-3 hours. 4 µl RnaseA (100 mg/ml) was 
added to the sample and mixed by vortex. Lysis Buffer II (200 µl) was added to the 
sample (mixed thoroughly by vortexing) and incubated at 70°C for 20 min. Absolute 
ethanol (200 µl) was added to the sample and again mixed by vortexing. The sample 
containing DNA precipitates was applied to a GeneiPureTM column and was 
centrifuged at 11,000 rpm for 5 min. Collection tube was discarded along with the 
flow through. The pellets bound to the column were washed with 500 µl of solution 
containing wash buffer and absolute ethanol in 1:3 ratios by spinning at 11,000 rpm 
for 1 minute. The pellets were further washed using 500 µl of solution containing 
wash buffer II and absolute ethanol in 1:3 ratio by Spinning at 11,000 rpm for 3 
minute. Washed fraction was discarded and was spans the empty column at 11,000 
rpm for 2 minutes for removing trace salt and protein contaminants. The DNA was 
eluted in 200 µl of pre-warmed (70°C)  Elution Buffer by incubating the column for 5 
minutes at room temperature and then spinning for 1-2 minutes. The DNA was stored 
at -20ºC. After 24 h, the quality of eluted genomic DNA was evaluated by subjecting 
it to 0.8% agarose gel electrophoresis and stored at -20°C. 
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3.10.2 DNA quantification 
 
 
Genomic DNA was quantified by spectrophotometrically using Nano Drop 
spectrophotometer, model number ND 1000, Nano Drop Technologies, Inc. 
Wilmington, DE, USA. Blank was prepared with TE buffer (pH 8.0). DNA 
quantification and estimation of DNA concentration was automatically done by pre-
installed software. DNA quality was judged on the basis of the ratio of the OD values 
at 260 and 280 nm. The 260/280 ratio was approximately 1.8 and that indicated the 
best quality of the DNA. The integrity of each DNA sample was also examined with 
0.8% agarose gel. 
 
3.10.3 Agarose gel electrophoresis 
 
Agarose gels (0.8% and 2%) were prepared by adding agarose powder in 1X TAE 
buffer and boiled for 5 min in a microwave oven. The boiled solution was allowed to 
cool approximately to 60°C and 5 µl/10 µl of ethidium bromide was added from the 
stock (1 mg ml-1) and mixed gently. The solution was poured in the loading chamber 
of horizontal submarine electrophoresis unit and the teflon comb was inserted before 
polymerization. Polymerization took place within 10-15 minutes. Thereafter the comb 
was removed and wells were prepared. The gel was submerged in 1X TAE buffer. 
 
Loading dye was mixed with PCR product and 10 µl of the sample was loaded in each 
well using a fine micropipette. Each gel 50 bp DNA ladder was loaded to judge the 
size of the amplified fragment. Electrophoresis was carried out in the horizontal 
submarine electrophoresis system supplied by Tarsons Products Pvt. Ltd., Kolkata, 
India. A constant power supply of 80V for 20 minutes was given using PowerPac HV 
Power supply, Bio-Rad, USA. Once the bromophenol blue stain reached more than 
two-thirds, the gel was viewed under a UV trans-illuminator for observing the actual 
band positions of the amplified DNA and documented in automated gel 
documentation scanner, ChemiImager supplied by Alpha Innotech Corporation, USA. 
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0.8 % Agarose gel   :  0.8 g Agarose in 100 ml 1X TAE 
 2.0 % Agarose gel   :  2.0 g Agarose in 100 ml 1X TAE 
                       
50 X TAE : 121 g Tris Base 
• 28.55 ml Glacial acetic acid 
• 50 ml 0.5 M EDTA (pH 8.0) 
• Volume up to 1 liter with deionized water 
6X Loading dye: 10 mM Tris ( pH-7.6 ) 
• 0.03% Bromophenol blue 
• 0.03% Xylene Cyanol FF 
• 60% Glycerol 60 mM EDTA 
 
3.10.4 Primers 
 
The mecA gene was amplified with primer pair 1 (MR1- Forward Primer and MR2- 
Reverse Primer), primer pair 2 (MR3- Forward Primer and MR4- Reverse Primer) 
and primer pair 3 (MR5- Forward Primer and MR6- Reverse Primer) (Murakami et 
al., 1991; Del Vechio et al., 1995; Al-Haj et al., 2009) (Table 3.1). Primers were 
procured from Bangalore Genei, Ltd. Bangalore, India. All PCR amplifications were 
carried out using Thermal cycler (Eppendrof - Mastercycler Pro, Germany). 
 
Table 3.1 Details of primers used 
 
Sr. No. Primers Primer sequence 
1 MR 1 5’TAGAAATGACTGAACGTCCG3’ 
2 MR 2 5’TTGCGATCAAATGTTACCGTAG3’ 
3 MR 3 5’AAAATCGATGGTAAAGGTTGGC3’ 
4 MR 4 5’AGTTCTGCAGTACCGGATTTTGC3’ 
5 MR 5 5’TAGAAATGACTGAACGTCCG3’ 
6 MR 6 5’AGTTCTGCAGTACCGGATTTTGC3’ 
 
 
3.10.5 PCR amplification 
 
PCR reactions were performed in 50 µl volumes containing 50 ng of DNA template, 
128  µM of each dNTPs, 10X buffer (1.5 mM MgCl2, 20 mM Tris-HCl (pH 8.4), 50 
mM KCl,), 200 nM (each) primers and 2.5 units of Taq DNA polymerase (HiperTM). 
Thermal cycling was conducted for 30 seconds at 94ºC; 30 seconds at 58ºC and 30 
seconds at 72ºC, 30 amplification cycles using primer pair 1 & primer pair 3. The 
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same procedure was followed for the amplification of mecA with primer pair 2 except 
that the annealing temperature was reduced to 55ºC and the extension time was 1 
minute. The 50 bp and 1 kb DNA ladders were used as DNA molecular weight 
standards. The amplified product was separated on 2% agarose gel electrophoresis 
(As described in 3.10.3). 
 
3.11 Sequence analysis of 16S rRNA and mecA gene  
 
The PCR product of 16S rRNA and mecA gene was sequenced in an ABI3730XL-
1414-008 genetic analyzer (Applied Biosystems). The obtained sequence was 
compared to known sequences using the BLAST database program maintained by the 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov) to find 
close evolutionary relatives. 
 
3.11.1 Phylogenetic analysis 
 
Alignment and phylogenetic analysis of 16S rRNA and mecA gene sequences were 
performed using CLC main workbench 5 (www.clcbio.com).    
 
3.12 Plant material 
 
Plant parts were collected / purchased from Saurashtra region, Gujarat, India (Table 
3.2). The plants were compared with voucher specimen deposited by Dr. P.S. Nagar 
and Dr. N.K. Thakrar at Department of Biosciences, Saurashtra University, Rajkot, 
Gujarat, India. Fresh plant materials of Callistemone lanceolatus (leaves), Polyalthia 
longifolia (leaves), Nelumbo nucifera (petals, pedicel, stem) and Rosa chinensis 
(flowers) were washed thoroughly with tap water and air dried under shade. Dried 
plant parts were homogenized to fine powder and stored in airtight bottles. 
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Table 3.2 Details of the plants studied for antibacterial activity  
 
Sr.  
No. Name of plants Family 
Vernacular 
name 
Parts used 
1 Callistemone lanceolatus D.C. 
(PSN294)   
Myrtaceae Bottle brush Leaves 
2 Mesua ferrea Linn. 
(SU/BIO/511/Thakrar) 
Guttiferae Nagkesar Stem + Fruit 
3 Nelumbo nucifera Gaertn. 
(SU/BIO/512/Thakrar) 
Nymphaeaceae Lotus Pedicel, stem, petals 
4 Polyalthia longifolia (Sonn.)  
(PSN4) 
Thw. var. pendula  
Annonaceae Asopalav Leaves 
5 Rosa chinensis Jacq. 
(SU/BIO/513/Thakrar) 
Rosaceae Kaantaa-Gulaab Flower 
6 Terminalia bellerica Roxb. 
(PSN290)  
Combretaceae Baheda Seed coat, fruit rind 
7 Terminalia chebula Retz.  
(PSN292) 
Combretaceae Harade Fruit rind, seed coat 
 
 
3.13 Extraction  
  
The dried powder of plant parts was defatted with hexane and then extracted in 
methanol for 24 h on rotary shaker by cold percolation method (Vaghasiya et al., 
2011). Ten grams of dried powder was added to 100 ml of solvent in a conical flask, 
plugged with cotton wool, and then kept on a rotary shaker at 190-220 rpm for 24 h. 
Then the extract was filtered with 8 layers of muslin cloth. The filtrate was 
centrifuged at 5000 g for 10 min. The supernatant was collected and the solvent was 
evaporated. The dried extract was stored at 4°C in air-tight bottles. The methanol 
extract was used for antibacterial study. 
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3.14 Fractionation of methanol extract of Polyalthia longifolia leaves 
 
Fractionation of the methanol extract was done by solvent-solvent partition (Tang et 
al., 2010). Five grams of methanol extract of P. longifolia was dissolved in hot 
methanol (200 ml). Slight precipitation obtained was discarded as methanol insoluble 
matter. The methanol-soluble fraction was filtered and collected. It was concentrated 
to about 50 ml volume and ethyl acetate was added to it till faint turbidity was 
obtained. Then it was allowed to settle down in a refrigerator. The settled gelatinous 
reddish mass and supernatant was separated and collected separately. The supernatant 
was further concentrated and ethyl acetate step was repeated till reddish gelatinous 
mass obtained. All the settled mass was collected together and dissolved in methanol. 
It was concentrated further to dryness and designated as Fraction I (FS-I). The yield 
obtained of FS I was 44.49%.  The collected supernatant was concentrated further to 
near dryness and then dissolved in methanol. Then chloroform was added to it and 
cooled. Light yellow waxy sediment was separated and light buff colored supernatant 
was collected. This supernatant was concentrated further to dryness and designated as 
Fraction II (FS-II). The yield obtained of FS II was 35.6%, which was less than FS I.  
 
3.15 Preparation of the extract for antimicrobial assay 
 
Plant extracts were dissolved in dimethylsulphoxide for antibacterial study. 
Concentration of the extracts was 15 mg/ml.  
 
3.16 Antibacterial assay by agar well diffusion method for plant extracts (Perez et 
al., 1990) 
 
Methanol extracts of seven different plants (eleven parts) were selected for study of 
antibacterial activity against ten Staphylococcus strains. A loop full of each strain was 
inoculated in 25 ml of Muller Hinton broth in a 150 ml conical flask and then 
incubated at room temperature on a rotary shaker for 24 h in order to activate the test 
bacteria. The final cellular concentration was 1 × 108 cfu/ml. The molten Mueller 
Hinton Agar No. 2 was inoculated with 200 µl of the inoculum and poured into the 
sterile petri plates. Care was taken to ensure proper homogenization. After media 
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were solidified a well was made in the plates with the help of a cup-borer (8.5 mm). 
The well was filled with 100 µl of extract (1.5 mg/well) and the plates were incubated 
overnight at 37°C. Bacterial growth was determined according to the diameter of the 
zone of inhibition. The experiments were performed 3 times and mean values are 
presented. For all bacterial strains, DMSO was used as negative control. 
 
3.17 Preparation of the extracts and/or antibiotic for MIC and MBC study 
 
Twofold serial dilutions of the extracts (8000–62.5 µg/ml) and rifampicin (160-1.25 
µg/ml) were prepared in DMSO. For synergistic study between plant extracts and 
antibiotic (Rifampicin), the drug was prepared 1:1 dilution of plant extracts: 
rifampicin from higher to lower concentration.   
 
3.18 Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal 
Concentration (MBC) 
 
Microbroth dilution method, using 96 well microtitre plates, was performed to 
evaluate MIC of the plant extracts (Andrews, 2001; Sampaio et al., 2009). An 
inoculum suspension was prepared in Mueller–Hinton broth. The inocula were 
adjusted to each bacterial strain to yield a cell concentration of 108 CFU/mL. A final 
volume of 200 µl was achieved in each well (180 µl bacterial suspension and 20 µl 
plant extract/antibiotic). Two control wells were maintained for each test batch. These 
included test control (well containing extract/antibiotic and the growth medium 
without inoculum) and organism control (the well containing the growth medium and 
the inoculum). The lowest concentration (highest dilution) of the extract/antibiotic 
that produced no visible bacterial growth (no turbidity) when compared with the 
control wells were regarded as MIC. However, the MBC was determined by 
subculturing the test dilution on to a fresh drug-free solid medium and incubated 
further for 18–24 hr. The highest dilution that yielded no single bacterial colony on a 
solid medium was taken as MBC (Akinyemi et al., 2005). 
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3.19 Fractional inhibitory concentration (FIC) index  
 
Fractional inhibitory concentration (FIC) was calculated for every organism. The 
following formulae were used (Agarwal et al., 2007; Odds, 2003): 
• FIC of plant extracts = MIC of plant extracts in combination/MIC of plant 
extracts alone 
• FIC of antibiotic = MIC of antibiotic in combination/MIC of antibiotic alone 
• FIC index = FIC of plant extract + FIC of antibiotic 
Synergy was defined as an FIC index of ≤0.5. Additive effect was defined as an FIC 
index of >0.5 but of ≤4.0. Antagonism was defined as an FIC index of >4.0. 
 
3.20 Statistical analysis 
 
Correlation analysis was done by Pearson's correlation coefficient at P>0.05 and 
P>0.01 significance level using IBM SPSS statistics 20 (Evaluation version). 
 
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
Chapter 4: Results and Discussion
4.1 Biochemical characterization of clinically isolated
Microorganisms have been classified and identified on the basis of a variety of
characteristic including morphologic
genetic. Recently there has been a tendency to determine definitive classification and
taxonomic assignment by nucleic acid hybridization, 16S r
and other molecular genetics
study, seventy clinical samples of s
laboratories and hospitals. The sa
4.1). The organisms were identified by conventional
Gram’s stain, catalase
Fig. 4.1 Staphylococcus
Staphylococcus is gram
in diameter with an entire edge and a
with radial striations. Some organisms
colonies clinging to the surface of the
most isolates on subculture.
Ph.D. Thesis | Harsha Patel | January, 2012
Saurashtra University | Sub:
Staphylococcus
al, growth, tolerance, metabolic, biochemical and
DNA sequence analysis
techniques (Bascomb and Manafi, 1998)
taphylococci were isolated from clinical
mples were isolated from different specimens
methods (Colonial morphology,
test and coagulase test) (Table 4.1).
strains isolated from clinical specimens
-positive coccus where the round cells are approximately
smooth or slightly granular surface sometim
when first isolated formed hard,
agar, but this property was unstable and lost by
They arranged characteristically in
Microbiology
Page | 70
strains
. In the present
(Fig.
1 µm
es
irregular
grape-like clusters.
 
 
Chapter 4: Results and Discussion       Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
                                
 
  
 
 
Page | 71  
 
Cluster formation is due to cell division occurring irregularly in different planes, with 
daughter cells tending to remain in close proximity. They may also be found singly, in 
pairs and in short chains of three or four cells especially when examined in liquid 
culture. They form characteristic golden or white colonies on blood agar. They 
produce catalase, coagulase and an extracellular cell clumping factor, and some 
strains produce capsules (Bannerma, 2003). In this study, all the strains were gram-
positive cocci in clusters on a gram stain. Staphylococci are among the most common 
nosocomial pathogens. They are usually found on the skin and mucous membranes of 
the body (particularly the perianal area, nasal membranes and hair follicles). 
Researchers can easily distinguish staphylococci from other clinically relevant gram-
positive bacteria, such as streptococci which are catalase-negative. All isolates were 
catalase and phosphatase positive. 
 Two clinically relevant species of staphylococci can be differentiated on the basis of 
the presence/absence of enzyme coagulase. Both coagulase-negative staphylococci 
(CoNS) and S. aureus can exist as part of the normal human flora. These bacteria can 
colonize individuals, but they generally cause disease only when the body’s defense 
systems are compromised. S. aureus colonization is widespread in the general 
population and the most common sites of colonization are the nares. Researchers 
estimate that 30-50% of healthy adults are colonized with S. aureus and 10-20% are 
chronically colonized (Sista et al., 2004). Staphylococcus aureus is known to produce 
coagulase, which can clot plasma into gel in tube or agglutinate cocci in slide. This 
test is useful in differentiating S. aureus from other coagulase-negative staphylococci. 
Most strains of S. aureus produce two types of coagulase, free coagulase and bound 
coagulase. Clumping factor (bound coagulase) differs from free coagulase in that it is 
cell-bound and requires only fibrinogen (Cookson, 1997). While free coagulase is an 
enzyme that is secreted extracellularly; bound coagulase is a cell wall associated 
protein. Free coagulase is heat labile while bound coagulase is heat stable. Free 
coagulase is detected in tube coagulase test and bound coagulase is detected in slide 
coagulase test. Slide coagulase test may be used to screen isolates of S. aureus and 
tube coagulase may be used for confirmation. Researchers also reported tube 
coagulase production is considered “gold standard” for identification of S. aureus 
(Brown et al., 2005). The data obtained showed that of the 70 clinically isolated 
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strains, fifty three strains were coagulase positive while seventeen strains were 
coagulase negative. Fifty three coagulase positive strains fermented mannitol while 
seventeen coagulase negative strains of which seven strains tested negative both in 
slide and tube test and did not ferment mannitol but the other ten strains tested 
coagulase positive in slide test and fermented mannitol. Mannitol salt agar (MSA) is 
used for the selective isolation and differentiation of S. aureus that ferment mannitol 
and can grow at a high salt concentration (Rajakaruna et al., 2009). MSA readily 
supports the growth of thymidine-dependent S. aureus and enhances the recovery of 
this organism. Some organisms cannot tolerate high osmotic pressures. Media 
containing higher than normal salt concentrations may inhibit the growth of these 
non-tolerant organisms. MSA contains a high salt concentration so only salt tolerant 
organisms grow. Additionally, mannitol salt agar contains the sugar mannitol. Some 
organisms can utilize mannitol as a carbon source and produce acidic end products. 
Since this process is invisible, phenol red is added as an indicator to the media to 
detect changes in pH. It is red at a neutral pH but turns yellow if conditions in the 
media become acidic. Most of the clinically isolated strains when grown on ORSAB 
produced blue color, but three coagulase negative strains remained colorless on 
ORSAB, this isolates turned out to be oxacillin-resistant as seen by using oxacillin 
salt screening method. Incorporation of aniline blue was used to detect mannitol 
fermentation, which resulted in intense blue colonies of S. aureus. This agar base was 
supplemented with polymyxin B (50,000 IU/l) and 2 mg/l oxacillin for selective 
identification of methicillin-resistant staphylococci. Colonies showing an intense blue 
coloration were considered to be positive for MRSA. The media used in our study 
were useful in aiding the detection of methicillin-resistant strains, but they cannot be 
used as a confirmation test for MRSA because of interaction with enzymatic 
substrates or fermentation of mannitol. Therefore, conventional identification of S. 
aureus and confirmation of resistance were still necessary. 
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Table 4.1 Biochemical characterization of clinically isolated Staphylococcus strains 
Strain 
No. 
Source Gram’s 
staining 
Catalase Coagulase   ORSAB PPA  MSA 
Slide Tube 
S1 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S2 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S3 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S4 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S5 Synovial Fluid GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S6 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S7 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S8 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S9 Endotracheal Tube GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
                     Cont…                                                                                                                                                                                                                    
 
 
 
 
Chapter 4: Results and Discussion            Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
Page | 74  
 
Strain 
No. 
Source Gram’s 
staining 
Catalase Coagulase   ORSAB PPA  MSA 
Slide Tube 
S10 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S11 Sputum GPC + _ _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S12 Pus GPC + Weak 
+ 
_ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S13 Urine GPC + + _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S14 Endotracheal 
Tube 
GPC + Weak 
+ 
_ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S15 Osteomyelytis 
Tissue 
GPC + + _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S16 Blood GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S17 Blood GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S18 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
                   Cont… 
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Strain 
No. 
Source Gram’s 
staining 
Catalase Coagulase   ORSAB PPA  MSA 
Slide Tube 
S19 Sputum GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S20 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S21 Tracheostomy 
Swab 
GPC + _ _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol 
not ferment 
Red to Red 
S22 Sputum GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S23 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S24 Pus GPC + + _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S25 Urine GPC + _ _ Oxacillin resistance 
but no color change 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S26  
Blood 
GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S27 Endotracheal 
Tube 
GPC + + Weak 
+ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
                     Cont… 
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Strain 
No. 
Source Gram’s 
staining Catalase 
Coagulase ORSAB PPA MSA 
Slide Tube 
S28 Blood GPC + _ _ 
Oxacillin resistance 
but no color change 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S29 Urine GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S30 Pus GPC + + _ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S31 
 
Blood 
GPC + + _ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S32 
Synovial 
Fluid 
GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S33 
Hip-Joint 
Tissue 
GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S34 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S35 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S36 Urine GPC + + _ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
                    Cont… 
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Strain 
No. 
Source Gram’s 
staining Catalase 
Coagulase ORSAB PPA MSA 
Slide Tube 
S37 Endotracheal 
tube 
GPC + + _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S38 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S39 Ear-swab GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S40 Endotracheal 
tube 
GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S41 Blood GPC + + + Oxacillin resistance 
blue color change 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S42 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S43 Blood GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S44 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S45 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
                    Cont… 
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Strain 
No. 
Source Gram’s 
staining Catalase 
Coagulase ORSAB PPA MSA 
Slide Tube 
S46 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S47 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S48 Pus GPC + + - 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S49 Sputum GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S50 Sputum GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S51 
Endotracheal 
tube 
GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S52 Sputum GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S53 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S54 
Endotracheal 
tube 
GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
      Cont… 
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Strain 
No. 
Source Gram’s 
staining Catalase 
Coagulase ORSAB PPA MSA 
Slide Tube 
S55 Ear-swab GPC + - - 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S56 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S57 
Endotracheal 
tube 
GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S58 Pus GPC + + 
Weak 
+ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S59 Pus GPC + + 
Weak 
+ 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S60 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S61 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S62 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S63 Pus GPC + + + 
Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
     Cont… 
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Strain 
No. 
Source Gram’s 
staining 
Catalase Coagulase   ORSAB PPA  MSA 
Slide Tube 
S64 Endotracheal 
tube 
GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S65 CVP 
Catheter tip 
GPC + - - Oxacillin resistance 
but no color change 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S66 Tracheostomy 
swab 
GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S67 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S68 Pus GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S69 Endotracheal 
tube 
GPC + + + Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol ferment 
Red to Yellow 
S70 Endotracheal 
tube 
GPC + _ _ Oxacillin resistance 
blue color present 
Phosphatase 
present 
Mannitol not ferment 
Red to Red 
S- Staphylococcus strains; GPC- Gram-positive cocci; (+) – Positive; (-) – Negative; ORSAB-Oxacillin resistance screening agar base; PPA-Phenolphthalein 
phosphate agar; MSA- Mannitol salt agar 
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4.2 Antibiotic susceptibility pattern  
 
Antibiotics are one of the pillars of modern medicine (Ball et al., 2004). However, 
bacterial resistance emerges in a very small proportion of patients when an 
antimicrobial agent is introduced into the market or just after its introduction (Bax et 
al., 1998). There is a huge variation in the time for emergence of resistance, which 
varies among organisms and antibiotics. For example, penicillin resistance in 
Staphylococcus spp. emerged rapidly. A variety of antibiotics are available in the 
market to treat the bacterial infectious diseases by working on various targets to 
inhibit pathogen growth (Williamson et al., 2006). The term ‘antibiotic resistance’ 
implies that a particular antibiotic is ineffective in a clinical infection. This may be 
because the organism is inherently becoming resistant to higher antibiotic 
concentration with the increased antibiotic use (McGowan, 1983). Resistance of 
Staphylococcus aureus and coagulase negative staphylococci to available antibiotics 
has assumed a steady and progressive increase since the mid 70s (Cespedes et al., 
2002; Levy, 1992). S. aureus can exemplify better than any other human pathogen the 
adaptive evolution of bacteria in the antibiotic era, as it has demonstrated a unique 
ability to quickly respond to each new antibiotic with the development of a resistance 
mechanism, starting with penicillin and methicillin, until the most recent, linezolid 
and daptomycin (Fowler et al., 2006).  
 
Antibiotic susceptibilities were determined for 53 coagulase positive staphylococci 
(CPS) and 17 coagulase negative staphylococci (CNS) isolated from infected patients.  
Antibiotic susceptibility patterns were classified according to resistant, intermediate 
and sensitive (Table 4.2).  
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Table 4.2 Range of inhibition zone of different antibiotic groups for antibiotic susceptibility 
patterns 
Antibiotics Range of zone of inhibition (mm) Resistance Intermediate Sensitive 
 
β-lactum group antibiotics 
Ampicillin (10 µg) ≤28 - ≥29 
Methicillin (5 µg) ≤9  10-13 ≥14 
Oxacillin (1 µg) for CPS  ≤10 11-12 ≥13 
Oxacillin (1 µg) for CNS ≤17 - ≥18 
Amoxyclav (30 µg) ≤19 20-27 ≥28 
Penicillin-G (10 units) ≤28 - ≥29 
Cephalosporins group antibiotics 
Cephotaxime (30 µg) ≤14 15-22 ≥23 
Cephoxitin (30 µg) ≤14 15-17 ≥18 
Cephalothin (30 µg) ≤14 15-17 ≥18 
Tetracycline group antibiotics 
Tetracycline (30 µg) ≤14 15-18 ≥19 
Minocycline  (30 µg) ≤14 15-18 ≥19 
Aminoglycoside group antibiotics 
Gentamycin (10 µg) ≤12 13-14 ≥15 
Tobramycin (30 µg) ≤15 16-18 ≥19 
Amikacin (30 µg) ≤14 15-16 ≥17 
Kanamycin (30 µg) ≤13 14-17 ≥18 
Streptomycin (25 µg) ≤22 23-25 ≥26 
Neomycin (30 µg) ≤12 13-16 ≥17 
Glycylcline group antibiotic  
Tigecyclin e(15 µg) ≤14 15-19 ≥20 
Macrolides group antibiotics 
Azithromycin (15 µg) ≤13 14-17 ≥18 
Erythromycin (15 µg) ≤13 14-22 ≥23 
Clarithromycin (15µg) ≤13 14-17 ≥18 
  Cont… 
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Antibiotics Range of zone of inhibition (mm) Resistance Intermediate Sensitive 
 
Fluoroquinolones group antibiotic 
Ofloxacin (5 µg) ≤14 15-17 ≥18 
Lincosamide group antibiotic 
Clindamycin (2 µg) ≤14 15-20 ≥21 
Chloramphenicol group antibiotic 
Chloramphenicol (30µg) ≤12 13-17 ≥18 
Trimethoprime group antibiotics 
Trimethoprime (5 µg) ≤10 11-15 ≥16 
Co-Trimoxazole (25 µg) ≤10 11-15 ≥16 
Fusidane group antibiotic  
Fucidic acid (10 µg) ≤15 16-20 ≥21 
Glycopeptides group antibiotics 
Vancomyin (30 µg) ≤10 11-14 ≥15 
Teicoplanin (30 µg) ≤10 11-13 ≥14 
Aminocoumarin group antibiotic 
Novobiocin (5 µg) ≤17 18-21 ≥22 
Rifampicin group antibiotic 
Rifampicin (30 µg) ≤20 21-25 ≥26 
Oxazolidinones group antibiotic 
Linezolid (30 µg) ≤14 15-20 ≥21 
Other group antibiotic 
Mupirocin (5 µg) ≤10 11-13 ≥14 
 
4.2.1 β-lactam group 
 
All strains tested positive for β-lactamase production, and were uniformly resistant to 
β-lactam group. Antibiotic treatment is typically started before susceptibility 
information is available, but inappropriate initial therapy is associated with adverse 
clinical outcomes (Gomez et al., 2007; Rodriguez-Bano et al., 2009).  
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In this work, the results of β-lactam group antibiotic susceptibility of fifty three 
coagulase positive (CPS) and seventeen coagulase negative (CNS) clinically isolated 
staphylococci are shown in Fig. 4.2. All the strains were resistant to ampicillin, 
penicillin-G, oxacillin and amoxyclav; while methicillin resistance was observed in 
47 (88%) CPS strains, 16 (94%) CNS strains and intermediate strains were present in 
4 (8%) CPS strains but there was no intermediate strains observed in CNS strains, 
Only 2 (4%) CPS and 1 (6%) CNS strains were susceptible to methicillin. The 
antibacterial potential of β-lactum group antibiotics was very poor against all CPS and 
CNS strains studied. The most common resistance mechanism of S. aureus to β-
lactams is penicillinase, which is encoded by the bla gene usually carried on a 
plasmid. The main mechanism of methicillin-resistance is not mediated by 
penicillinase but the newly acquired PBP2a, encoded by mecA gene (de Jonge and 
Tomasz, 1993).  
 
 4.2.2 Cephalosporins group 
 
Cephalosporins (CEPs) have been widely used for the treatment of staphylococcal 
infections. Recently, an increase in the number of CEPs-resistant Staphylococcus 
aureus strains has been reported (Ayers et al., 1982). The cephalosporins are semi-
synthetic antibiotics derived from products of various microorganisms, including 
Cephalosporium and Streptomyces. All cephalosporins have a 7-
aminocephalosporanic acid composed of a dihydrothiazine ring fused to a β-lactam 
ring. We observed that antibacterial activity of cephalothin against 53 CPS strains 
showed 40 (76%) were resistant, 8 (15%) were intermediate and 5 (9%) were 
susceptible while against 17 CNS strains 14 (82%) were resistant, 2 (12%) were 
intermediate and only 1 (6%) was susceptible (Fig. 4.3). For S. aureus, the cephoxitin 
disk test is comparable to the oxacillin disk test for prediction of mecA-mediated 
resistance to oxacillin; however, the cephoxitin disk test is easier to read and thus is 
the preferred method (CLSI, 2007). Antibacterial susceptibility of cephoxitin against 
53 CPS strains showed 41 (77%) were resistant, 5 (10%) were intermediate and 7 
(13%) were susceptible while against 17 CNS strains 12 (71%) were resistant and 5 
(29%) were susceptible but no intermediate strains were observed and the results of 
antibacterial susceptibility of cephotaxime against 53 CPS strains showed 46 (87%) 
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were resistant, 7 (13%) were intermediate while against 17 CNS strains 16 (94%) 
were resistant and only 1 (6%) was intermediate but no susceptible strains were 
observed in both CPS and CNS strains. Thus, all the strains were highly resistant to 
cephalosporin group antibiotics, only 8 strains were intermediate amongst 70 strains. 
Cephalosporins are more stable than penicillins to many bacterial β-lactamases and 
therefore usually have a broader spectrum of activity. However, their bactericidal 
action alters gut flora and selects for overgrowth of resistant organisms (Barker, 
1999).  
 
4.2.3 Tetracycline group 
 
Interpretation of tetracycline derivatives must be carried out regularly because S. 
aureus strains are tetracycline-resistant but have relatively lower value of MICs of 
minocycline and/or doxycycline may harbor inducible efflux genes (Trzcinski et al., 
2000; Schmitz et al., 2001). The expanded-spectrum tetracyclines, doxycycline and 
minocycline demonstrate excellent oral bioavailability, tissue penetration, and 
tolerability (Klein and Cunha, 1995), along with the susceptibility of CA-MRSA 
strains of up to 95%; they appear to be a reasonable treatment option for 
mild/moderate MRSA infection (Ruhe and Menon, 2007). The results of antibacterial 
susceptibility of tetracycline against 53 CPS strains showed 22 (42%) were resistant, 
14 (26%) were intermediate and 17 (32%) were susceptible. Of the 17 CNS strains 
studied, 10 (59%) were resistant, 2 (12%) were intermediate and 5 (29%) were 
susceptible (Fig. 4.3). Tetracyclines are bacteriostatic agents that act by binding to the 
bacterial ribosome to inhibit protein synthesis. Tetracycline resistance in S. aureus is 
either based on modification of the ribosome encoded by the widely disseminated 
tetM gene or mediated by tetK encoded efflux. tetK is most often found in S. aureus 
(Tenover et al., 2006). Minocycline may be a useful drug in treating infection caused 
by staphylococci which are resistant to the semisynthetic penicillins and 
cephalosporins and have a more-potent activity than doxycycline (Leigh and 
Simmons, 1974). In this study, antibacterial potency of minocycline against 53 CPS 
strains showed 28 (53%) strains were resistant, 12 (23%) strains were intermediate 
and 13 (24%) strains were susceptible while against 17 CNS strains showed, 11 (65%) 
were resistant, 4 (23%) were intermediate, 2 (12%) were susceptible (Fig. 4.3).  
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Previous studies found minocycline to have a more-potent in vitro anti-staphylococcal 
activity than doxycycline (Minuth et al., 1974). Minocycline was also used 
successfully in a few reported cases of serious infections, such as endocarditis or 
osteomyelitis (Lawlor et al., 1990; Yuk et al., 1991).  Thus, both the tetracycline 
group antibiotics possess better antibacterial activity against CPS strains than CNS 
strains. 
 
4.2.4 Aminoglycosides group 
 
Aminoglycosides group antibiotics are potent bactericidal agents that play an 
important role in antistapylococcal therapy (Yadegar et al., 2009). Aminoglycoside 
molecules bind to the bacterial 30S ribosomal subunit rendering the ribosomes 
unavailable for translation, which results in cell death (Tolmasky, 2000). Our work 
provides the data of antibacterial activity of gentamicin against 53 CPS strains that 
showed 37 (70%) were resistant, 4 (7%) were intermediate and 12 (23%) were 
susceptible while against 17 CNS strains 15 (88%) were resistant and 2 (12%) were 
susceptible but no intermediate strains were observed (Fig. 4.4). Antibiotic 
susceptibility of tobramycin against 53 CPS strains showed 45 (85%) were resistant, 7 
(13%) were intermediate, only 1 (2%) was susceptible and against 17 CNS strains 14 
(82%) were resistant, 2 (12%) were intermediate, only 1 (6%) was susceptible. 
Resistant to kanamycin and streptomycin was 100% to all 53 CPS strains and against 
CNS strains 16 (94%) were resistant to both antibiotics, while 1 (6%) strain was 
susceptible to kanamycin and 1 (6%) intermediate to streptomycin.  Antibiotic 
susceptibility of neomycin against 53 CPS strains showed 45 (85%) were resistant, 6 
(11%) were intermediate, only 2 strains (4%) were susceptible and against 17 CNS 
strains 15 (88%) were resistant, only 2 (12%) were susceptible (Fig. 4.4). Antibiotic 
susceptibility of amikacin against 53 CPS strains showed 34 (64%) were resistant, 6 
(11%) were intermediate and 13 (25%) were susceptible while against 17 CNS strains 
13 (76%) were resistant, 4 (24%) were susceptible but no intermediate strain was 
observed (Fig. 4.4). More susceptible strains were obseved to amikacin and 
gentamycin than other aminoglycoside group antibiotics.  
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The main mechanism of aminoglycoside resistance in staphylococcal isolates is drug 
inactivation by cellular aminoglycoside modifying enzymes: resistance to gentamicin 
and concomitant resistance to tobramycin and kanamycin in staphylococci is mediated 
by the bifunctional enzyme AAC(6′)/APH(2‴) encoded by the aac(6′)-Ie-aph(2‴) 
gene; resistance to neomycin, kanamycin, tobramycin and amikacin is mediated by an 
ANT(4′)-I enzyme encoded by the ant(4′)-Ia gene; and resistance to neomycin and 
kanamycin is mediated by the APH(3′)-III enzyme encoded by the aph(3′)-III gene 
(Schmitz et al., 1999). 
 
4.2.5 Glycylcycline group 
 
Tigecycline, a glycylcycline, is a synthetic analog of the tetracycline class of 
antibiotics and is currently approved in the US for treatment of complicated skin and 
skin structure infections, complicated intra abdominal infections, and community-
acquired bacterial pneumonia (Rose and Rybak, 2006). Glycylcyclines were 
developed in 1993 at Lederle Laboratories, where the first tetracyclines had been 
isolated in 1945 (Chopra and Roberts, 2001). Glycylcyclines are modified 
antimicrobial agents that possess the central 4-ring carbocyclic skeleton that is 
essential for antibacterial activity. Substitution of an N-alkyl-glycylamido group at the 
9 position on the D ring confers to these new agents a broader spectrum of activity 
and permits evasion of resistance to tetracycline (Zhanel et al., 2004). Tigecycline 
promotes the expression of initiation factors, elongation factors and ribosomal 
proteins. The drug elicits its antimicrobial effect on bacteria by binding to the 30S 
ribosomal subunit, which blocks the entry of amino-acyl tRNA molecules into the A 
site of the ribosome, which prevents the incorporation of amino acid residues into the 
elongating peptide chain and inhibits protein synthesis (Projan, 2000). In the present 
work, the results of antibacterial susceptibility of tigecycline against 53 CPS strains 
showed 24 (45%) were resistant and another 24 (45%) were intermediate, 5 (10%) 
were susceptible while against 17 CNS strains, 11 (64%) were resistant, 3 (18%) were 
intermediate and another 3 (18%) were susceptible (Fig. 4.5). Tigecycline resistant 
strains indicated similar results as with tetracycline group antibiotics. Tigecycline is 
not affected by most of the known mechanisms of resistance to tetracycline 
encountered in bacteria (Bauer et al., 2004) and it has activity against bacterial 
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isolates that are resistant to other antibiotic classes, such as β-lactams and 
fluoroquinolones.  
 
4.2.6 Macrolides group 
 
In macrolides group, erythromycin A is a broad spectrum of antimicrobial agent and 
used primarily for respiratory, skin and soft tissue infections (Blondeau et al., 2002). 
Macrolides target the 50S subunit of the prokaryotic ribosome, binding reversibly to 
domain V of the 23S rRNA (Schlunzen et al., 2001). Ribosome modification and drug 
efflux are the most frequent resistance mechanisms in S. aureus. It is mediated by the 
erm gene, which encodes a methylase that adds one or two methyl groups to the 23S 
rRNA (Zhanel et al., 2002). Our results of antibacterial activity of erythromycin 
against 53 CPS strains showed 47 (89%) were resistant, 6 (11%) were intermediate 
while all CNS strains were resistant (Fig. 4.5) and antibacterial potency of 
azithromycin against 53 CPS strains showed 44 (83%) were resistant, 7 (13%) were 
intermediate and only 2 (4%) were susceptible while 17 CNS strains were 100% 
resistant (Fig. 4.5). Macrolides group including 3rd antibiotic like clarithromycin 
against 53 CPS strains showed 46 (87%) were resistant, 5 (9%) were intermediate and 
2 (4%) were susceptible while against 17 CNS strains 16 (94%) were resistant and 
only 1 (6%) was intermediate (Fig. 4.5). Macrolides group antibiotics showed poor 
antibacterial effect against all CPS and CNS strains. Higher resistance to macrolides 
group having erythromycin was also observed by other researchers (Nagaraju et al., 
2004). The resistance of gram-positive pathogens to macrolides, including the newer 
semisynthetic derivatives azithromycin and clarithromycin, has increased globally in 
the last decade. The new macrolides have similar indications for use as erythromycin 
but with some additional areas of potential value (Montejo-Bernardo et al., 2006). 
 
4.2.7 Fluoroquinolones group 
 
Fluoroquinolones are one of the first families of fully synthetic antibiotics with large 
clinical use, and they represent a wide range of molecules, which permits the 
establishment of in-depth structure-activity relationships (Chu and Fernandes, 1989; 
Domagala, 1994). Over the last 20 years, most fluoroquinolone research efforts have 
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been focused on new molecules with improved activity toward Gram positive cocci 
because of the increasing spread of multi-resistant staphylococci and streptococci. 
Ofloxacin is a new fluoroquinolone antimicrobial agent that possesses excellent in 
vitro activity against a broad range of bacteria, including methicillin-susceptible and -
resistant strains of Staphylococcus aureus (Mitsuhashi, 1988). In this study, 
antibacterial susceptibility of ofloxacin against 53 CPS strains showed 52 (98%) were 
resistant, only 1 (2%) was susceptible and against CNS strains 16 (94%) were 
resistant, only 1 (6%) was intermediate but no susceptible strains were observed (Fig. 
4.5). However, in the clinical experience, ofloxacin-resistant S. aureus has emerged 
very rapidly and the majority of the ofloxacin-resistant strains consisted mainly of 
MRSA (Shalit et al., 1989). It interferes with the activity of the bacterial type II 
topoisomerase enzymes, DNA gyrase and topoisomerase IV, with bactericidal 
consequences for the organism (Drlica and Hooper, 2003). In Staphylococcus aureus, 
fluoroquinolones act against both enzymes, although topoisomerase IV is usually the 
primary target (Takei et al., 2001). Fluoroquinolones show good activity in vitro 
against S. aureus and are used clinically to treat staphylococcal infections. However, 
emergence of resistance to these antimicrobials has limited their use (Trong et al., 
2005).  
 
4.2.8 Lincosamide group 
 
In lincosamide group, clindamycin is among the limited choices of antimicrobials 
effective against MRSA. It has not been recommended for treatment of severe 
infection caused by nosocomial MRSA because of high-level resistance. As compared 
with the macrolides, clindamycin is more commonly used to treat staphylococcal 
infections. It has specific use in patients with β-lactam hypersensitivity, in the 
treatment of infections caused by isolates resistant to alternative agents and in the 
treatment of staphylococcal toxin-mediated disease. The obtained data showed that 
antibacterial activity of clindamycin against 53 CPS strains showed 25 (47%) were 
resistant, 21 (40%) were intermediate and 7 (13%) were susceptible while against 17 
CNS strains 12 (70%) were resistant, 3 (18%) were intermediate and only 2 (12%) 
were susceptible (Fig. 4.5).  
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Higher number of intermediate and resistant strains was observed to clindamycin 
indicated the studied strains are near to resistant with lincosamide group antibiotic and 
resistant to clindamycin was also reported by other research groups recently (Shenoy  
et al., 2010 ; Diaz  et al., 2011). One of the most common mechanisms of resistance 
to these classes of antimicrobials involves posttranscriptional alteration of a specific 
base of rRNA that results in ribosomes with reduced drug affinity (Weisblum, 1995). 
 
4.2.9 Chloramphenicol group 
 
A very high proportion of MRSA isolates in different areas of the world remain 
susceptible to chloramphenicol, including community-acquired isolates (Mendes et 
al., 2008). Mechanism of chloramphenicol resistances in staphylococci to be one of 
antibiotics inactivation via the inducible enzyme chloramphenicol acetyltransferase 
(CAT), which catalyzes the O-acetylation of chloramphenicol by acetyl-coenzyme A 
(CoA) (Shaw, 1970). In the present study antibacterial susceptibility of 
chloramphenicol against 53 CPS strains showed 22 (42%) were resistant, 16 (30%) 
were intermediate and 15 (28%) were susceptible while against 17 CNS strains 6 
(35%) were resistant and another 6 (35%) were intermediate, 5 (30%) were 
susceptible (Fig. 4.6). As compared to other antibiotics, chloramphenicol showed 
good antibacterial effect against CPS and CNS strains. In six sequential multicentre 
national studies of Staphylococcus in Spain from 1986 to 2006, the rates of 
chloramphenicol susceptibility ranged from 92% to 98% (Cuevas et al., 2008). 
 
4.2.10 Trimethoprim group 
 
In trimethoprim group, antibiotic is a synthetic, broad-spectrum antimicrobial agent. 
This drug is mainly used in combination with sulfonamides for prophylaxis and 
treatment of urinary tract infection and certain types of pneumonia (Manius, 1978). It 
is bactericidal but does not have any activity against Group A Streptococcus infection 
that may also cause skin and soft-tissue cellulitis. Co-trimoxazole, an antibiotic in use 
for several decades, has been shown to be active against S. aureus (including MRSA) 
in vitro (Kaka et al., 2006). In our work, the data of susceptibility of trimethoprim 
against 53 CPS strains showed 43 (81%) were resistant, 8 (15%) were intermediate 
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and only 2 (4%) were susceptible. Of the 17 CNS strains 13 (76%) were resistant, 3 
(18%) were intermediate and 1 (6%) was susceptible (Fig.4.6). Co-trimoxazole 
against CPS strains showed that 40 (75%) were resistant, 9 (17%) were intermediate 
and 4 (8%) were susceptible. Of the CNS strains 12 (71%) were resistant, 4 (23%) 
were intermediate and only 1 (6%) was susceptible (Fig. 4.6). Trimethoprim (TMP) 
and sulfamethoxazole (SMX) are potent and selective inhibitors of dihydrofolate 
reductase (DHFR) and dihydropteroate synthase (DHRS), respectively, two essential 
enzymes in the folate biosynthetic pathway. This alarming capacity for resistance 
necessitates the elucidation of antibiotic resistance mechanisms in S. aureus and the 
development of new therapeutic strategies to combat wild-type and resistant MRSA 
infections (Dale et al., 1997). TMP-SMX is available in oral and IV formulations. 
Because of its renal elimination dosing must be adjusted for renal function. Among 
the side effects associated with TMP-SMX are gastrointestinal upset, dermatologic 
reactions, cytopenias and hepatic and renal dysfunction (Zinner et al., 2005). Folate 
antagonists, such as TMP-SMX, are not recommended for use during pregnancy 
(Lawson and Paice, 1982). Previous studies showed that synergistic effect of TMP-
SMX was bactericidal against MSSA and MRSA (Yeldandi et al., 1988; Bordon et 
al., 2010), in contrast we have observed high resistance to TMP-SMX.  
 
4.2.11 Fusidane group 
 
Fusidic acid is the only commercially available member of the fusidane antibiotic 
group. It acts by inhibiting bacterial protein synthesis through interference with 
elongation factor G in the translocation step (Burns et al., 1974).  It has been used to 
treat infections with S. aureus for over 35 years. It is usually used in combination with 
agents such as vancomycin or rifampin in the treatment of systemic treatment of 
conditions such as osteomyelitis and joint graft infections caused by MRSA (Howden 
and Grayson, 2006) In this study, antibacterial susceptibility of fusidic acid against 53 
CPS strains showed 28 (53%) were resistant, 16 (30%) were intermediate and 9 (17%) 
were susceptible while against CNS strains 10 (59%) were resistant, 5 (29.41%) were 
intermediate and only 2 (12%) were susceptible (Fig. 4.6). The resistance mechanisms 
of S. aureus to fusidic acid may arise from one of at least three different resistance 
classes: the FusA class (mutation of elongation factor G), (Savelsbergh et al., 2009) 
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FusB class (plasmid-mediated resistance), and FusC class (chromosomal fusC gene) 
(O’Neill et al., 2007; Lannergard et al., 2009). The genes fusB and fusC were found in 
S. aureus and coagulase-negative staphylococci (McLaws et al., 2008). The frequency 
of fusidic acid resistance is not very high; however, the emergence of clinical 
staphylococcal species that are resistant to fusidic acid has been reported, which is 
similar to this present work (Osterlund et al., 2006; Castanheira et al., 2010). 
 
4.2.12 Glycopeptide group 
 
Glycopeptide group antibiotics, teicoplanin and vancomycin are excellent antibiotics 
for the nosocomial treatment of multidrug-resistant Gram-positive pathogens, 
particularly MRSA (Linden, 2002). They should not be used as first-line treatment 
against β-lactam–susceptible organisms (Chang et al., 2003). Vancomycin and 
teicoplanin bind to the terminal D-alanyl-D-alanine (D-Ala-D-Ala) of the 
pentapeptide-glycosyl cell wall intermediate, inhibiting the transpeptidase reaction of 
bacterial cell wall synthesis (Ge et al., 1999; Courvalin, 2006). It is observed from our 
data that, antibacterial susceptibility of vancomycin against CPS strains showed 22 
(41%) were resistant, 29 (55%) were intermediate and only 2 (4%) were susceptible 
while against 17 CNS strains were 8 (47%) were resistant, 6 (35%) were intermediate 
and 3 (18%) were susceptible (Fig. 4.6). Vancomycin intermediate S. aureus (VISA) 
strains have now been isolated from many areas of the world but detection of VISA 
requires MIC measurement because disc diffusion tests have been shown to be 
unreliable (Marchese et al., 2000) In other glycopeptides group, antibiotic 
susceptibility of teicoplanin against 53 CPS strains showed 35 (66%) were resistant, 
16 (30%) were intermediate and 2 (4%) were susceptible while against 17 CNS 
strains 12 (71%) were resistant, 4 (23%) were intermediate and only 1 (6%) was 
susceptible (Fig. 4.6). As per present results, the susceptibility of MRSA to 
vancomycin has decreased (vancomycin-intermediate and -resistant S. aureus), that 
was also reported by other authors (Neoh et al., 2007; Buzaid et al., 2011). 
Furthermore, a decrease in the susceptibility of MRSA to teicoplanin has been 
reported in some hospitals worldwide (Vaudaux et al., 2001; Picazo et al., 2011). The 
emergence of MRSA resistant to the ‘last resort’ antibiotics like vancomycin and 
teicoplanin has created an urgent need for the discovery of alternative antibiotics.  
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4.2.13 Aminocoumarin group 
 
In aminocoumarin group novobiocin, a dihydroxl-glycosylated coumarin derivative 
has an antimicrobial activity that was used, to treat infections in humans, with Gram-
positive bacteria prior to the development of the penicillinase-resistant anti-
staphylococcal penicillins (French et al., 1993). This agent is produced by 
Streptomyces caeruleus and is a potent inhibitor of bacterial gyrase (Maxwell and 
Lawson, 2003). Novobiocin was widely used in the 1950s as a potent antibiotic 
against a wide range of staphylococcal infections (Finland and Nichols, 1957). In this 
study, antibacterial potency of novobiocin against 53 CPS strains showed 32 (60%) 
were resistant, 14 (27%) were intermediate, 7 (13%) were susceptible while against 
17 CNS strains 12 (71%) were resistant, 3 (17%) were intermediate and only 2 (12%) 
were susceptible (Fig. 4.7). Novobiocin inhibits bacterial DNA gyrase, interfering 
with protein and nucleic acid synthesis, and bacterial cell wall synthesis (Anderle et 
al., 2008). DNA gyrase and topoisomerase IV (topo IV) are essential bacterial type II 
topoisomerases that play important roles in DNA replication, chromosome 
segregation and DNA compaction (Khodursky et al., 2000). Novobiocin is a 
bactericidal antimicrobial agent that has been used for the treatment of susceptible 
Gram-positive bacteria and some urinary tract infections with Proteus species but 
most Gram-negative organisms are resistant (Plumb, 2005). Increase in resistance 
against staphylococci to novobiocin observed in this work is in consonance repots 
(Stieger et al., 1996). 
 
4.2.14 Rifampicin group 
 
Rifampicin is an antibiotic of substantial interest in assessing the rise of MRSA 
infections, Single use of rifampicin results in the rapid emergence of resistance 
(Perlroth et al., 2008). From our work it is observed susceptibility of rifampicin 
against CPS strains showed 25 (47%) were resistant, 12 (23%) were intermediate and 
16 (30%) were susceptible while against CNS strains 9 (52%) were resistant, 4 (24%) 
were intermediate and another 4 (24%) were susceptible (Fig. 4.7). Rifampicin 
resistance in S. aureus, as in other bacteria, is associated with mutations in particular 
regions (clusters I and II) located in the b-subunit gene rpoB of bacterial RNA 
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polymerase (Severinov et al., 1993).  Rifampicin should never be used as a single 
agent for the treatment of MRSA (Strausbaugh et al., 1992) but combinations of 
rifampicin with other anti-staphylococcal agents such as quinolones (Zimmerli et al., 
1998) or fusidic acid (Drancourt et al., 1997) could prevent the emergence of 
rifampicin resistance during therapy (Moellering, 2008) but rifampicin susceptibility 
testing should be performed before considering combination treatment with 
rifampicin in MRSA infection (Tan et al., 2011). Rifampicin has numerous potential 
adverse effects, including anaphylaxis, hemolytic anemia, gastrointestinal symptoms, 
acute renal failure, thrombocytopenia, uveitis, and rash, in addition to hepatic toxicity 
(Vesely et al., 1998).  
 
4.2.15 Oxazolidinones group 
 
Linezolid is a novel and fully synthetic antimicrobial agent belonging to a new class, 
the oxazolidinones. (Stevens et al., 2004) Linezolid therapy is safe, well tolerated and 
superior to vancomycin in the treatment of hospital and community acquired 
pneumonia and CSSTIs due to MRSA (Devasahayam et al., 2010). The oral form of 
linezolid is 100% bioavailable (Welshman et al., 2001). Patients with MRSA 
infections who are treated with linezolid have shorter i.v. treatment times and an 
increased chance of being discharged from the hospital in 1 week (Noskin, 2001; Hau, 
2002). From our data it is observed that, antibacterial potency of linezolid against 53 
CPS strains showed 17 (32%) were resistant, 18 (34%) were intermediate and another 
18 (34%) were susceptible while against 17 CNS strains 3 (18%) were resistant, 7 
(41%) each were intermediate and susceptible (Fig. 4.7). The drug binds to ribosomal 
RNA specifically to domain V of the 23S rRNA, on the 50S ribosomal subunit near 
its interface with the 30S subunit these two subunits join to form the 70S ribosome, 
used by prokaryotes in protein synthesis (Aksoy and Unal, 2008). Major advantage of 
linezolid is that it has excellent, nearly 100% absorption from the gastrointestinal tract 
(Gee et al., 2001). Common adverse effects of linezolid include headache, 
nausea/vomiting, diarrhea and hematologic side effects. A potentially more serious 
problem associated with linezolid is myelosuppression. If this antibiotic is used for 
more than 2 weeks, it is recommended that a baseline complete blood cell count 
(CBC) be obtained and that the CBC be monitored at least weekly (Peeters and Sarria, 
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2005). Higher antibacterial effect of linezolid encourages more use of this antibiotic 
in hospitals, but the treatment of the patient with linezolid must be observed by 
doctors properly.  
 
4.2.16 Mupirocin (other group) 
 
In other group antibiotic like mupirocin, one of the most powerful topical anti-
staphylococcal antibiotics discovered to date, decolonization of patients colonized 
with MRSA remains a challenge (Wilcox et al., 2003). Mupirocin (pseudomonic acid) 
is an antibiotic derived from cultures of Pseudomonas fluorescens that inhibits 
bacterial protein synthesis by reversibly binding to bacterial isoleucyl-tRNA 
synthetase (Laupland and Colby, 2003).  The data presented here about antibiotic 
susceptibility of mupirocin showed 53 CPS strains 16 (30%) were resistant, 4 (8%) 
were intermediate and 33 (62%) were susceptible while 17 CNS strains 2 (12%) were 
resistant, 3 (18%) were intermediate and 12 (70%) were susceptible (Fig. 4.7). 
Mupirocin resistance has occurred following its extensive and widespread use, which 
is highly problematic since mupirocin is currently the only effective agent for MRSA 
decolonization (Patel et al., 2009). Mupirocin is used mainly to inhibit methicillin-
resistant Staphylococcus aureus during skin infections (Mori et al., 2005). Higher 
numbers of susceptible strains were observed it’s indicating that mupirocin is a good 
choice for the treatment of the staphylococcal infections.  
 
The emergence of antibiotic resistant strains poses a significant problem both in 
community as well as hospital practice in deciding empiric therapy. It is therefore 
important to monitor the changing trends in bacterial infections and their 
antimicrobial susceptibility patterns. Studies like the present one help in establishing 
the etiological agents and deciding empiric therapy from time to time. The increasing 
resistance observed to β-lactam, cephalosporins, aminoglycoside, macrolides, 
fluoroquinolones and trimethoprime groups limits their use as first choice 
antimicrobial agents. The older β-lactams, penicillin and ampicillin are ineffective 
against most of the isolated strains, and resistance to many of the non-β-lactam agents 
such as the tetracyclines, gentamycin, chloramphenicol and clindamycin has gradually 
increased and reached alarming levels by the 1990s in many parts of the world (Bell  
010
20
30
40
R I S
32
14
7
12
3 2
Novobiocin
(5 µg)
0
10
20
30
R I S
25
12
16
9
4 4
Rifampicin
(30 µg)
Linezolid
(30 µg)
Mupirocin
(5 µg)
N
o.
of
st
ra
in
s
Chapter 4: Results and Discussion Ph.D. Thesis | Harsha Patel | January, 2012
Saurashtra University | Sub: Microbiology
0
5
10
15
20
R I S
17 18 18
3
7 7
0
10
20
30
40
R I S
16
4
33
2 3
12
Antibiotic susceptibility of aminocoumarin, rifampicin, oxazolidinones
and other group antibiotics against Staphylococcus strains
Coagulase positive strains Coagulase negative strains
R – Resistant; I – Intermediate; S- Susceptible
Fig. 4.7
Antibiotic susceptibility
Page | 101
 
 
Chapter 4: Results and Discussion       Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
                                
 
 
Page | 102  
 
and Turnidge, 2002). So an antibiotic policy and the monitoring of susceptibility 
patterns of MRSA may also help in decreasing the prevalence of MRSA and 
antibiotic resistance. Linezolid and mupirocin showed better anti-staphylococcal 
effects as reported by other researchers (Perez-Roth et al., 2002; Samra et al., 2005; 
Efe et al., 2009; Fulham et al., 2011; Meyer et al., 2011), which is evidence in our 
results. So it can be concluded that both mupirocin and linezolid are good choice as 
compared to other antibacterial agents for the treatment of staphylococcal infections 
because of its higher anti-staphylococcal activity.  
 
4.3 Minimum Inhibitory Concentration (MIC) studies  
 
Minimum inhibitory concentrations (MICs) are considered the ‘gold standard’ for 
determining the susceptibility of organisms to antimicrobials and are therefore used to 
judge the performance of all other methods of susceptibility testing. MICs are used in 
diagnostic laboratories to confirm unusual resistance, to give a definitive answer when 
a borderline result is obtained by other methods (Andrews, 2001). There are many 
laboratory methods for the detection of methicillin resistance in S. aureus. Most 
laboratories use disk diffusion method for routine tests. The gold standard, for 
antimicrobial susceptibility testing has been the MIC determined by a dilution or E-
test method. The E-test method gives an MIC result and is affected by test conditions 
in a similar way to other MIC and diffusion methods. The test conditions 
recommended by the manufacturer are based on providing results comparable with 
National committee on clinical laboratory standards (NCCLS) methods (Brown et al., 
2005). E-test has been previously evaluated for testing the antimicrobial susceptibility 
of a variety of bacteria. The E-tests are plastic strips coated with a continuous gradient 
of antibiotic. This test is also easy to use and presents a practical alternative to 
conventional antimicrobial susceptibility test systems when only a few drugs require 
testing, when a special growth medium is required, or both (Huang et al., 1992). 
 
4.3.1 MIC of oxacillin 
 
MIC strips of oxacillin, vancomycin, tigecycline, linezolid and rifampicin were used 
for MIC determination against 53 CPS and 17 CNS strains. For the determination of 
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MIC of oxacillin, MHA with 2% NaCl can be used, for reliable detection of oxacillin 
resistance; an inoculums, density equivalent to 0.5 McFarland standards was applied 
with a swab and incubated at 35ºC for 24 h. The MIC strips containing a gradient of 
oxacillin concentrations ranging from 0.016 to 256 µg/ml were placed on the agar 
surface. MIC strips contain a continuous gradient of antimicrobial agent were placed 
on the underside of the strip which diffuses into the medium when the strip is placed 
on the surface of the agar plate. Inhibition of growth appears in the shape of an ellipse 
and MIC was read at the point of intersection between the zone edge or ellipse and the 
MIC strip. Because of the transparent nature of MHA, using transmitted light and 
allowing it to shine through the underside of the plate allowed greater ease in 
interpretation of the MIC. The results of MIC of oxacillin are presented in Fig. 4.8. 
The isolates that had MIC value ≥4 µg/ml for CPS and ≥0.5 µg/ml for CNS strains 
were accepted as oxacillin-resistant. The strip showed a wide range of oxacillin MICs 
(0.512 - > 256 µg/ml) among these 53 CPS isolates, fourteen isolates (27%) were 
highly resistant with MIC of > 256 µg/ml while 32 (60%) strains were resistant with 
MIC between 4-128 µg/ml. Only 7 (13%) strains were susceptible to oxacillin with 
MIC between 0.512 - 2 µg/ml. Results of MIC against 17 CNS strains showed 11 
strains (65%) were highly resistant with > 256 µg/ml MIC value, while other 6 (35%) 
strains were resistant with MIC between 1.024-32 µg/ml. Susceptible strains were not 
observed amongst any of the CNS strains.  
 
4.3.2 MIC of vancomycin and teicoplanin 
 
In recent times, multidrug-resistant organisms have been shown to be able to develop 
resistance to the last antibiotic family, the glycopeptides to which they were still 
susceptible (Heym et al., 2002). Since 1997, two major categories of vancomycin 
resistance in Staphylococcus aureus have been defined. The first category refers to 
vancomycin-resistant S. aureus (VRSA) clinical isolates with exogenously acquired 
vanA-mediated high-level resistance (vancomycin MICs, ≥16 µg/ml) (Chang et al., 
2003; Sievert et al., 2008); the second category includes vancomycin-intermediate S. 
aureus (VISA) isolates that developed low-level resistance (vancomycin MICs, ≥4 to 
<16 µg/ml) (Tenover and Moellering, 2007). In 2006, the Clinical and Laboratory 
Standards Institute (CLSI) lowered the S. aureus vancomycin susceptibility 
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breakpoint from 4 µg/ml to 2 µg/ml in response to evidence that vancomycin has 
reduced efficacy against isolates with MIC ≥ 4 µg/ml. The resistance breakpoint was 
also lowered (16 - 32 µg/ml), reflecting clinical judgment that S. aureus strains with 
MIC ≥ 16 µg/ml are fully resistant to vancomycin. The reduction of these breakpoints 
has also resulted in the redefinition of intermediate resistance as those strains with 
MIC between 4 µg/ml to 8 µg/ml (Gould, 2008). The results of MIC of vancomycin 
and teicoplanin are presented in Fig. 4.8. In the present investigation, the MIC strips 
containing different concentrations of vancomycin ranging from 0.016 - 256 µg/ml 
were placed on the agar surface. Analysis of the vancomycin resistance level by strip 
test showed a wide range of vancomycin MICs (0.032 - 32 µg/ml). Among 53 CPS 
isolates, vancomycin resistance was observed in only one strain (2%) with 32 µg/ml 
MIC value. Eight strains (15%) were intermediate with 4 - 8 µg/ml and other 44 
strains (83%) were susceptible with MIC between 0.032 - 2.048 µg/ml. In the year 
1996, first VISA was reported in Japan and later on in USA, Europe and other Asian 
countries (Hiramatsu et al., 1997; Hamilton-Miller, 2002). In recent studies, VISA 
and VRSA have been reported from different parts of the World (Howden et al., 
2010; Meziane-Cherif et al., 2010; Kelley et al., 2011). In glycopeptides group 
containing other antibiotic like teicoplanin is known to have high distribution features, 
a longer elimination half-life and lower adverse effects than vancomycin (Ahn et al., 
2011). In the present work, MIC of teicoplanin was determined at different 
concentrations ranging from 0.001 - 240 µg/ml. The results showed that among 53 
CPS stains, three strains (6%) were intermediate (MIC value ≥16 µg/ml) with 30 
µg/ml MIC value, MIC of one strain was 10 µg/ml, while other 49 strains (92%) were 
susceptible (MIC value ≤8 µg/ml) with MIC between 0.01 and  5 µg/ml. Results of 17 
CNS strains showed one strain (6%) was intermediate with 30 µg/ml MIC value, MIC 
of one strain was 10 µg/ml and other 15 strains (88%) were susceptible with MIC 
between 0.01 and 5 µg/ml. In this study teicoplanin resistant (MIC value ≥32 µg/ml) 
strains were not found among all CPS and CNS strains.  Our observations highlight 
several important issues regarding the detection of MRSA with reduced susceptibility 
to glycopeptide antibiotics may not be treated successfully with vancomycin or 
teicoplanin, making it important to closely observe MRSA with reduced susceptibility 
to glycopeptide antibiotics.  
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4.3.3 MIC of linezolid 
 
Linezolid is a synthetic antibiotic belonging to the oxazolidinone family (Lentino et 
al., 2008). It is active against Gram-positive micro-organisms, including multi-
resistant strains, being bacteriostatic against Staphylococcus species (Jacqueline et al., 
2003). In patients with MRSA infections, linezolid has shown comparable efficacy to 
vancomycin (Stevens et al., 2002). Its unique mechanism of action by inhibiting 
ribosomal protein synthesis at an early stage of bacterial DNA replication leads to the 
absence of cross resistance with other antimicrobials (Rubinstein et al., 2001). 
Although linezolid non-susceptible strains are unusual (Jones et al., 2007); long 
courses of oxazolidinone therapy could possibility of resistant mutants (Wilson et al., 
2003). The most frequently reported mechanism of resistance being the G2576T point 
mutation, which has been documented in Staphylococcus aureus (Tsiodras et al., 
2001), Staphylococcus epidermidis (Kelly et al., 2008), Enterococcus faecalis 
(Burleson et al., 2004) and Enterococcus faecium (Scheetz et al., 2008). The results of 
MIC of linezolid are presented in Fig. 4.9. The MIC strips containing different 
concentrations of linezolid ranging from 0.001-240 µg were used in this study. All 
CPS and CNS strains were considered resistant if MIC value was more than 4 µg/ml 
and susceptible if MIC value was less than or equal to 4 µg/ml. Results showed that 
among 53 CPS strains, four strains (8%) were resistant with MIC between 8 - 30  
µg/ml and the other remaining 49 strains (92%) were susceptible with MIC ranging 
from 0.1 - 4 µg/ml. MIC of 17 CNS strains showed two strains (12%)  were resistant 
with 8 µg/ml value and other 15 strains (88%) were susceptible with MIC ranging 
from 0.1 - 2 µg/ml to linezolid. According to other researchers, resistance to linezolid 
is uncommon, and some cases have been reported for Staphylococcus species (Meka 
et al., 2004; Potoski et al., 2006). One of the main features of linezolid is that it has a 
high oral bioavailability, which makes it easy to administer and adhere to the 
treatment (Gee et al., 2001). Compared to vancomycin therapy, linezolid therapy is 
associated with a decreased length of stay after treatment initiation, as indicated by 
the significantly higher discharge rate, while length of stay was generally lower (1 to 
3.5 days) for patients treated with linezolid (Caffrey et al., 2010). 
 
 
 
 
Chapter 4: Results and Discussion       Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
                                
 
 
Page | 107  
 
4.3.4 MIC of rifampicin 
 
Rifampicin resistance in S. aureus is associated with mutations in particular regions 
(cluster I and II) of the gene rpoB (Wichelhaus et al., 1999). Rifampicin cannot be 
used as a single agent to treat MRSA infections because of the rapid mutation in the 
bacteria (Aubry-Damon et al., 1998). However, combinations of rifampicin with other 
anti-staphylococcal agents such as quinolones (Zimmerli et al., 1998) or fusidic acid 
(Drancourt et al., 1997) could prevent the emergence of rifampicin resistance during 
therapy (Moellering, 2008). The results of MIC of rifampicin against 53 CPS strains 
and 17 CNS strains are shown in Fig. 4.9. The MIC strips containing different 
concentrations of rifampicin was ranging from 0.001 - 240 µg. Resistant strains were 
considered if MIC value was more than or equal to 4 µg/ml, considered intermediate 
if MIC value was 2 µg/ml and susceptible if MIC value was less than or equal to 1 
µg/ml. Among 53 CPS strains, 6 strains (11%) were resistant with MIC ranging from 
>240 to 4 µg/ml and other 47 (89%) strains were susceptible with MIC between 0.001 
and 1 µg/ml while against 17 CNS strains, 7 (41%) strains were resistant with MIC 
ranging from 4 to >240  µg/ml and other 10 (59%) strains were susceptible with MIC 
between 0.001  and 1 µg/ml. Tosun et al. (2005) also reported similar results of 
rifampicin resistance against 23 clinically isolated S. aureus.  
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4.4 Characterization of Staphylococcus strains using molecular method  
 
Methicillin-resistant Staphylococcus strains possess the ability to grow in the presence 
of derivatives of β-lactams (Tang et al., 2007). Methicillin-resistance is transferred to 
susceptible strains through horizontal transfer of mecA gene (Wielders et al., 2002). 
The mecA gene encodes penicillin-binding protein 2a (Moisan et al., 2010) and it is a 
useful molecular marker of methicillin-resistant strains. Isolates of S. aureus that 
carry mecA gene or that produce PBP2a should be reported as MRSA and isolates 
lacking mecA gene or do not produce PBP2a should be reported as MSSA (Gradelski 
et al., 2001). Methicillin-resistance may be complex and difficult to detect because 
mecA-positive strains differ in their levels of expression of methicillin-resistance 
(Hartman and Tomasz, 1984). Detection of methicillin-resistance by conventional 
methods such as oxacillin disk agar diffusion and oxacillin salt screening tests are 
widely used in routine microbiological laboratories (Chomvarin et al., 2004). 
However final identification cannot be determined without the support of genetic data 
because expression of methicillin-resistance in a clinical laboratory setting is subject 
to environmental conditions like temperature (Canawati et al., 1982), medium, pH 
(Sabath et al., 1972) and NaCl conc. (Chambers and Hackbarth 1987) of the medium 
and other factors like inoculum size, incubation time, (Brown, 2001) etc. 
Conventional bacterial culture method is reliable but relatively time-consuming, 
laborious and expensive but may not be sensitive enough for the diagnosis of 
infections with fastidious bacteria, or for specimens collected after initiation of an 
antibiotic therapy (Rosey et al., 2007). PCR-based assay for the detection of 
methicillin-resistance by mecA gene is considered ‘gold standard’ and results can be 
obtained quickly (Ozel et al., 2011).  
 
In molecular biology, nucleic acids are generally quantifid done to determine the 
average concentrations of DNA or RNA present in a mixture, as well as their purity 
(Table 4.3). Reactions that use nucleic acids often require particular amounts and 
purity for optimum performance. The ratio of absorbance at 260 nm and 280 nm is 
used to assess the purity of DNA and RNA respectively. A ratio of ~1.8 is generally 
accepted as “pure” for DNA; a ratio of ~2.0 is generally accepted as “pure” for RNA. 
For the purpose of evaluation of DNA purity, DNA was taken after extraction using 
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the GeneiPureTM Bacterial DNA Purification kit and A260/A280 was determined. Only 
those genomic DNA samples were used which had the ratio of A260 and A280 between 
1.8 and 2.0 using Nano Drop Spectrophotometer (Model number ND 1000, Nano 
Drop Technologies, Inc. Wilmington, DE, USA) (Table 4.3). Quality of genomic 
DNA was also assessed by electrophoresis on 0.8% agarose gel followed by ethidium 
bromide staining.  
 
Table 4.3 Quantification and quality test of genomic DNA of clinically isolated 
Staphylococcus strains 
 
Strain No. Qty. (ng/µl) A260/A280  Strain No. Qty. (ng/µl) A260/A280 
S1 48.1 1.84  S36 19.1 1.91 
S2 28.2 1.85  S37 13.5 1.86 
S3 94.3 1.76  S38 13.2 1.97 
S4 37.7 1.88  S39 22.8 1.93 
S5 21.5 1.90  S40 43.7 1.94 
S6 40.0 1.93  S41 14.0 1.79 
S7 63.3 1.71  S42 25.1 1.79 
S8 19.5 1.94  S43 15.0 1.88 
S9 22.9 1.89  S44 16.2 1.80 
S10 11.7 2.00  S45 10.8 1.78 
S11 25.1 1.84  S46 29.4 1.77 
S12 17.7 1.91  S47 15.9 1.67 
S13 12.6 1.81  S48 25.9 1.89 
S14 17.9 2.01  S49 28.5 1.96 
S15 13.3 1.86  S50 10.2 1.81 
S16 20.3 1.87  S51 50.1 2.05 
S17 32 1.91  S52 26.1 1.93 
S18 14.9 1.83  S53 68.3 1.81 
S19 78.7 1.94  S54 23.3 1.81 
S20 89.1 1.80  S55 23.3 1.77 
S21 26.9 1.88  S56 22.1 2.01 
S22 70.3 1.79  S57 41.1 1.76 
S23 10.2 1.72  S58 23.5 1.85 
S24 18.1 1.97  S59 11.4 1.99 
S25 87.6 2.03  S60 10 1.75 
S26 25.8 1.87  S62 13.2 1.78 
S27 22.3 1.97  S63 13.3 1.93 
S28 14.9 1.75  S64 15.5 1.94 
S29 20.8 1.77  S65 15.4 1.84 
S31 12.2 1.88  S66 17.6 1.86 
S32 10.4 1.82  S67 9.8 1.89 
S33 63.3 1.81  S68 20.9 1.94 
S34 62.5 1.89  S69 14.4 1.89 
S35 18.6 1.79  S70 11.7 2.00 
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4.4.1 Detection of mecA gene using PCR assay 
 
The heterogeneous nature of methicillin-resistance is an inherent limitation of the 
accuracy of susceptibility testing. Thus, detection of the mecA gene by PCR has been 
found to be a potentially sensitive method to identify heterogeneous strains of 
methicillin-resistant Staphylococcus (Prasad et al., 2000). Several PCR techniques 
were used with different primers to detect the mecA gene for oxacillin-resistance. The 
mecA gene is highly conserved among staphylococcal species (Archer et al., 1994). 
Selection of primers for the amplification of mecA gene can have significant impact 
on the accuracy of test results.  
 
DNA extraction was done by bacterial purification kit and two different primer pairs 
were used for mecA gene identification, primer pair-1 (MR1 and MR2) with 154 bp 
and primer pair-2 (MR3 and MR4) with 533 bp (Fig. 4.10). The gene fragments 
amplified spanned position 179 to1814 on the gene. In this study primer pair-3 (MR5 
and MR6) was also designed by picking forward of primer pair-1 and reverse primer 
of pair-2 for the identification and verification of amplicon generated by pair-1 and 
pair-2 primers. Frequency percentage obtained from primer pair-3 revealed 
amplification of the whole gene fragment from pair-1 and pair-2 primers. The size of 
amplified fragment of primer pair-3 was approximately 1600 bp (Fig. 4.10). 
Furthermore, primer pair-3 verified the amplification of primer pair-1 and primer pair-
2. Confirmation of the results obtained and the absence of amplification when the 
efficiency of the primers was tested using forward primer of pair-2 and reverse primer 
of pair-1, further supported our data obtained earlier and the efficiency of the primers 
(forward primer of pair-1 and reverse primer of pair-2). The actual band position of 
the amplified DNA was observed in automated gel documentation scanner, 
ChemiImager supplied by Alpha Innotech Corporation, USA. 
 
 
 
 
 
L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 L11 L12 L13 L14 L15 L16 L17 L18 L19 L20
533 bp
L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 L11 L12 L13
154 bp
Chapter 4: Results and Discussion Ph.D. Thesis | Harsha Patel | January, 2012
Saurashtra University | Sub: Microbiology
2% Agarose gel electrophoresis of the 154 bp, 533 bp and 1600 bp DNA
fragment corresponding to the mecA gene of PCR primer pair 1 (L1: DNA
leader- 50 bp; L2-L13: mecA gene- 154 bp), PCR primer pair 2 (L1: DNA
leader- 50 bp; L2 –L11, L13-16, L18: mecA gene- 533 bp) and PCR primer
pair 3 (L1: DNA leader- 1 kb; L2-L13: mecA gene- 1600 bp).
1600 bp
Fig. 4.10
Page | 112
 
 
Chapter 4: Results and Discussion       Ph.D. Thesis | Harsha Patel | January, 2012 
Saurashtra University | Sub: Microbiology 
                                
 
 
Page | 113  
 
Table 4.4 Oxacillin MIC, antibiotic susceptibility (oxacillin and cephoxitin) and genotypic 
identification of clinically isolated Staphylococcus strains  
  
Strain 
No. Source OSS CSS 
 
MIC of 
oxacillin 
Detection of mecA gene by 
primer base pairs (bp) 
154 bp 533 bp 1600 bp 
S1 Pus R R R + + + 
S2 Pus R R R + + + 
S3 Pus R S S + - + 
S4 Pus R R R + + + 
S5 
Synovial 
fluid 
R R R + + + 
S6 Pus R R R + + + 
S7 Pus R R R + + + 
S8 Pus R R R + + + 
S9 
Endotracheal 
tube 
R R R + + + 
S10 Pus R R R + + + 
S11 Sputum R S R - - - 
S12 Pus R R R + + + 
S13 Urine R R R + + + 
S14 
Endotracheal 
tube 
R R R + + + 
S15 
Osteomyelytis 
tissue 
R R R + + + 
S16 Blood R S R - - - 
S17 Blood R R R + + + 
S18 Pus R I R + - + 
S19 Sputum R R R + + + 
S20 Pus R R R + + + 
S21 
Tracheostomy 
swab 
R R R + + + 
S22 Sputum R R R + + + 
S23 Pus R R R + + + 
S24 Pus R S R + - + 
S25 Urine R R R + + + 
Cont… 
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Strain 
No. Source OSS CSS 
 
MIC of 
oxacillin 
Detection of mecA gene by 
primer base pairs (bp) 
154 bp 533 bp 1600 bp 
S26 Blood R R R + + + 
S27 
Endotracheal 
tube 
R R R + + + 
S28 Blood R R R + + + 
S29 Urine R I R + - + 
S30 Pus R R R + + + 
S31 Blood R S R + - + 
S32 
Synovial 
fluid 
R R I + + + 
S33 
Hip-Joint 
tissue 
R R R + + + 
S34 Pus R R R + + + 
S35 Pus R R R + + + 
S36 Urine R R R + + + 
S37 
Endotracheal 
tube 
R R R + + + 
S38 Pus R S S + - + 
S39 Ear-swab R R R + + + 
S40 
Endotracheal 
tube 
R R R + + + 
S41 Blood R R R + + + 
S42 Pus R S S + + + 
S43 Blood R R R + + + 
S44 Pus R I R + + + 
S45 Pus R R R + + + 
S46 Pus R R R + + + 
S47 Pus R R S + + + 
S48 Pus R S R + - + 
S49 Sputum R R R + + + 
S50 Sputum R R R + + + 
S51 
Endotracheal 
tube 
R R R + + + 
S52 Sputum R R R + + + 
Cont… 
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Strain 
No. Source OSS CSS 
 
MIC of 
oxacillin 
Detection of mecA gene by 
primer base pairs (bp) 
154 bp 533 bp 1600 bp 
S53 Pus R R R + + + 
S54 
Endotracheal 
tube 
R S R + - + 
S55 Ear-swab R R R + + + 
S56 Pus R R R + + + 
S57 
Endotracheal 
tube 
R R R + + + 
S58 Pus R S S + - + 
S59 Pus R S I + - + 
S60 Pus R R R + + + 
S61 Pus R R R + + + 
S62 Pus R I R + + + 
S63 Pus R I R + + + 
S64 
Endotracheal 
tube 
R R R + + + 
S65 
CVP Catheter 
tip 
R R R + + + 
S66 
Tracheostomy 
swab 
R R R + + + 
S67 Pus R R R + + + 
S68 Pus R R R + + + 
S69 
Endotracheal 
tube 
R R R + + + 
S70 
Endotracheal 
tube 
R S R + - + 
S: Staphylococcus strains; OSS: oxacillin salt screening; CSS: cephoxitin susceptibility study; (+): 
presence; (-): absent; R: resistant; I: intermediate; S: susceptible 
 
The results obtained from MIC determinations, oxacillin salt screening (OSS), 
cephoxitin susceptibility study (CSS) and PCR with primer pairs - 1, 2, and 3 are 
summarized in Table 4.4.  
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In this study, 70 clinically isolated strains showed that number of strains isolated from 
pus carried mecA gene. Of the fifty three CPS strains, fifty two strains were mecA 
gene positive in two pairs of primers (primer pair-1 and primer pair-3) while 
amplification was not observed in only one strain in primer pair-1 and primer pair-3 
(amplification frequencies were 98%). Of the seventeen CNS strains, sixteen strains 
were mecA positive and only one strain was mecA negative in both primer pair-1 and 
pair-3 (amplification frequencies were 94%). Amplification of mecA gene in primer 
pair-2 showed that amongst fifty three CPS strains, forty five strains were mecA 
positive (amplification frequencies were 85%) while twelve CNS strains were mecA 
positive (amplification frequencies were 71%). All the isolates tested for 
amplification showed strong positive signal of single DNA band for mecA gene 
through PCR assay. The successful amplification of the gene of interest is dependent 
upon the amount and quality of the template DNA.  
 
Phenotypic and genotypic analysis like MIC of oxacillin, antibiotic susceptibility 
(oxacillin and cephoxitin) and mecA gene showed that the all strains were resistant to 
oxacillin (1 µg disk) salt screen agar testing. Five strains were susceptible to oxacillin 
with MIC ranging from 2 to 0.512 µg/ml and two strains were intermediate with MIC 
2.048 µg/ml which is nearest to susceptible. This was confirmed by the presence of 
the mecA gene using the PCR. The seven strains (susceptible / intermediate) tested 
positive in PCR assay with primer pair -1 and primer pair -3 but 4 tested negative in 
primer pair-2. The other three strains were susceptible but mecA gene was present. 
Clinical and Laboratory Standards Institute (CLSI) stated that the oxacillin MIC and 
cephoxitin disk test are equivalent in sensitivity and specificity for the detection of 
mecA mediated resistance in Staphylococcus aureus (CLSI, 2005). Cephoxitin 
susceptibility showed 12 strains to be cephoxitin sensitive phenotypically and was 
also negative with primer pair-2 except one strain. Our results indicate that cephoxitin 
disk test is more sensitive as compared to the oxacillin salt screen agar test. Oxacillin 
MIC and cephoxitin disk were comparable for the phenotypic detection of mecA 
mediated resistance in S. aureus.  
The results indicated that the molecular biology tools through genomic analysis using 
primer pair-2 are more accurate and sensitive than when using primer pair-1 and 
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primer pair-3. This was also reported by Siripornmongcolchai et al., 2002. Our results 
also indicated that in phenotypic methods, cephoxitin disk diffusion was better than 
oxacillin screen agar, as reported by others (Cauwelier et al., 2004; Fernandes et al., 
2005; CLSI, 2009). Antibiogram analysis of cephoxitin (30 µg) disk has been a good 
epidemiological marker for MRSA phenotypic detection. Cephoxitin disk is far 
superior to most of the phenotypic methods like oxacillin disc diffusion and oxacillin 
screen agar testing and is recommended by CLSI (CLSI 2007). MRSA strains 
exhibiting inducible resistance to methicillin grow more readily in the presence of 
cephoxitin than oxacillin, due to enhanced induction of PBP 2a by cephoxitin 
(Murakami et al., 1987; Higashi et al., 1999). Cephoxitin is a potent inducer of the 
mecA regulatory system and is being widely used as a surrogate marker for detection 
of mecA gene-mediated methicillin resistance (Swenson and Tenover, 2005).   
 
4.5 Analysis of 16S rRNA 
 
DNA sequence information from the 1.5 kb small subunit 16S ribosomal RNA 
(rRNA) gene has been used to successfully identify and phylogenetically classify 
microorganisms from environmental and medical samples (Kong et al., 2002). The 
development of rapid diagnostic identification methods and genotypic resistance 
testing at a competitive price should greatly reduce the emergence of drug resistance. 
This will be achieved by prescribing antibiotics only to the patients where 
requirement is a must (Bergeron and Ouellette, 1998). Species identification can 
provide important information to predict clinical significance and guide etiological 
diagnosis and the management of infections (Parisi, 1985). 
 
The 16S rRNA gene has received more attention than 5S or 23S rRNA genes as it is a 
more appropriate size for study. The 16S rRNA molecule contains both highly 
conserved regions and variable regions (Stackebrandt et al., 1991). The highly 
conserved regions provide priming sites suitable for the polymerase chain reaction 
(PCR) and sequencing applications while the intervening variable region sequences 
are unique to a particular organism and hence are of diagnostic value. 
 In the present study five strains were chosen for 16S rRNA, on the basis of the 
conventional and molecular results. Phylogenetic determination, based on 16S rRNA 
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gene homology, the organisms were related to their nearest homologous and the 
sequences deposited in NCBI (Fig. 4.11 – 4.15) as SU-BIO1 (GenBank accession No. 
JN831368), SU-BIO2 (Accession No. JN831369), SU-BIO3 (Accession No. 
JN831370), SU-BIO4 (Accession No. JN831371), SU-BIO5 (Accession No. 
JN831372). Our 16S rRNA sequencing data support the idea of identifying of 
Staphylococcus aureus.  The sequences obtained were blast at NCBI and result 
showed that the organism is closely related to the genus Staphylococcus. These five 
isolated strains have shown 96-99% similarity to other Staphylococcus aureus 16S 
rRNA sequence available in the GenBank data base.  
>Staphylococcus_aureus_SU-BIO1_JN831368.1 
CATTTCGGGGCAGCTATATAATGCAGTCGAGCGAACGGACGAGAAGCTTGCTTCTCTGATGTTAGCGGCGGACGGGTGAGTAACAC
GTGGATAACCTACCTATAAGACTGGGATAACTTCGGGAAACCGGAGCTAATACCGGATAATATTTTGAACCGCATGGTTCAAAAGT
GAAAGACGGTCTTGCTGTCACTTATAGATGGATCCGCGCTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAACGATGCA
TAGCCGACCTGAGAGGGTGATCGGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGC
AATGGGCGAAAGCCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTCTTCGGATCGTAAAACTCTGTTATTAGGGAAGAACATATG
TGTAAGTAACTGTGCACATCTTGACGGTACCTAATCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGG
CAAGCGTTATCCGGAATTATTGGGCGTAAAGCGCGCGTAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCACGGCTCAACCGTGGAG
GGTCATTGGAAACTGGAAAACTTGAGTGCAGAAGAGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGCAGAGATATGGAGGAA
CACCAGTGGCGAAGGCGACTTTCTGGTCTGTAACTGACGCTGATGTGCGAAAGCGTGGGGATCAAACAGGATTAGATACCCTGGTA
GTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGG
GAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCG
AAGAACCTTACCAAATCTGACATCCTTTGACACTCTAGAGATAGAGCCTTCCCCTTCGGCGGACAAAGTGACAGTGGTGCATGGTT
GTCGTCAGCTCTGTCGTGAGATGTTGGGGTTAATCCGCAACACCGCAACCTTAGCTTAGTTGCCTCATTAAGTTGGGCACTCTTAA
TTACTGTCCGCTGCCCACCGAGAAGAATGTGATTAGCTTCAATCATA 
Fig. 4.11 Staphylococcus aureus strain SU-BIO1 16S ribosomal RNA gene, partial   
sequence: (Accession No. JN831368)  
 
 
>Staphylococcus_aureus_SU-BIO2_JN831369 
AAGGAATTTTGCTTATAGAATAGTATAAGCGGCGGACGGGTTTTTAAAAAACGTGGATAACCTACCTATAAGACTGGGATAACTTC
TGGAAACCGGAGCTAATACCGGATAATATTTTGAACCGCATGGTTCAAAAGTGAAAGACGGTCTTGCTGTCACTTATAGATGGATC
CGCGCTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAACGATGCATAGCCGACCTGAGAGGGTGATCGGCCACACTGGA
ACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGGCGAAAGCCTGACGGAGCAACGCCGCGTG
AGTGATGAAGGTCTTCGGATCGTAAAACTCTGTTATTAGGGAAGAACATATGTGTAAGTAACTGTGCACATCTTGACGGTACCTAA
TCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGAATTATTGGGCGTAAAGCGC
GCGTAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCACGGCTCAACCGTGGAGGGTCATTGGAAACTGGAAAACTTGAGTGCAGAAG
AGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGCAGAGATATGGAGGAACACCAGTGGCGAAGGCGACTTTCTGGTCTGTAAC
TGACGCTGATGTGCGAAAGCGTGGGGATCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAG
GGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATT
GACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAATCTTGACATCCTTTGACAA
CTCTAGAGATAGAGCCTTCCCCTTCGGGGGACAAAGTGACAGGTGGTTGCATGGATTGTTCGTCAGCTCGTGTCGTGAGATGTTGG
GGTTAGGTCCCGCAACGAGCGCAACCCTTAAGCTTAGTTGCCATCATTTAGTTGGGCACTCTAAGTTGACTGCCCGTTGACAACCC
GGAGGAAGGGTGGGGATTGACGTCAATTCATCATGGCCCCTTATGTAATTCGGCCTTAACCCACGGTTGCCTAACAATGTGAACAA
TATACAAAGAGGCACA 
Fig. 4.12 Staphylococcus aureus strain SU-BIO2 16S ribosomal RNA gene, partial 
sequence: (Accession No. JN831369) 
 
>Staphylococcus_aureus_SU-BIO3_JN831370 
GCCCCCCTTGGGGGGCTGCCTTATACATGCAAGTCGAGCGAACGGACGAGAAGCTTGCTTCTCTGATGTTAGCGGCGGACGGGTGA
GTAACACGTGGATAACCTACCTATAAGACTGGGATAACTTCGGGAAACCGGAGCTAATACCGGATAATATTTTGAACCGCATGGTT
CAAAAGTGAAAGACGGTCTTGCTGTCACTTATAGATGGATCCGCGCTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAA
CGATGCATAGCCGACCTGAGAGGGTGATCGGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAAT
CTTCCGCAATGGGCGAAAGCCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTCTTCGGATCGTAAAACTCTGTTATTAGGGAAGA
ACATATGTGTAAGTAACTGTGCACATCTTGACGGTACCTAATCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACG
TAGGTGGCAAGCGTTATCCGGAATTATTGGGCGTAAAGCGCGCGTAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCACGGCTCAAC
CGTGGAGGGTCATTGGAAACTGGAAAACTTGAGTGCAGAAGAGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGCAGAGATAT
GGAGGAACACCAGTGGCGAAGGCGACTTTCTGGTCTGTAACTGACGCTGATGTGCGAAAGCGTGGGGATCAAACAGGATTAGATAC
CCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCC
GCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAG
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CAACGCGAAGAACCCTTACCAAATCTTGACATCCTTTGACAACTCTAGAGATAGAGCCTTCCCCTTCGGGGGACAAAGTGACAGTG
GTGCATGGATGTCGTCAGCTCGTGTCGTGAGATGTGGGTTAAGTCCCCGCAACGAGCGCACCCCTTAAGCTTAGCTGCCATCATTA
AGTTGGCCACCTCTAGTTGGACTGCCGTGACCAACCGGAGGAAGGTGGGAATGAACGTCAAATCATCATGCCCTAATGAATTGGGC
CTACACACCAGCGGTGTCCTATCACATAGTGGGGAC 
Fig. 4.13 Staphylococcus aureus strain SU-BIO3 16S ribosomal RNA gene, partial sequence: 
(Accession No. JN831370) 
 
>Staphylococcus_aureus_SU-BIO4_JN831371 
TGGCAGGTAGGGGCCGCTATATAATGCAGTCGAGCGAACGGACGAGAAGCTTGCTTCTCTGATGTTAGCGGCGGACGGGTGAGTAA
CACGTGGATAACCTACCTATAAGACTGGGATAACTTCGGGAAACCGGAGCTAATACCGGATAATATTTTGAACCGCATGGTTCAAA
AGTGAAAGACGGTCTTGCTGTCACTTATAGATGGATCCGCGCTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAACGAT
GCATAGCCGACCTGAGAGGGTGATCGGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTC
CGCAATGGGCGAAAGCCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTCTTCGGATCGTAAAACTCTGTTATTAGGGAAGAACAT
ATGTGTAAGTAACTGTGCACATCTTGACGGTACCTAATCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGG
TGGCAAGCGTTATCCGGAATTATTGGGCGTAAAGCGCGCGTAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCACGGCTCAACCGTG
GAGGGTCATTGGAAACTGGAAAACTTGAGTGCAGAAGAGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGCAGAGATATGGAG
GAACACCAGTGGCGAAGGCGACTTTCTGGTCTGTAACTGACGCTGATGTGCGAAAGCGTGGGGATCAAACAGGATTAGATACCCTG
GTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCT
GGGGAGTACGACCGCAAGGGTTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAA
CGCGAAGAACCCTTACCAAATCCTTGACATCCTTTGACAACTCTAGAGATAGAGCCTTCCCCTTCGGGGGACAAAGTGAACAGGTG
GTGCCATGGCTTGTCGTTCAGCTCCGTGTCCGATGAAGAATGTTGGGTTTAGGTCCCGCAACCGAGCCGCCACCCTAAGCTTAGTT
GCCCATCATTTAAGCTGGGCCACCTCTAAGATTGAACTGGCCGGTGACCAATCCGGAGAGGTGGTGAATGGACGGTCATCATCATG
CCCCCTAATGCACTCGGCCTACCAACGCGGTGTCCCTTACAATACGTGGCACGCCAT 
Fig. 4.14 Staphylococcus aureus strain SU-BIO4 16S ribosomal RNA gene, partial sequence: 
(Accession No. JN831371) 
 
 
>Staphylococcus_aureus_SU-BIO5_JN831372 
ATGTAATTAGCAGGCTATAGATTGTTATTGGTGCGCGCGGACGAGAAGCTTGCTTCTCTGATGTTAGCGGCGGACGGGTGAGTAAC
ACGTGGATAACCTACCTATAAGACTGGGATAACTTCGGGAAACCGGAGCTAATACCGGATAATATTTTGAACCGCATGGTTCAAAA
GTGAAAGACGGTCTTGCTGTCACTTATAGATGGATCCGCGCTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAACGATG
CATAGCCGACCTGAGAGGGTGATCGGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCC
GCAATGGGCGAAAGCCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTCTTCGGATCGTAAAACTCTGTTATTAGGGAAGAACATA
TGTGTAAGTAACTGTGCACATCTTGACGGTACCTAATCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGT
GGCAAGCGTTATCCGGAATTATTGGGCGTAAAGCGCGCGTAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCACGGCTCAACCGTGG
AGGGTCATTGGAAACTGGAAAACTTGAGTGCAGAAGAGGAAAGTGGAATTCCATGTGTAGCGGTGAAATGCGCAGAGATATGGAGG
AACACCAGTGGCGAAGGCGACTTTCTGGTCTGTAACTGACGCTGATGTGCGAAAGCGTGGGGATCAAACAGGATTAGATACCCTGG
TAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTG
GGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACG
CGAAGAACCTTACCAAATCTTGACATCCTTTGACAACTCTAGAGATAGAGCCTTCCCCTTCGGGGGACAAGTGACAGGTGGTGCAT
GGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTAAGCTTAGTTGCCATCATTTAAGTTG
GGCACATCTTAAGTTGACTGGCCGGTGACCAACCGAGA 
Fig. 4.15 Staphylococcus aureus strain SU-BIO5 16S ribosomal RNA gene, partial sequence: 
(Accession No. JN831372) 
 
16S rRNA, as “living fossil” of bacteria, is selected principally for the classification 
and identification of bacteria (Petrosino et al., 2009). mecA gene specific for 
methicillin-resistant (Frebourg et al., 1998) has been reported for the rapid and 
specific detection and characterization of MRSA. In this study five strains were 
chosen for 16S rRNA and out of these five strains, the four mecA-positive strains 
were subjected to gene sequencing analysis and the sequences were deposited in 
NCBI (Fig. 4.16-4.19) as SU-BIO6 to SU-BIO9 (Table 4.5). These four strains 
showed 99% similarity than other Staphylococcus aureus mecA gene for penicillin 
binding protein2a sequence available in the GenBank data base. 
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>mecA_gene_SU-BIO6 
CCGTTGGTCCTTGCATAGGGTGGGTTCCAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAAT
CATCAGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGT
GAAGATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGG
TTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCAC
CTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATG
CAACAAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTATGGCGAAACTGAT
ATAATGCTGATAGGACTTACTTGTTGTCCACCATAAATTTGCGTTAATACAATGCTCACTATAAATTGATAAACCATGACAAGTGC
AAATCCGGTACTGCAAAAAATAAAAAAAA 
Fig. 4.16 mecA gene sequence of Staphylococcus aureus SU-BIO6 strain  
 
 
>mecA_gene_SU-BIO7 
AAAAATTATTGGGGGTGGTTACACGTTACAAGATAAGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGA
TAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGATA
TACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACGGA
CAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCACTT
ATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAG
TCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTATGGCCGGAACTGATACAATA
GGTGCCATGACGCAAGGGCAGTACTTCATAAAAATCCGGTACTGCAAAACTCACTAATATTTGATAAATCATTACCAATGCAAATC
CGGTACTGAAAGAAAAAAAAAATATAA 
Fig. 4.17 mecA gene sequence of Staphylococcus aureus SU-BIO7 strain  
 
 
>mecA_gene_SU-BIO8 
CGAAAGTCTTGGTTGCGTGGTACACAGTTACAAGATAAGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCA
GATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAGA
TATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTACG
GACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCAC
TTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACA
AGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGATGGCAGGAAACATAACAAT
ACGGCTCATGACGCAAGGGCTAGTACACCATAAAAATGCGTTACTGCAAAGCTAACTAATATTTGATAAATCATTACCAATGCAAA
TCCGGTACTGCAGAAATAAAAATATAA 
Fig. 4.18 mecA gene sequence of Staphylococcus aureus SU-BIO8 strain  
 
 
>mecA_gene_SU-BIO9 
ACCTTAATTCCGGGGGACGGTTTAAACGTTACAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATC
AGATAACATTTTCTTTGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAAG
ATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTATTAGCTGATTCAGGTTAC
GGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGCATTAGAAAATAATGGCAATATTAACGCACCTCA
CTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAAAATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAAC
AAGTCGTAAATAAAACACATAAAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTATGGCGGAACTGATACAA
TGGGGCACATGACGCACGGTCTTTACTTCATTCAAATCCGGTACTGCAAGAGACTAACTAATATTTGATAAAATCATTACA 
Fig. 4.19 mecA gene sequence of Staphylococcus aureus SU-BIO9 strain  
 
Table 4.5 Oligonucleotide sequence parameters of five 16S rRNA and 
four mecA gene sequences 
Sequences %GC content Molecular weight (Daltons) 
Melting 
temperature (oC) 
SU-BIO1 51 361412 85 
SU-BIO2 50 378578 85 
SU-BIO3 52 384653 86 
SU-BIO4 52 391044 86 
SU-BIO5 51 358893 85 
SU-BIO6 32 195303 77 
SU-BIO7 31 194821 77 
SU-BIO8 32 194758 77 
SU-BIO9 32 184780 77 
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4.5.1 Pair-wise, multiple 
Pair-wise sequence alignment is a way of arranging the sequences of DNA, RNA, or 
protein to identify regions of similarity that may indicate functional, s
evolutionary relationships between the 
carried out using BioEdit softwere
Alignments of homologous DNA sequences can provide great insight into the 
structures, functions and evolutionary histories of DNA molecules. A global 
alignment is one that compares the two sequences over their entire lengths, and is 
appropriate for comparing sequences that are expected to share similarity over the 
whole length. 
    Fig. 4.20 Pair-wise alignment of 16S rRNA sequences (JN831368 to JN831372 and 
EU604543.1)
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Table 4.6 Identities of Pair-wise sequences alignment 
Pair-wise Alignment Identities 
JN831368 and EU604543.1* 0.7284981 
JN831369 and EU604543.1* 0.7413030 
JN831370 and EU604543.1* 0.7696737 
JN831371 and EU604543.1* 0.7555275 
JN831372 and EU604543.1* 0.7277386 
JN831368 and JN831369 0.8705322 
JN831368 and JN831370 0.9123794 
JN831368 and JN831371 0.9048374 
JN831368 and JN831372 0.9434122 
JN831369 and JN831370 0.9033778 
JN831369 and JN831371 0.8958009 
JN831369 and JN831372 0.8648221 
JN831370 and JN831371 0.9349530 
JN831370 and JN831372 0.8992806 
JN831371 and JN831372 0.8963608 
* Downloaded from NCBI GenBank database 
Multiple sequence alignment is an extension of pair-wise alignment to incorporate 
more than two sequences at a time.  Sequence alignment is a standard technique in 
bioinformatics for visualizing the relationships between residues in a collection of 
evolutionarily or structurally related DNA sequences. Multiple sequence alignment of 
five nucleotide sequences (SU-BIO1-JN831368, SU-BIO2-JN831369, SU-BIO3-
JN831370, SU-BIO4-JN831371 and SU-BIO5-JN831372) was constructed (Fig.4.21) 
by CLC main workbench 5. Subsequently the Phylogenetic tree was also constructed 
with the same software (Fig. 4.22).  
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Fig.4.21 Snapshot of Multiple sequence alignment of 16S rRNA sequences of SU-
BIO1 to SU-BIO5
Fig.4.22 Phylogenetic tree of Staphylococcus aureus SU-BIO1 to SU-BIO5 using
neighbor joining method in CLC main workbench 5
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The similarity score among the five sequences is more than 93. It was observed that, 
the tree was clustered into various subgroups. The clock calibration to convert 
distance to time was 0.01 (time/node height). The tree was drawn to scale, with 
branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. From the root, the distance is 0.046, 0.093, 0.015, 0.048 and 
0.045 for SU-BIO1, SU-BIO2, SU-BIO3, SU-BIO4 and SU-BIO5 respectively. The 
isolates BIO1 and SU-BIO5 are very close to each other. BIO2 and BIO4 diverged / 
evolved before BIO1 and BIO5. BIO3 is diverged / evolved as diverse.  
Table 4.7 List of organisms with accession No. for 16S rRNA sequences used in the 
phylogenetic study 
 
No. Accession No. Title Max. identity 
1. D83356.1 Staphylococcus aureus gene for 16S rRNA, partial 
sequence, strain: OA1 
96% 
2. AB305019.1 Staphylococcus aureus gene for 16S rRNA, partial 
sequence, strain: SA1 
96% 
3. BX571856.1 Staphylococcus aureus subsp. aureus strain 
MRSA252, complete genome 
99% 
 
4. AB353073.1 Staphylococcus aureus gene for 16S ribosomal 
RNA, partial sequence, strain: MPU99 
96% 
5. DQ630753.1 Staphylococcus aureus 16S ribosomal RNA gene, 
partial sequence 
96% 
6. DQ306891.1 Staphylococcus aureus strain SMKV-2 16S 
ribosomal RNA gene, partial sequence 
96% 
7. D83353.1 Staphylococcus aureus gene for 16S rRNA, partial 
sequence, strain: FU16A2 
96% 
8. L37597.1 Staphylococcus aureus 16S ribosomal RNA (16S 
rRNA) gene 
96% 
9. AF015929.1 Staphylococcus aureus 16S ribosomal RNA gene, 
partial sequence 
97% 
10. EU604543.1 Staphylococcus aureus strain 185060 (VRSA) 16S 
ribosomal RNA gene, partial sequence 
96% 
11. AM980864.1 Staphylococcus aureus partial 16S rRNA gene, 
strain ATCC 43300 
96% 
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Fig. 4.23 Phylogenetic tree of Staphylococcus aureus SU-BIO1 – SU-BIO5 using Neighbor
Joining method in CLC main workbench 5
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Table 4.8 List of organisms with accession No. for mecA gene sequences used in the 
phylogenetic study 
 
No. Accession   
No. 
Title Max. 
identity 
1.  EF190335.1 Staphylococcus aureus penicillin-binding protein 2a 
(mecA) gene, complete cds 
99% 
2.  AB236888.1 Staphylococcus aureus mecA gene for penicillin-
binding protein 2', complete cds 
99% 
3.  AB221124.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: NN1 
99% 
4.  AB221123.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: 90s 
99% 
5.  AB221122.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: 80s-4 
99% 
6.  AB221121.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: 80s-3 
99% 
7.  AB221120.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: 80s-2 
99% 
8.  AB221119.1 Staphylococcus aureus mecA gene for penicillin 
binding protein 2', complete cds, strain: 80s-1 
99% 
9.  FJ810876.1 Staphylococcus aureus strain ATCC 33591 penicillin 
binding protein 2a (mecA) gene, partial cds 
99% 
 
The obtained sequences were subjected to BLAST at NCBI and result showed that the 
organisms are closely related to the genus Staphylococcus, which was also conformed 
from conventional and molecular studies. The Phylogenetic analysis was performed 
by CLC main workbench 5 software (Table 4.7; Fig. 4.23). It was observed that tree 
was clustered into various subgroups of Staphylococcus aureus strain. 16s rRNA of 
all five strains (SU-BIO1 to SU-BIO5) having more than 96% sequence identities 
with other strains of Staphylococcus aureus. The clock calibration to convert distance 
to time was 0.01 (time/node height).  
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Fig. 4.24 Phylogenetic tree of mecA gene SU-BIO6 - SU-BIO9 using
Neighbor Joining method in CLC main workbench 5
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The tree was drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. From the root the distance 
is 0.277, 0.248, 0.222, 0.245 and 0.278 for SU-BIO1, SU-BIO2, SU-BIO3, SU-BIO4 
and SU-BIO5 respectively. The four isolates SU-BIO1, SU-BIO3, SU-BIO4 and SU-
BIO5 are very close to vancomycin resistant Staphylococcus aureus 185060 (Acc. No: 
EU604543.1). The isolate SU-BIO2 is very close to the Staphylococcus aureus (Acc. 
No: AF015929.1). In this study mecA gene sequences analysis was also performed. 
The mecA gene sequence data from the Staphylococcus strains formed a highest 
similarity, 99% sequence identities was found with other strains of Staphylococcus 
aureus penicillin-binding protein 2a (mecA) gene. In the Phylogenetic tree constructed 
(Table 4.8; Fig. 4.24) from the studied strains (SU-BIO6 to SU-BIO9) belongs to 
methicillin-resistant Staphylococcus aureus. The three isolates SU-BIO6, SU-BIO7 
and SU-BIO8 are very close to Staphylococcus aureus mecA gene for penicillin 
binding protein 2' (Acc. No: AB221123.1) and the isolate SU-BIO9 is very close to 
the Staphylococcus aureus strain ATCC 33591 penicillin binding protein 2a (mecA) 
gene (Acc. No: FJ810876.1). Thus, it was confirmed based on BLAST and 
phylogenetic tree analysis that, studied strains (SU-BIO1 to SU-BIO5) belongs to 
Staphylococcus aureus and the presence of mecA gene. 
 
4.6 Anti-Staphylococcus activity of some plant extracts   
 
Antibacterial screening tests of crude extracts obtained from a 100% methanol extract 
of seven different plants (eleven parts); i.e. P. longifolia (leaves), C. lanceolatus 
(leaves), R. chinensis (flowers), M. ferrea (stem + fruit), T. chebula (fruit rind, seed 
coat), T. bellerica (fruit rind, seed coat) and N. nucifera (petals, pedicel, stem) were 
selected for antibacterial activity against ten strains of clinically isolated MRSA by 
agar well diffusion method (Table 4.9). Among the methanol extracts, only of P. 
longifolia and M. ferrea showed good antibacterial activity as compared to other 
extracts. Among two fractions of P. longifolia (fraction-1 and fraction-2), fraction-2 
was more active against MRSA. Methanol extract of P. longifolia showed inhibition 
zone between 19-24 mm and M. ferrea showed between 15-21 mm. Methanol extracts 
of seed coat and fruit rind of T. bellerica showed similar anti-MRSA activity with 12-
18 mm zone of inhibition. Like T. bellerica, both the parts of T. chebula showed 
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similar anti-MRSA activity with 12-19 mm zone of inhibition. Methanol extract of R. 
chinensis showed moderate anti-MRSA activity with 11-18 mm zone of inhibition. 
Among three parts (petals, pedicel and stem) of N. nucifera, methanol extract of stem 
showed better activity but it was lower than other plant extracts studied. Thus, 
methanol extracts of P. longifolia, M. ferrea and fraction-2 of P. longifolia showed 
potent antibacterial activity, both the parts (fruit rind, seed coat) of T. cebula and T. 
bellerica, flowers of R. chinensis and N. nucifera stem showed moderate activity 
against MRSA while C. lanceolatus (leaves), N. nucifera (petals and pedicel) and 
fraction–1 of P. longifolia showed poor antibacterial activity.  
 
Table 4.9 Antibacterial screening of methanol extracts of some plants against ten clinically 
isolated MRSA 
Plants 
EY 
(%) 
Zone of inhibition in mm 
S1 S2 S3 S4 S50 S51 S52 S62 S63 S32 
T. bellerica (Sc) 3.67 12 15 17 17 14 16 14 14 13 15 
T. bellerica (Fr) 34.12 13 15 16 18 15 17 16 14 14 15 
M. ferrea (SF) 7.93 23 20 15 21 16 18 19 19 16 17 
T. chebula (Sc) 4.16 16 16 17 19 12 19 16 15 13 16 
T. chebula (Fr) 40.09 14 15 16 18 14 18 16 16 15 16 
R. chinensis (F) 27.39 13 15 16 15 11 16 12 14 12 13 
C. lanceolatus (L) 8.28 10 11 12 12 10 11 11 11 9 11 
N. nucifera (Pt) 9.04 - - 11 10 9 11 - - 10 10 
N. nucifera (Pd) 6.33 - - 11 10 9 12 - - 10 10 
N. nucifera (S) 2.21 14 11 14 12 10 17 11 14 16 15 
P. longifolia (L) 11.31 23 19 21 23 20 24 20 21 19 24 
P. longifolia 
 (Frc1)* 
44.49 12 10 10 10 9 11 10 9 9 10 
P. longifolia  
(Frc2)* 
35.6 20 17 18 18 16 23 16 16 18 20 
Vancomycin - 13 13 13 13 10 8 10 15 11 8 
Linezolid - 13 26 18 17 15 9 20 23 20 9 
Mupirocin - 30 26 28 17 15 - 20 22 20 - 
*Extractive yield for fraction-1 and 2 was calculated from per 10 g methanol extract of P. longifolia; S – 
Staphylococcus strains; Sc-Seed coat; Fr-Fruit rind; SF-Stem+Fruit; F- Flower;  L-Leaves; Pt- Petals; Pd-
Pedicel; S-Stem; Frc-Fraction; EY- Extractive Yield 
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When methanol extract of P. longifolia and its fractions were compared crude extract 
was more potent than both the fractions. This result may be because of inter-
synergism between various compounds of methanolic crude extract. Reduction of 
activity may be because of alone fraction rather than the mixture of the compounds. 
There are many reports on isolated compounds of plants givins better antibacterial 
activity than crude extracts (Hohtola, 2011), but the present study suggested that 
crude extract was more potent than its fractions. Different parts of the same plant may 
also give different biological activity. But in this study, antibacterial activity did not 
show major difference between methanol extracts of fruit rind and seed coat of T. 
bellerica and T. chebula, while three different parts of N. nucifera showed difference 
in their antibacterial potency. Vancomycin, linezolid and mupirocin were used as 
positive controls.  Most of the antibiotics are inactive against MRSA but still 
vancomycin, linezolid and mupirocin are the choice of drugs for MRSA infection 
(Bode et al., 2010; Steed et al., 2011; Torres-Sangiao et al., 2011). There are also 
some reports that showed MRSA resistance/intermediate to these drugs (Leonard et 
al., 2011; Ikeda-Dantsuji et al., 2011). In this study, comparison for antibacterial 
study between plant extracts and antibiotics showed plant extracts has comparable 
activity with antibiotics. From the above antibacterial screening, methanol extract of 
P. longifolia, M. ferrea and fraction-2 of P. longifolia were selected for further studies 
against seventy clinically isolated Staphylococcus strains.    
 
4.7 Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal 
Concentration (MBC) studies  
 
From anti-MRSA screening of thirteen extracts, three potential extracts i.e. methanol 
extract of P. longifolia (PLM), methanol extract of M. ferrea (MFM) and fraction-2 of 
P. longifolia (PLF2) were selected for MIC and MBC studies against seventy 
clinically isolated Staphylococcus strains. Rifampicin (Ri) was used as positive 
control. The concentrations of MIC and MBC for plant extracts and rifampicin were 
125-8000 µg/ml and 1.25-160 µg/ml respectively. The MIC was interpreted as the 
lowest concentration that inhibited visible microbial growth, whereas the MBC was 
interpreted as the lowest concentration that can completely remove the 
microorganisms. MIC and MBC was expressed in terms of µg/ml. The MIC values 
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were evaluated after 24 h of incubation and MBC values were obtained from further 
analysis of the MIC results.  
 
Results of MIC and MBC of PLM, MFM, Ri and PLF2are presented in Table 4.10. 
The range of MIC values of PLM, MFM, Ri and PLF2 was between 62.5 - 500, <62.5 
- 1000, <1.25 - 160 and <62.5 - 1000 µg/ml, respectively. The range of MBC values 
of PLM, MFM, Ri and PLF2 was between 125 - 2000, <62.5 – 4000, <1.25 - >160 
and <62.5 – 4000 µg/ml, respectively. PLM showed 62.5 µg/ml MIC value against 5 
strains and 125 µg/ml MBC value against 7 strains. MFM and PLF2 showed <62.5 
µg/ml MIC and MBC values against 2 strains. Ri showed <1.25 µg/ml MIC and MBC 
values against 2 and 3 strains respectively.  
 
Present results showed that all the three extracts possess good antibacterial activity 
against Staphylococcus strains. Results also showed that there was no significant 
difference between coagulase positive and coagulase negative staphylococci. PLM 
showed higher antibacterial activity than PLF2 with agar well diffusion method but in 
contrast PLF2 showed lower MIC and MBC values than PLM.  PLF2 showed lower 
MBC value than Ri against strain No. 22 and 54. This results show the potency of 
PLF2 which is higher than the standard antibiotic studied. MFM also showed lower 
MBC value than Ri against strain No. 33.  
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Table 4.10 MIC and MBC studies of P. longifolia, M. ferrea, rifampicin and fraction 2 of     
P. longifolia  
Strains 
PLM  MFM Ri PLF2 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
 
        S1 250 500 125 2000 5 20 125 250 
S2 500 1000 250 500 <1.25 <1.25 250 500 
S3 250 500 250 500 1.25 2.5 500 1000 
S4 500 1000 1000 2000 <1.25 <1.25 250 500 
S5 125 1000 250 500 80 160 250 1000 
S6 250 250 125 125 1.25 2.5 125 250 
S7 62.5 125 250 1000 <1.25 <1.25 125 250 
S8 250 1000 250 500 2.5 10 250 1000 
S9 500 2000 250 1000 80 >160 500 2000 
S10 125 250 250 500 80 160 125 250 
S11 250 500 500 1000 20 80 250 1000 
S12 500 1000 1000 2000 10 40 500 1000 
S13 250 500 250 1000 1.25 5 250 500 
S14 250 2000 250 500 80 >160 250 500 
S15 250 500 250 2000 1.25 2.5 250 1000 
S16 500 2000 62.5 125 40 >160 500 4000 
S17 250 500 125 250 1.25 5 250 500 
S18 250 1000 125 1000 5 20 125 250 
S19 250 1000 125 500 1.25 2.5 62.5 125 
S20 125 250 125 250 1.25 2.5 250 500 
S21 250 500 250 1000 160 >160 250 1000 
S22 125 1000 250 1000 20 >160 <62.5 <62.5 
S23 125 500 125 500 160 >160 125 500 
S24 125 500 62.5 125 40 80 62.5 125 
S25 125 250 62.5 125 1.25 5 62.5 125 
S26 125 500 500 4000 10 80 125 500 
S27 62.5 250 62.5 250 40 >160 125 1000 
S28 125 250 250 2000 80 >160 125 250 
Cont… 
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Strains 
PLM MFM Ri PLF2 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
 
        S29 500 2000 500 4000 1.25 2.5 125 1000 
S30 125 125 62.5 250 2.5 5 62.5 250 
S31 125 250 250 500 10 160 250 250 
S32 125 250 <62.5 <62.5 1.25 2.5 <62.5 <62.5 
S33 125 250 62.5 125 80 >160 250 500 
S34 125 500 62.5 500 20 80 62.5 125 
S35 125 125 125 250 10 40 62.5 125 
S36 125 250 125 500 20 80 62.5 125 
S37 125 250 62.5 250 20 160 125 250 
S38 125 125 125 500 10 40 62.5 125 
S39 125 250 125 500 40 160 250 500 
S40 250 500 250 500 10 20 62.5 125 
S41 250 2000 250 2000 80 >160 1000 2000 
S42 62.5 500 62.5 250 2.5 10 62.5 125 
S43 125 250 125 500 1.25 10 250 250 
S44 125 250 125 250 5 20 125 250 
S45 125 500 125 250 1.25 10 62.5 62.5 
S46 125 250 62.5 125 5 40 125 1000 
S47 62.5 250 125 500 40 >160 125 250 
S48 125 1000 62.5 500 10 80 62.5 125 
S49 250 1000 125 500 40 160 125 250 
S50 125 250 62.5 500 10 80 62.5 250 
S51 125 125 125 250 2.5 20 62.5 62.5 
S52 125 250 125 500 2.5 40 62.5 250 
S53 125 250 125 250 1.25 2.5 250 500 
S54 125 250 125 250 20 >160 62.5 125 
S55 125 2000 250 4000 20 160 125 2000 
S56 125 500 250 1000 40 80 125 500 
S57 125 250 62.5 500 5 10 62.5 125 
S58 125 250 250 1000 20 >160 125 250 
S59 62.5 125 <62.5 <62.5 2.5 5 125 125 
Cont… 
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Strains 
PLM  MFM Ri PLF2 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
MIC 
(µg/ml) 
MBC 
(µg/ml) 
S60 125 500 250 500 2.5 40 250 250 
S61 250 1000 500 2000 2.5 10 125 500 
S62 125 500 125 500 1.25 5 62.5 250 
S63 125 250 250 1000 2.5 10 125 500 
S64 125 250 125 250 5 80 62.5 1000 
S65 125 250 62.5 250 5 >160 62.5 500 
S66 125 250 62.5 500 5 80 125 500 
S67 125 125 125 500 2.5 80 125 125 
S68 125 250 125 1000 5 10 62.5 250 
S69 125 250 125 250 20 40 62.5 125 
S70 125 1000 125 1000 20 160 125 1000 
PLM - Methanol extract of P. longifolia; MFM - Methanol extract of M. ferrea; Ri -Rifampicin; PLF2 – 
Fraction-2 of P. longifolia 
 
There are many reports of antibacterial potency of P. longifolia and M. ferrea by 
many researchers. Marthanda Murthy et al., 2005 isolated diterpenoids from hexane 
extract of P. longifolia and it showed significant antibacterial and antifungal 
activities. Faizi et al. (2003) isolated alkaloids from root extract of P. longifolia and it 
showed good antibacterial activity with 0.2 - 20 µg/ml MIC value. Sashidhara et al. 
(2009) studied antibacterial activity of diterpenoid isolated from ethanol extract of P. 
longifolia leaves against Staphylococcus aureus and Sporothrix schenckii with 6.25 
µg/ml MIC value. Diterpenoids from methanol extract of P. longifolia leaves and 
berries showed antibacterial activity with 7.8 and 500 µg/ml MIC value (Faizi et al., 
2008). Present study also showed potent antibacterial efficacy of methanol extract of 
P. longifolia leaves against multi-drug resistant staphylococci. Nair and Chanda 
(2006) studied antibacterial activity of P. longifolia leaves with 32 mm zone of 
inhibition diameter against S. epidermidis.  
 
In vivo antibacterial activity and in vitro bactericidal activity of methanol extract of 
M. ferrea against Salmonella typhimurium was studied by Mazumder et al. (2004; 
2005).  Verotta et al. (2004) reported potential efficacy of compounds from M. ferrea 
against S. aureus strains (MIC value ranging from 2-128 µg/ml) which was similar 
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with our results of anti-staphylococcus potency but in our study crude extract was 
used (MIC value ranging from <62.5 - 1000 µg/ml). This finding confirms the 
interesting antibiotic properties of extracts of P. longifolia and M. ferrea. 
 
4.8 Synergistic activity of plant extracts with rifampicin 
 
When two different compounds combine and enhance their individual activity, it is 
called synergism between these compounds. If this combination decreases the 
activity, it is called antagonism (Chung et al., 2011). When antibacterial effect of 
single antibiotic is reduced, combination therapy is used with other antibiotics. There 
are many examples which showed the effective antibacterial therapy with 
combination of different antibiotics (Liu et al., 2007; Alexopoulos et al., 2011; 
Toroglu, 2011). But some bacterial strains are resistant to these combinations of 
antibiotics also ;for example methicillin-resistant S. aureus, vancomycin resistant 
enterococci, multidrug resistant Gram negative bacteria etc. Inhibitory activity of 
different antibiotics on various pathogens is either by killing them outright 
(microbicidal action) or by arresting the growth of the causal organism (microbistatic 
action). The impact of antibiotic on a pathogen is specific and differs from pathogen 
to pathogen and vice-versa (Ahmed et al., 2010). Sometimes the use of a single 
antibiotic does not produce the desired or effective inhibitory effects and to overcome 
this, combination of drugs often exercises their synergistic effect which surpasses 
their individual performance (Cai et al., 2009). Plants are the most effective 
therapeutic agents against pathogens because they contain a variety of 
phytochemicals. Drug synergism between known antibiotics and bioactive plant 
extracts is a novel concept and could be beneficial (synergistic or additive interaction) 
or deleterious (antagonistic or toxic outcome) (Adwan and Mhanna, 2009). 
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Table 4.11 Synergistic effect of PLM with rifampicin against 70 staphylococci strains 
 
Strains 
PLM + Ri (Combination) FIC 
MIC MBC MIC MBC 
PLM Ri PLM Ri PLM Ri FIC index PLM Ri 
FIC 
index 
1 62.5 1.25 125 2.5 0.25 0.25 0.5 0.25 0.13 0.38 
2 31.25 0.625 125 2.5 0.06 0.5 0.56 0.13 2 2.13 
3 31.25 0.625 62.5 1.25 0.13 0.5 0.63 0.13 0.5 0.63 
4 31.25 0.625 62.5 1.25 0.06 0.5 0.56 0.06 1 1.06 
5 62.5 1.25 250 5 0.5 0.02 0.52 0.25 0.03 0.28 
6 31.25 0.625 62.5 1.25 0.13 0.5 0.63 0.25 0.5 0.75 
7 31.25 0.625 62.5 1.25 0.5 0.5 1 0.5 1 1.50 
8 31.25 0.625 500 10 0.13 0.25 0.38 0.5 1 1.50 
9 125 2.5 250 5 0.25 0.03 0.28 0.13 0.03 0.16 
10 31.25 0.625 125 2.5 0.25 0.01 0.26 0.5 0.02 0.52 
11 62.5 1.25 125 2.5 0.25 0.06 0.31 0.25 0.03 0.28 
12 125 2.5 250 5 0.25 0.25 0.5 0.25 0.13 0.38 
13 31.25 0.625 125 2.5 0.13 0.5 0.63 0.25 0.5 0.75 
14 62.5 1.25 250 5 0.25 0.02 0.27 0.13 0.03 0.16 
15 31.25 0.625 250 5 0.13 0.5 0.63 0.5 2 2.50 
16 125 2.5 250 5 0.25 0.03 0.28 0.13 0.03 0.16 
17 31.25 0.625 125 2.5 0.13 0.5 0.63 0.25 0.5 0.75 
18 62.5 1.25 500 10 0.25 0.25 0.5 0.5 0.5 1.00 
19 31.25 0.625 125 2.5 0.13 0.5 0.63 0.13 1 1.13 
20 62.5 1.25 62.5 1.25 0.5 1 1.5 0.25 0.5 0.75 
21 62.5 1.25 250 5 0.25 0.01 0.26 0.5 0.03 0.53 
22 31.25 0.625 250 5 0.25 0.03 0.28 0.25 0.03 0.28 
23 62.5 1.25 125 2.5 0.5 0.01 0.51 0.25 0.02 0.27 
24 31.25 0.625 250 5 0.25 0.02 0.27 0.5 0.06 0.56 
25 62.5 1.25 125 2.5 0.5 1 1.5 0.5 0.5 1.00 
Cont… 
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Strains  
PLM + Ri (Combination) FIC 
MIC MBC MIC MBC 
PLM Ri PLM Ri PLM Ri FIC  index PLM Ri 
FIC  
Index 
26 31.25 0.625 125 2.5 0.25 0.06 0.31 0.25 0.03 0.28 
27 62.5 1.25 125 2.5 1 0.03 1.03 0.5 0.02 0.52 
28 62.5 1.25 125 2.5 0.5 0.02 0.52 0.5 0.02 0.52 
29 62.5 1.25 250 5 0.13 1 1.13 0.13 2 2.13 
30 62.5 1.25 62.5 1.25 0.5 0.5 1 0.5 0.25 0.75 
31 31.25 0.625 125 2.5 0.25 0.06 0.31 0.5 0.02 0.52 
32 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.25 0.5 0.75 
33 62.5 1.25 125 2.5 0.5 0.02 0.52 0.5 0.02 0.52 
34 62.5 1.25 125 2.5 0.5 0.06 0.56 0.25 0.03 0.28 
35 31.25 0.625 62.5 1.25 0.25 0.06 0.31 0.5 0.03 0.53 
36 125 2.5 250 5 1 0.13 1.13 1 0.06 1.06 
37 125 2.5 125 2.5 1 0.13 1.13 0.5 0.02 0.52 
38 62.5 1.25 62.5 1.25 0.5 0.13 0.63 0.5 0.03 0.53 
39 62.5 1.25 62.5 1.25 0.5 0.03 0.53 0.25 0.01 0.26 
40 31.25 0.625 62.5 1.25 0.13 0.06 0.19 0.13 0.06 0.19 
41 125 2.5 250 5 0.5 0.03 0.53 0.13 0.03 0.16 
42 31.25 0.625 125 2.5 0.5 0.25 0.75 0.25 0.25 0.50 
43 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.25 0.13 0.38 
44 62.5 1.25 62.5 1.25 0.5 0.25 0.75 0.25 0.06 0.31 
45 31.25 0.625 125 2.5 0.25 0.5 0.75 0.25 0.25 0.50 
46 31.25 0.625 125 2.5 0.25 0.13 0.38 0.5 0.06 0.56 
47 31.25 0.625 62.5 1.25 0.5 0.02 0.52 0.25 0.01 0.26 
48 62.5 1.25 250 5 0.5 0.13 0.63 0.25 0.06 0.31 
49 31.25 0.625 125 2.5 0.13 0.02 0.14 0.13 0.02 0.14 
50 125 2.5 125 2.5 1 0.25 1.25 0.5 0.03 0.53 
Cont… 
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Strains 
PLM + Ri (Combination) FIC 
MIC MBC MIC MBC 
PLM Ri PLM Ri PLM Ri FIC 
index 
PLM Ri FIC 
index 
51 31.25 0.625 62.5 1.25 0.25 0.25 0.5 0.5 0.06 0.56 
52 31.25 0.625 62.5 1.25 0.25 0.25 0.5 0.25 0.03 0.28 
53 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.25 0.5 0.75 
54 62.5 1.25 125 2.5 0.5 0.06 0.56 0.5 0.02 0.52 
55 31.25 0.625 125 2.5 0.25 0.03 0.28 0.06 0.02 0.08 
56 62.5 1.25 125 2.5 0.5 0.03 0.53 0.25 0.03 0.28 
57 125 2.5 125 2.5 1 0.5 1.5 0.5 0.25 0.75 
58 62.5 1.25 62.5 1.25 0.5 0.06 0.56 0.25 0.01 0.26 
59 31.25 0.625 62.5 1.25 0.5 0.25 0.75 0.5 0.25 0.75 
60 62.5 1.25 62.5 1.25 0.5 0.5 1 0.13 0.03 0.16 
61 31.25 0.625 125 2.5 0.13 0.25 0.38 0.13 0.25 0.38 
62 31.25 0.625 125 2.5 0.25 0.5 0.75 0.25 0.5 0.75 
63 31.25 0.625 62.5 1.25 0.25 0.25 0.5 0.25 0.13 0.38 
64 62.5 1.25 62.5 1.25 0.5 0.25 0.75 0.25 0.02 0.27 
65 62.5 1.25 125 2.5 0.5 0.25 0.75 0.5 0.02 0.52 
66 31.25 0.625 62.5 1.25 0.25 0.13 0.38 0.25 0.02 0.27 
67 62.5 1.25 62.5 1.25 0.5 0.5 1 0.5 0.02 0.52 
68 62.5 1.25 250 5 0.5 0.25 0.75 1 0.5 1.50 
69 31.25 0.625 62.5 1.25 0.25 0.03 0.28 0.25 0.03 0.28 
70 62.5 1.25 125 2.5 0.5 0.06 0.56 0.13 0.02 0.14 
PLM - Methanol extract of P. longifolia; Ri -Rifampicin; FIC- Fractional inhibitory concentration  
 
Based on the MIC and MBC values obtained by broth dilution assay, combinations of 
PLM + Ri and MFM + Ri were evaluated against 70 clinically isolated 
Staphylococcus strains (Table 4.11 and 4.12). Synergistic effect was determined by 
calculating FIC index of plant extracts and antibiotics. The MIC of combination of 
PLM and Ri showed synergistic effect against 25 strains with FIC index between 0.14 
and 0.5, while against other 45 strains additive effect was observed with FIC index 
between 0.51 and 1.5. The MBC of combination of PLM and Ri showed synergistic 
effect against 32 strains with FIC index between 0.08 and 0.5, while against other 37 
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strains additive effect was observed with FIC index between 0.52 and 2.5. 
Antagonistic effect was not seen against any of the strains studied.  
 
Table 4.12 Synergistic effect of MFM with rifampicin against 70 staphylococci strains 
 
Strains 
MFM + Ri (Combination) FIC 
MIC MBC MIC MBC 
MFM Ri MFM Ri MFM Ri FIC index MFM Ri 
FIC 
index 
S1 62.5 1.25 1000 20 0.5 0.25 0.75 0.5 1 1.5 
S2 31.25 0.625 62.5 1.25 0.13 0.5 0.63 0.13 1 1.13 
S3 31.25 0.625 250 5 0.13 0.5 0.63 0.5 2 2.5 
S4 125 2.5 500 10 0.13 2 2.13 0.25 8 8.25 
S5 62.5 1.25 250 5 0.25 0.02 0.27 0.5 0.03 0.53 
S6 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.5 0.5 1 
S7 31.25 0.625 125 2.5 0.13 0.5 0.63 0.13 2 2.13 
S8 62.5 1.25 125 2.5 0.25 0.5 0.75 0.25 0.25 0.5 
S9 125 2.5 500 10 0.5 0.03 0.53 0.5 0.06 0.56 
S10 125 2.5 250 5 0.5 0.03 0.53 0.5 0.03 0.53 
S11 125 2.5 500 10 0.25 0.13 0.38 0.5 0.13 0.63 
S12 500 10 500 10 0.5 1 1.5 0.25 0.25 0.5 
S13 31.25 0.625 250 5 0.13 0.5 0.63 0.25 1 1.25 
S14 62.5 1.25 125 2.5 0.25 0.02 0.27 0.25 0.02 0.27 
S15 62.5 1.25 250 5 0.25 1 1.25 0.13 2 2.13 
S16 31.25 0.625 62.5 1.25 0.5 0.02 0.52 0.5 0.01 0.51 
S17 62.5 1.25 125 2.5 0.5 1 1.5 0.5 0.5 1 
S18 62.5 1.25 250 5 0.5 0.25 0.75 0.25 0.25 0.5 
S19 62.5 1.25 125 2.5 0.5 1 1.5 0.25 1 1.25 
S20 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.25 0.5 0.75 
S21 125 2.5 500 10 0.5 0.02 0.52 0.5 0.06 0.56 
S22 62.5 1.25 125 2.5 0.25 0.06 0.31 0.13 0.02 0.14 
S23 62.5 1.25 125 2.5 0.5 0.01 0.51 0.25 0.02 0.27 
S24 31.25 0.625 62.5 1.25 0.5 0.02 0.52 0.5 0.02 0.52 
S25 31.25 0.625 62.5 1.25 0.5 0.5 1 0.5 0.25 0.75 
Cont… 
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Strains 
MFM + Ri (Combination) FIC 
MIC MBC MIC MBC 
MFM Ri MFM Ri MFM Ri FIC index MFM Ri 
FIC 
index 
S26 62.5 1.25 500 10 0.13 0.13 0.25 0.13 0.13 0.25 
S27 62.5 1.25 250 5 1 0.03 1.03 1 0.03 1.03 
S28 125 2.5 500 10 0.5 0.03 0.53 0.25 0.06 0.31 
S29 125 2.5 1000 20 0.25 2 2.25 0.25 8 8.25 
S30 62.5 1.25 62.5 1.25 1 0.5 1.5 0.25 0.25 0.5 
S31 62.5 1.25 62.5 1.25 0.25 0.13 0.38 0.13 0.01 0.13 
S32 <31.25 <0.625 62.5 1.25 0.5 0.5 1 1 0.5 1.5 
S33 31.25 0.625 250 5 0.5 0.01 0.51 2 0.03 2.03 
S34 125 2.5 125 2.5 2 0.13 2.13 0.25 0.03 0.28 
S35 31.25 0.625 125 2.5 0.25 0.06 0.31 0.5 0.06 0.56 
S36 62.5 1.25 250 5 0.5 0.06 0.56 0.5 0.06 0.56 
S37 62.5 1.25 500 10 1 0.06 1.06 2 0.06 2.06 
S38 62.5 1.25 250 5 0.5 0.13 0.63 0.5 0.13 0.63 
S39 62.5 1.25 500 10 0.5 0.03 0.53 1 0.06 1.06 
S40 62.5 1.25 125 2.5 0.25 0.13 0.38 0.25 0.13 0.38 
S41 250 5 2000 40 1 0.06 1.06 1 0.25 1.25 
S42 31.25 0.625 250 5 0.5 0.25 0.75 1 0.5 1.5 
S43 62.5 1.25 62.5 1.25 0.5 1 1.5 0.13 0.13 0.25 
S44 62.5 1.25 125 2.5 0.5 0.25 0.75 0.5 0.13 0.63 
S45 125 2.5 250 5 1 2 3 1 0.5 1.5 
S46 62.5 1.25 125 2.5 1 0.25 1.25 1 0.06 1.06 
S47 62.5 1.25 250 5 0.5 0.03 0.53 0.5 0.03 0.53 
S48 62.5 1.25 125 2.5 1 0.13 1.13 0.25 0.03 0.28 
S49 62.5 1.25 250 5 0.5 0.03 0.53 0.5 0.03 0.53 
S50 62.5 1.25 250 5 1 0.13 1.13 0.5 0.06 0.56 
 
 
 
 
Cont… 
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Strains 
MFM + Ri (Combination) FIC 
MIC MBC MIC MBC 
MFM Ri MFM Ri MFM Ri FIC index MFM Ri 
FIC 
index 
S51 31.25 0.625 125 2.5 0.25 0.25 0.50 0.5 0.13 0.63 
S52 31.25 0.625 250 5 0.25 0.25 0.50 0.5 0.13 0.63 
S53 62.5 1.25 125 2.5 0.5 1 1.5 0.5 1 1.5 
S54 62.5 1.25 250 5 0.5 0.06 0.56 1 0.03 1.03 
S55 62.5 1.25 2000 40 0.25 0.06 0.31 0.5 0.25 0.75 
S56 62.5 1.25 250 5 0.25 0.03 0.28 0.25 0.06 0.31 
S57 31.25 0.625 250 5 0.5 0.13 0.63 0.5 0.5 1 
S58 125 2.5 125 2.5 0.5 0.13 0.63 0.13 0.02 0.14 
S59 <31.25 <0.625 62.5 1.25 0.5 0.25 0.75 1 0.25 1.25 
S60 62.5 1.25 125 2.5 0.25 0.5 0.75 0.25 0.06 0.31 
S61 62.50 1.25 250 5 0.13 0.5 0.63 0.13 0.5 0.63 
S62 31.25 0.625 62.5 1.25 0.25 0.5 0.75 0.13 0.25 0.38 
S63 62.5 1.25 250 5 0.25 0.5 0.75 0.25 0.5 0.75 
S64 62.5 1.25 250 5 0.5 0.25 0.75 1 0.06 1.06 
S65 31.25 0.625 125 2.5 0.5 0.13 0.63 0.5 0.02 0.52 
S66 31.25 0.625 250 5 0.5 0.13 0.63 0.5 0.06 0.56 
S67 62.5 1.25 62.5 1.25 0.5 0.5 1 0.13 0.02 0.14 
S68 31.25 0.625 250 5 0.25 0.13 0.38 0.25 0.5 0.75 
S69 31.25 0.625 125 2.5 0.25 0.03 0.28 0.5 0.06 0.56 
S70 62.5 1.25 250 5 0.5 0.06 0.56 0.25 0.03 0.28 
MFM - Methanol extract of M. ferrea; Ri -Rifampicin; FIC- Fractional inhibitory concentration  
 
The MIC of combination of MFM and Ri showed synergistic effect against 14 strains 
with FIC index between 0.25 and 0.5, while against other 56 strains additive effect 
was observed with FIC index between 0.51 and 3. The MBC of combination of MFM 
and Ri showed synergistic effect against 20 strains with FIC index between 0.13 and 
0.5, while against 48 strains additive effect was observed with FIC index between 
0.51 and 2.5. Antagonistic effect was observed against 2 strains (FIC index 8.25).  
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Rifampicin is an important antibiotic in combination therapy, especially for deep-
seated staphylococcal infections, due to its excellent pharmacokinetic properties and 
bactericidal activity. Rifampicin resistance is frequent among MRSA because of 
mutations in rpoB, the gene encoding β-subunit of RNA polymerase, are responsible 
for rifampicin resistance (Wichelhaus et al., 2001). John et al. (2009) have studied the 
combination of deptomycin and rifampicin and found it to be a promising treatment 
option for MRSA. Garrigos et al. (2011) have reported the combination of rifampicin 
with tigecycline prevented rifampicin resistance against MRSA infection. Falagas et 
al. (2007) have studied rifampicin treatment against MRSA infections and they have 
reported increase in the resistance to rifampicin when used alone compared with the 
use of rifampicin in combination. The linezolid-rifampin combination against 
quinolone-resistant MRSA was effective treatment rather than linezolid or rifampicin 
alone (Baldoni et al., 2009). Thus, the effective in the treatment against MRSA was 
studied by some researchers with rifampicin in combination with other antibiotics, 
but, as per our knowledge, there is no report on any combination of rifampicin and 
plant extracts for the treatment of MRSA.  Results of the present study showed the 
MIC and MBC values reduced when treated with a combination of rifampicin and 
PLM/MFM. After combination of Ri and PLM/MFM, many strains had been 
converted from rifampicin resistant to rifampicin susceptible (Rifampicin resistance 
was considered if MIC/MBC values were more than 4 µg/ml). The MIC results of 
rifampicin alone and in combination with PLM showed, 43 strains were resistant to 
rifampicin when used alone but after combination all these strains were susceptible to 
rifampicin. The MBC results also showed a similar trend, 58 strains were resistant to 
rifampicin alone but after combination with PLM, 47 of the strains were susceptible to 
rifampicin. Combination of rifampicin with MFM showed, MIC values decreased and 
reached a susceptible level in 41 strains among 43 rifampicin resistant strains. MBC 
values also decreased in 25 strains to susceptible level among 58 rifampicin resistant 
strains. Many researchers have studied combinations of plant extracts/compounds 
with antibiotics and they have confirmed synergistic effect against S. aureus 
infections (Sato et al., 2004;  Betoni et al., 2006; Lee et al., 2008; Adwan and 
Mhanna, 2009; Ahmed et al., 2010;  Aboulmagd et al., 2011). Our results revealed 
that the combined use of plant extracts and antibiotics could be useful in fighting drug 
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resistance problems. In vivo and clinical trials are needed to confirm MRSA 
protection using these combinations.  
 
4.9 Pearson’s correlation analysis  
 
Correlation analyses of antibiotic susceptibility of 32 antibiotics against 53 coagulase 
positive and 17 coagulase negative Staphylococcus strains are presented in Table 4.13 
and 4.14. Most of the strains were correlated with each other significantly. It implies 
that these strains have similar antibiotic susceptibility pattern. Data highlighted with 
green color show higher level of significance (P>0.01), so, it may have acquired 
antibiotic resistance genes from common ancestor. Data highlighted with blue color 
also show significant correlation (P>0.05) indicating that these strains have moderate 
similarity in their antibiotic susceptibility pattern. Data not highlighted show poor 
correlation. These strains have different antibiotic susceptibility pattern than the other 
strains. Negative values of correlation (highlighted with pink color) indicate that these 
strains are highly different from other strains regarding their antibiotic susceptibility. 
Strains 22, 24, 31, 32 and 58 have lower correlation with the other studied strains 
indicate that these strains have different antibiotic susceptibility pattern. Correlation 
analysis of 11 plant extracts and three antibiotics against 10 coagulase positive 
Staphylococcus strains are presented in Table 4.15. The results showed that most of 
the strains correlated with each other with high significance level (P>0.01). Thus, it 
can be said that the plant extracts have higher anti-staphylococcal potency against 
most of the strains. Strain No. 32 and 51 did not correlate with other strains, 
indicating that these strains have different antibiotic susceptibility pattern against the 
plant extracts. Correlation analyses of MIC of 3 plant extracts and 5 antibiotics 
against 70 clinically isolated Staphylococcus strains are presented in Table 4.16. All 
the three plant extracts significantly correlated with each other (P>0.01). Significant 
correlation was found between MFM-vancomycin (P>0.01), PLM-teicoplanin 
(P>0.05) and PLF2-rifampicin (P>0.05), oxacillin-rifampicin (P>0.01), linezolid-
teicoplanin (P>0.01) and vancomycin-teicoplanin (P>0.01). Thus, this study gives 
possibility of potent activity of combination between plant extracts and antibiotics 
against Staphylococcus strains.  
 


Strains S11 S12 S13 S14 S15 S21 S24 S25 S28 S30 S31 S36 S37 S48 S55 S65 S70
S11 1 0.623** 0.547** 0.085 0.354* 0.386* 0.332 0.519** 0.478** 0.506** 0.212 0.423* 0.555** 0.463** 0.650** 0.368* 0.512**
S12 0.623** 1 0.637** 0.348 0.460** 0.457** 0.413* 0.851** 0.532** 0.599** 0.206 0.526** 0.679** 0.371* 0.721** 0.473** 0.450**
S13 0.547** 0.637** 1 0.456** 0.399* 0.318 0.266 0.744** 0.438* 0.607** 0.156 0.380* 0.711** 0.400* 0.701** 0.307 0.561**
S14 0.085 0.348 0.456** 1 0.329 0.450** -0.096 0.398* 0.614** 0.614** -0.183 0.277 0.585** 0.329 0.495** 0.334 0.499**
S15 0.354* 0.460** 0.399* 0.329 1 0.513** 0.237 0.482** 0.489** 0.625** 0.199 0.537** 0.500** 0.473** 0.662** 0.139 0.414*
S21 0.386* 0.457** 0.318 0.450** 0.513** 1 -0.014 0.407* 0.680** 0.510** 0.036 0.374* 0.367* 0.366* 0.539** 0.489** 0.477**
S24 0.332 0.413* 0.266 -0.096 0.237 -0.014 1 0.296 -0.041 0.068 0.503** 0.367* 0.156 0.284 0.306 0.044 0.247
S25 0.519** 0.851** 0.744** 0.398* 0.482** 0.407* 0.296 1 0.551** 0.749** 0.105 0.529** 0.848** 0.559** 0.664** 0.420* 0.608**
S28 0.478** 0.532** 0.438* 0.614** 0.489** 0.680** -0.041 0.551** 1 0.756** 0.04 0.348 0.700** 0.495** 0.650** 0.721** 0.686**
S30 0.506** 0.599** 0.607** 0.614** 0.625** 0.510** 0.068 0.749** 0.756** 1 -0.081 0.506** 0.889** 0.642** 0.654** 0.553** 0.750**
S31 0.212 0.206 0.156 -0.183 0.199 0.036 0.503** 0.105 0.04 -0.081 1 0.443* -0.012 0.361* 0.296 0.053 0.089
S36 0.423* 0.526** 0.380* 0.277 0.537** 0.374* 0.367* 0.529** 0.348 0.506** 0.443* 1 0.468** 0.492** 0.528** 0.123 0.339
S37 0.555** 0.679** 0.711** 0.585** 0.500** 0.367* 0.156 0.848** 0.700** 0.889** -0.012 0.468** 1 0.629** 0.696** 0.473** 0.743**
S48 0.463** 0.371* 0.400* 0.329 0.473** 0.366* 0.284 0.559** 0.495** 0.642** 0.361* 0.492** 0.629** 1 0.509** 0.236 0.844**
S55 0.650** 0.721** 0.701** 0.495** 0.662** 0.539** 0.306 0.664** 0.650** 0.654** 0.296 0.528** 0.696** 0.509** 1 0.481** 0.567**
S65 0.368* 0.473** 0.307 0.334 0.139 0.489** 0.044 0.420* 0.721** 0.553** 0.053 0.123 0.473** 0.236 0.481** 1 0.492**
S70 0.512** 0.450** 0.561** 0.499** 0.414* 0.477** 0.247 0.608** 0.686** 0.750** 0.089 0.339 0.743** 0.844** 0.567** 0.492** 1
**Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at the 0.05 level (2-tailed); S- Strains; n=32
Table 4.14 Pearson's correlation analysis of antibiotic susceptibility of 17 coagulase negative Staphylococcus  strains 
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Strains S01 S02 S03 S04 S32 S50 S51 S52 S62 S63
S01 1 0.851** 0.805** 0.727** 0.12 0.718** 0.08 0.869** 0.863** 0.739**
S02 0.851** 1 0.791** 0.739** 0.016 0.729** -0.03 0.956** 0.971** 0.799**
S03 0.805** 0.791** 1 0.669** -0.073 0.720** -0.097 0.739** 0.746** 0.820**
S04 0.727** 0.739** 0.669** 1 0.550* 0.926** 0.507* 0.850** 0.769** 0.709**
S32 0.12 0.016 -0.073 0.550* 1 0.492 0.985** 0.253 0.146 0.174
S50 0.718** 0.729** 0.720** 0.926** 0.492 1 0.421 0.818** 0.749** 0.812**
S51 0.08 -0.03 -0.097 0.507* 0.985** 0.421 1 0.203 0.087 0.134
S52 0.869** 0.956** 0.739** 0.850** 0.253 0.818** 0.203 1 0.962** 0.777**
S62 0.863** 0.971** 0.746** 0.769** 0.146 0.749** 0.087 0.962** 1 0.806**
S63 0.739** 0.799** 0.820** 0.709** 0.174 0.812** 0.134 0.777** 0.806** 1
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Table 4.15 Pearson's correlation analysis of 10 Staphylococcus strains  for anti-Staphylococcus activity of plant extracts
**Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at the 0.05 level (2-tailed); S- Strains; n=14
Plant 
extracts / 
antibiotic
PLM MFM PLF2 OXA LIN RIF TEC VAN
PLM 1 0.591** 0.510** -0.068 0.045 -0.02 0.275* 0.211
MFM 0.591** 1 0.335** -0.047 0.022 0.024 0.224 0.365**
PLF2 0.510** 0.335** 1 0.018 -0.025 0.242* 0.202 0.187
OXA -0.068 -0.047 0.018 1 -0.137 0.371** 0.012 0
LIN 0.045 0.022 -0.025 -0.137 1 -0.027 0.754** 0.306*
RIF -0.02 0.024 0.242* 0.371** -0.027 1 0.033 -0.035
TEC 0.275* 0.224 0.202 0.012 0.754** 0.033 1 0.669**
VAN 0.211 0.365** 0.187 0 0.306* -0.035 0.669** 1
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Table 4.16 Pearson's correlation analysis of MIC of plant extracts and antibiotics 
**Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at the 0.05 level (2-
tailed); S- Strains; n=70
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
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 Methicillin-resistant Staphylococcus is a major nosocomial pathogen with 
frequent resistance, leading to the overuse of antibiotics in therapy. The 
accurate and early determination of methicillin-resistance is of key importance 
in the prognosis of infections caused by Staphylococcus. This study found the 
prevalence of MRSA and the emergence of VISA/VRSA and linezolid 
resistant strains in immunosupressed patients.  
 
 Careful use of existing antibiotics and regular monitoring of strains circulating 
in particular hospitals at regular time intervals is essential to tackle the spread 
of highly resistant Staphylococcus aureus strains and also to predict and 
prevent the emergence of even more resistant strains.  
 
 16S rRNA gene sequences allow bacterial identification and mecA gene 
sequence analysis for methicillin-resistance that is more robust and more 
accurate than phenotypic testing. The results indicate that the two different 
amplified polymorphic DNA primers and the 16S rRNA gene sequence 
analyses in this study revealed that the strains tested were 96-99% similar and 
identical to the Staphylococcus aureus strains available in the GenBank 
database. In disc diffusion tests, cephoxitin appeared to be a better indicator of 
the presence of the mecA gene than oxacillin salt screening. Thus, this test can 
be an alternative to PCR for detection of Staphylococcus resistance in resource 
constraint settings.  
 
 The development of new classes of anti-MRSA compounds is the necessary 
step to control multi-drug resistant Staphylococcus, especially from natural 
source. Phytochemicals from medicinal plants showing antimicrobial activities 
have the potential of filling this need, because their structures are different 
from those of the more studied microbial sources, and therefore their mode of 
actions may very likely differ.  
 
 Potent anti-staphylococcal efficacy of methanol extracts of Polyalthia 
longifolia and Mesua ferrea are of great interest and require further 
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investigation. These preliminary studies are highly interesting as they open 
new avenues for further studies which would support the validation of the 
traditional use of these plants in the treatment of infections.  
 
 Combinations of antimicrobials with plant extracts demonstrate an in vitro 
synergism against infecting strains and are more likely to result in successful 
therapy. The possible advantage of this approach is that the same old drug can 
be reused in combination and is a less cost intensive approach as compared to 
new drug discovery altogether.  
 
 This work has justified the ethnobotanical uses of P. longifolia and M. ferrea 
and also encourages their combination with standard antibiotics since 
synergism in this study produced higher inhibitory effect on Staphylococcus 
strains. 
 
 Pearson’s correlation analysis showed that most of the strains correlated with 
each other with high significance level regarding their antibiotic susceptibility 
pattern (P>0.01) and anti-staphylococcal activity of plant extracts (P>0.01). 
Correlation of MIC of plant extracts and antibiotics showed significant 
correlation between all the plant extracts and also with the antibiotics which 
gives an idea for combinations between them against staphylococcal infection 
therapy.   
 
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
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 The increasing phenomenon of acquisition of resistance among 
microorganisms against antimicrobial drugs is attributed to their 
indiscriminate and improper use of current antimicrobials and the genetic 
plasticity of microorganisms converting themselves into drug resistant super 
infectious agents. These are difficult to treat and are responsible for a variety 
of chronic infections. 
 The problem of multi-drug resistant microorganisms is growing and the 
outlook for the use of antimicrobial drugs in the future is still uncertain. The 
clinicians are in a lurch wherein they find themselves trapped in two opposite 
trends, the first one is the prevalence and rapid increase in the number of 
human pathogens and decrease in the contribution of research and 
development of antimicrobial drugs which is a cost intensive proposition 
demanding billions of dollars. Moreover, there is no assurance that the product 
developed would encounter resistance in due course of time.  
 Therefore, actions must be taken to control the use of antibiotics, intensify 
research to better understand the genetic mechanisms of resistance and to 
continue studies to develop new drugs, either synthetic or natural. 
 Natural products produced from plant extracts have a great potential as 
antimicrobial compounds against drug resistant microorganisms. Their role is 
twofold in the development of new drugs by becoming  
 A base for the development of a medicine, a natural blueprint for the 
development of new drugs, or 
 A phytomedicine to be used for the treatment of diseases 
 Plants produce scores of phytochemicals which have the innate ability to be 
used as antimicrobial drugs. However, there are some phytochemicals which 
enhance the bioactivity of other compounds, referred to as biopotentiators or 
bioenhancers. These bioenhancers also work as synergists by reversing the 
antimicrobial drug resistance. The mechanisms of drug resistance reversal are 
being looked at for development of newer and effective drug formulations of 
bioenhancers to overcome antimicrobial drug resistance.  
An electron micrograph
of Staphylococcus aureus
(Cook and Cook, 2006)
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CHAPTER-1 [INTRODUCTION] 
 
 Staphylococcus, is a known pyogenic coccus responsible for various suppurative and 
pus forming diseases. It has a wide distribution and carriage rate among hospital 
personnel as well as the patients. Moreover, two types of strains are observed (1) 
coagulase-positive staphylocci (CPS) and (2) coagulase-negative staphylococci 
(CNS). 
 CPS is one of the most important nosocomial pathogens, and now CNS is also 
recognized as an important cause of nosocomial infections because resistance in CNS 
is attributed to the same mechanisms as in CPS.  
 Staphylococcus aureus is a well-armed super pathogen since it possesses extreme 
genetic plasticity and an array of virulence factors that confers resistance to different 
classes of antimicrobial agents.  
 The key determinant of methicillin-resistance is the mecA gene, which encodes in a 
novel penicillin-binding protein 2a, which reduces the binding of all β-lactam drugs to 
the cell wall and therefore, mediates cross-resistance to all these compounds. 
 Hospital associated methicillin resistant Staphylococcus aureus (MRSA) is usually 
resistant not only to β-lactams but also to other types of antibiotics. However, 
Community associated-MRSA isolates are usually susceptible to numerous non-β-
lactam antibiotics including trimethoprim-sulfamethoxazole, tetracyclines and 
clindamycin etc. 
 The emergence of MRSA organisms with reduced susceptibility to several antibiotics 
is a serious and ongoing concern. Vancomycin is considered the last-line treatment 
against a variety of serious infections caused by MRSA. However, reports of 
vancomycin-resistant strains have generated great concerns regarding the treatment to 
overcome these infections and the emergence of VRSA is a serious public health 
concern and is likely to have a dramatic negative impact on many current medical 
practices. 
 The increase in isolates of S. aureus with resistance to meticillin and decreased 
susceptibility to vancomycin has created an urgent need for the development of new 
antistaphylococcal agents that kill the resistant mutants. So, the identification of an 
alternative and safer drug for the control of MRSA is necessary to combat this 
worldwide problem.  
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 Nature is the only source to provide a variety of chemical compounds that can be used 
for new drug discovery. Interest in plants as sources of antimicrobial agents is 
growing. This is because plant-derived medicines have been part of traditional health 
care in most parts of the world. Screening of the natural products in a search for new 
anti-staphylococcal agents that would be active against this organism is the need of 
the hour. Here in the present study, antibacterial activity of extracts of eleven parts out 
of seven different plants extracts were studied against a battery of clinically important 
MRSA strains.  
 
CHAPTER-2 [REVIEW OF LITERATURE] 
 
 The pathogen Staphylococcus aureus may use a variety of strategies to resist 
antibiotic therapy. Before the availability of antibiotics, invasive infections caused by 
S. aureus were often fatal. Antibiotics are an essential part of modern medicine and 
that has helped dramatically in curing patients suffering from bacterial infections.  
 In the early 1940s, the major treatment available to combat this organism was 
penicillin and all isolates were sensitive to penicillin. During the next 2 decades, this 
pathogen developed resistance to penicillin. Resistance to these drugs occurs because 
of the acquisition of genes that encode drug-inactivating enzymes, initially known as 
penicillinases and now called β-lactamases.  
 The prevalence of penicillin-resistant strains increased in the 1960s. It was during this 
period that a new class of antibiotics was developed to target this pathogen 
specifically. 
 Since the introduction of methicillin into clinical use, one year after this class of 
antibiotics was developed, a resistant strain known as methicillin-resistant S. aureus.  
 MRSA infection is a persistent infection which may have serious effects on the 
healing process in hospitals, other care centers and lately in the community and has 
become a worldwide phenomenon.  
 This organism is resistant to all commercially available antibiotics and also represents 
a therapeutic challenge because effective therapeutic options are becoming limited.  
 Resistance is a major concern with any new agent and will become even more 
important in the future as new classes of drugs are established. Many studies tried to 
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find alternative ways to reduce and prevent the problem of antibiotic resistance in 
bacteria. 
  Hence, the plants may have evolved compounds which evade multidrug resistance 
mechanisms and plant antimicrobials may be developed into broad spectrum 
antibiotics in combination with inhibitors of multidrug resistance. So, there is a 
revival of interest in herbal medicines and widespread belief that ‘‘green medicine’’ is 
safe, more accessible and more affordable than costly synthetic drugs, many of which 
have adverse side effects.   
 Pharmaceutical industries have started taking more interest in plant products to isolate 
active constituents from different plant parts and use them directly as drug or develop 
them as pharmacologically active compounds with or without addition of synthetic 
ones. 
  Many researchers have conducted antimicrobial screening of plant extracts or 
isolated compounds. The screening of plant extracts for antimicrobial activity is by 
itself a research area of major significance with resistance modifying action is of 
special interest. Natural products, either as pure compounds or as standardized plant 
extracts provide unlimited opportunities for new drug leads because of the unmatched 
availability of chemical diversity.  
 
CHAPTER-3 [MATERIALS AND METHODS] 
 
 Clinical samples of Staphylococcus strains isolated from different specimens were 
collected from Gujarat region and isolates were initially identified based on their 
morphological characteristics followed by the studies on colony characteristics, gram 
reaction, catalase test, slide and tube coagulase test, mannitol salt agar, 
phenolphthalein phosphate agar, oxacillin resistance screening agar base.  
 Antibiotic susceptibility pattern of 32 different antibiotics was done by agar disc 
diffusion method and minimum inhibitory concentrations (MIC) of five selected 
antibiotics were determined by E-test against 70 clinically isolated Staphylococcus 
strains.  
 For molecular characterization, mecA gene was amplified in all the strains by using 
different primer pairs with PCR assay. Five strains were chosen for 16S rRNA 
analysis and out of these five strains, four strains were analyzed for mecA gene 
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sequencing and the sequences were deposited in NCBI GenBank database. 
Phylogenetic analysis and multiple sequences alignment were done with CLC main 
workbench 5. Pair wise alignment was done with BioEdit software.  
 Anti-staphylococcal activity of eleven plant parts (from seven plants) was studied by 
agar well diffusion method. Cold percolation method was used for extraction of plant 
material (methanol was used as solvent). Two different fractions were isolated from 
methanol extract of P. longifolia by solvent-solvent partition. Three potent extracts 
i.e. methanol extract of P. longifolia (PLM), M. ferrea (MFM) and fraction-2 of P. 
longifolia (PLF2) were selected for MIC and MBC studies, using 96 well microtitre 
plates. Rifampicin was used as reference drug. Combinations of rifampicin and 
PLM/MFM were used for MIC and MBC studies to determine synergistic interaction 
of plant extracts and antibiotic.   
 
CHAPTER-4 [RESULTS AND DISCUSSION] 
 
 The overall study was planned keeping in view of the realization that Staphylococcus 
is more dangerous for both hospital and community infections. In this study, seventy 
Staphylococcus strains were clinically isolated from different specimens. Most of the 
strains were isolated from pus samples.  
 Studies of biochemical reactions of clinically isolated Staphylococcus strains exposed 
all strains to be gram positive cocci, catalase positive, produce phenolphthalein 
phosphatase enzyme and grew on oxacillin resistance screening agar base. 53 out of 
70 strains were coagulase positive S. aureus while 17 strains were coagulase negative. 
All CPS strains ferment mannitol. Mannitol salt agar (MSA) is used for the selective 
isolation and differentiation of S. aureus that ferment mannitol and can grow in a high 
salt concentration. Seven out of seventeen CNS strains did not ferment mannitol. 
Additionally, MSA contains sugar mannitol, so that organisms can utilize mannitol as 
a carbon source and produce acidic end products; result indicates color change from 
red to yellow.  
 The antibiogram profile was quite useful in generating the microbial susceptibility 
profile among the isolates. Overall, all isolates were resistant to oxacillin, penicillin-
G, ampicillin and amoxyclav.  The data obtained also showed that all strains were less 
susceptibility to other antibiotic groups like cephalosporins, aminoglycoside, 
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macrolid, fluoroquinolones and trimethoprime. So these antibiotics have limitations of 
their use as first choice antimicrobial agents. Other antibiotic groups like 
tetracyclines, chloramphenicol, lincosamide, glycylcline fusidane, aminicoumarin 
showed moderate susceptibility. Linezolid and mupirocin showed better anti-
staphylococcus effects as compared to vancomycin and rifampicin.  
 Appearance of resistance against a particular antibiotic in a specific region may be 
due to its frequent and long-term use. In this study MIC of oxacillin showed most of 
the strains were highly resistant with MIC>256-4 µg/ml. For our study we also 
obtained VISA/VRSA, rifampicin and linezolid resistant strains from 
immunosupressed patients. Isolates were resistant to oxacillin by disc diffusion and 
MIC method which shows that the mecA gene is the primary structural gene 
responsible for methicillin-resistance in staphylococci and it is essential for 
expression of methicillin-resistance in true MRSA strains.  
 Extremely low-level resistant MRSA strains are dangerous as they often evade 
phenotypic detection. While they appear phenotypically susceptible, these strains still 
carry the mecA gene which encodes the β-lactam resistance protein PBP2a, and 
express resistance heterogeneously. To identify gene for methicillin-resistant from S. 
aureus, three specific pairs of primers were used for 70 methicillin-resistant clinically 
isolated strains and used for the amplification of mecA gene. Two different primer 
pairs were used for mecA gene identification, primer pair-1 has 154 bp and primer 
pair-2 has 533 bp. The gene fragments amplified span position 179 to1814 on gene. In 
this study primer pair-3 was also designed by picking forward primer of primer pair-1 
and reverse primer of primer pair-2 to identify and verify amplicon generated by pair-
1 and pair-2 primers. The size of amplified fragment of primer pair-3 was 
approximately 1600 bp. In these three primer pairs containing primer pair -2 was 
more reliable for the detection of mecA gene and much more similar to antibiogram 
pattern of cephoxitin disk diffusion test as compared to oxacillin screen agar testing. 
Cephoxitin is a potent inducer of the mecA regulatory system and is being widely used 
as a surrogate marker for detection of mecA gene-mediated methicillin-resistance. In 
antibiogram pattern, a disc diffusion test of cephoxitin appeared to be a better 
indicator of the presence of the mecA gene than oxacillin salt screening. Thus, the test 
can be an alternative to PCR for detection of methicillin-resistant Staphylococcus but 
final identification cannot be determined without the support of genetic data because 
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expression of methicillin-resistance in the clinical laboratory setting is subject to 
environmental conditions like temperature, medium pH and NaCl content in the 
medium. 
 At molecular level 16S rRNA analysis is faster for species identification and can 
provide important information to predict clinical significance and guide etiological 
diagnosis and the management of infections and mecA gene sequence specific for 
methicillin/oxacillin resistance. Results of BLAST of our sequences showed 96-99% 
similarity with other Staphylococcus aureus 16S rRNA sequence available in the 
GenBank data base. All the five sequences were deposited in NCBI (Accession No: 
JN831368, JN831369, JN831370, JN831371, JN831372).  The phylogenetic analysis 
showed that the four isolates SU-BIO1, SU-BIO3, SU-BIO4 and SU-BIO5 are very 
close to vancomycin resistant Staphylococcus aureus 185060 (Acc. No: EU604543.1). 
BLAST analysis of mecA gene sequences of four selected strains showed 99% 
similarity with Staphylococcus aureus mecA gene penicillin binding protein2a. The 
phylogenetic tree was divided in to various subgroups of S. aureus strains. Based on 
phylogenetic tree and BLAST analysis it was confirmed that studied strains belong to 
S. aureus as also the presence of mecA gene.  
 The continuing emergence and development of resistance to existing antibacterial 
agents by bacteria has created the need for new antibacterial compounds that exhibit 
activity against these resistant strains. Medicinal plants, particularly their active 
components, have been a dependable source of therapeutics for the treatment of 
various ailments since time immemorial. In our study, antibacterial screening of 11 
methanol extracts of 7 different plant parts were evaluated against 10 Staphylococcus 
strains by agar well diffusion method.  
 Our results showed that plant extracts were potent as well as antibiotic. From this 
screening, methanol extract of P. longifolia (PLM), M. ferrea (MFM) and fraction-2 
of P. longifolia (PLF2) were selected for MIC and MBC studies against seventy 
clinically isolated Staphylococcus strains. Results of MIC and MBC studies showed 
comparative activity PLM, PLF2 and MFM with standard antibiotic rifampicin (Ri).  
 Combination antibiotic therapy has been shown to delay the emergence of bacterial 
resistance and may also produce desirable synergistic effects in the treatment of 
bacterial infections. Our investigation of combination between PLM/MFM and 
rifampicin showed more anti-staphylococcal activity than plant extract/antibiotic 
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alone. After combination, rifampicin resistant strains were converted to rifampicin 
susceptible. Synergistic effects (FIC index less than 0.5) were also observed between 
PLM with Ri and MFM with Ri. Therefore, screening of crude plant extracts for 
synergistic interaction with antibiotics is expected to provide leads for the isolation of 
multi-drug resistant inhibitors. 
 Data of Pearson’s correlation analysis showed most of the strains correlated with each 
other regarding their antibiotic susceptibility pattern and anti-staphylococcal activity 
of plant extracts. Correlation of MIC of plant extracts and antibiotics gives possibility 
of combination therapy between plant extracts and antibiotics against Staphylococcus 
strains.  
 
CONCLUSIONS 
 
 Presence of MRSA is a major problem both in hospitals and community. Multi-drug 
resistance in MRSA created a need to find another option for the treatment and also 
regular monitoring of antibiotic susceptibility is essential to tackle the spread of 
highly resistant Staphylococcus aureus strains.  
 Data of biochemical identification and antibiotic susceptibility aid in shaping public 
health policy to predict emergent outbreaks and serve as an important tool in 
preventive medicine.  
 PCR method is a useful tool for the detection and identification of S. aureus from 
clinical samples.  Ciphoxitin disc diffusion test may be useful as an alternative to PCR 
method for identifying the presence of mecA gene in staphylococci. 16S rRNA gene 
sequences allow bacterial identification and mecA gene sequences analysis for 
methicillin-resistance that is more robust and more accurate than that obtained by 
phenotypic testing.  
 Medicinal plant extracts are alternative sources for the treatment of MRSA. Methanol 
extracts of P. longifolia and M. ferrea were more potent antibacterial agents against 
MRSA. This work encourages the combination of plant extracts and antibiotics to 
increase the antibacterial potential. Pearson’s correlation analysis showed most of the 
strains correlated with each other and also suggested the probable combinations of 
plant extracts and antibiotics for combination therapy against Staphylococcal 
infections.  
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